DRAVP_ID Sequence Sequence_Length Name Source Target_Organism Patent_Type Patent_No Publication_Date Family_Info Patent_Title Comment Abstract Other_link Connectives DRAVPa1672 EAQSQEVKNW MTETLLVQNA N 21 Sequence 2 from Patent US 20090281041 Homo sapiens HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides No cooments found in patent Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1673 AQEVKNWMTETLLVA 15 Sequence 3 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides No cooments found in patent Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1671 KRKKRRHR 8 Sequence 94 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1670 KKEKKKSKK 9 Sequence 93 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1669 PQSRKKLR 8 Sequence 92 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1668 KHRKHPG 7 Sequence 91 from Patent US 20090258815 Saccharomyces cerevisiae Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1667 KTRKHRG 7 Sequence 90 from Patent US 20090258815 Saccharomyces cerevisiae Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1666 IKYFKKFPKD 10 Sequence 89 from Patent US 20090258815 Saccharomyces cerevisiae Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1665 SKRVAKRKL 9 Sequence 88 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1664 PQPKKKP 7 Sequence 87 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1663 PPQKKIKS 8 Sequence 86 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1662 PLLKKIKQ 8 Sequence 85 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1661 EEDGPQKKKRRL 12 Sequence 84 from Patent US 20090258815 Polyomavirus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1660 PNKKKRK 7 Sequence 83 from Patent US 20090258815 Simian virus 40 Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1659 APTKRKGS 8 Sequence 82 from Patent US 20090258815 Simian virus 40 Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1658 VSRKRPR 7 Sequence 81 from Patent US 20090258815 Polyomavirus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1657 PKKARED 7 Sequence 80 from Patent US 20090258815 Polyomavirus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1656 MNKIPIKDLLNPG 13 Sequence 79 from Patent US 20090258815 Saccharomyces cerevisiae Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1655 KRPAEDMEEEQAFKRSR 17 Sequence 78 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1654 PAAKRVKLD 9 Sequence 77 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1653 YNNQSSNFGPMKGGN 15 Sequence 76 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1652 KRKKEMANKSAPEAKKKK 18 Sequence 75 from Patent US 20090258815 Gallus gallus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1651 KRPAATKKAGQAKKKK 16 Sequence 74 from Patent US 20090258815 Xenopus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1649 EYLSRKGKLEL 11 Sequence 72 from Patent US 20090258815 Agrobacterium tumefaciens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1650 PKRPRDRHDGELGGRKRARG 20 Sequence 73 from Patent US 20090258815 Agrobacterium tumefaciens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1647 PRGRRQPIPKARQP 14 Sequence 70 from Patent US 20090258815 Hepatitis C virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1648 KRSAEGGNPPKPLKKLR 17 Sequence 71 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1645 KVNSRKRRKEVPGPNGATEED 21 Sequence 68 from Patent US 20090258815 Rattus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1646 PRRGPR 6 Sequence 69 from Patent US 20090258815 Hepatitis C virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1643 VNEAFETLKRC 11 Sequence 66 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1644 MPTEERVRKRKESNRESARRSRYRKAAHLK 30 Sequence 67 from Patent US 20090258815 Zea mays Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1642 CKRKTTNADRRKA 13 Sequence 65 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1640 LKRKLQR 7 Sequence 63 from Patent US 20090258815 avian neuroretina Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1641 RRKGKEK 7 Sequence 64 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1638 RKRRTKK 7 Sequence 61 from Patent US 20090258815 Arabidopsis sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1639 SDKKVRSRLIECA 13 Sequence 62 from Patent US 20090258815 Thermoplasma acidophilum Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1636 REKKEKEQKEKCA 13 Sequence 59 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1637 LEKKVKKKFDWCA 13 Sequence 60 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1635 GRKRKKRT 8 Sequence 58 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1633 RIRKKLR 7 Sequence 56 from Patent US 20090258815 Mus musculus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1634 KRAAEDDEDDDVDTKKQK 18 Sequence 57 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1631 RKRKKMPASQRSKRRKT 17 Sequence 54 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1632 RAIKRRPGLDFDDDGEGNSKFLR 23 Sequence 55 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1630 KKQTTLAFKPIKKGKKR 17 Sequence 53 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1629 RKEWLTNFMEDRRQRKL 17 Sequence 52 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1628 KKSKKGRQEALERLKKA 17 Sequence 51 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1627 KRMRNRIAASKCRKRKL 17 Sequence 50 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1626 RRERNKMAAAKCRNRRR 17 Sequence 49 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1625 RKCLQAGMNLEARKTKK 17 Sequence 48 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1624 PAKRARRGYK 10 Sequence 47 from Patent US 20090258815 canine parvovirus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1623 RRSMKRK 7 Sequence 46 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1622 RKRKK 5 Sequence 45 from Patent US 20090258815 Saccharomyces cerevisiae Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1621 KRPRP 5 Sequence 44 from Patent US 20090258815 adenovirus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1620 LKDVRKRKLGPGH 13 Sequence 43 from Patent US 20090258815 epstein-barr virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1619 YKRPCKRSFIRFI 13 Sequence 42 from Patent US 20090258815 epstein-barr virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1618 PPRKKRTVV 9 Sequence 41 from Patent US 20090258815 Hepatitis C virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1617 RKRR 4 Sequence 40 from Patent US 20090258815 Arabidopsis sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1616 PRRRK 5 Sequence 39 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1615 KRPMNAFIVWAQAARRK 17 Sequence 38 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1614 RPRRK 5 Sequence 37 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1613 KRPMNAFIVWSRDQRRK 17 Sequence 36 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1612 MPKTRRRPRRSQRKRPPT 18 Sequence 35 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1611 RQARRNRRRRWR 12 Sequence 34 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1610 RKKRRQRRR 9 Sequence 33 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1609 APKRKSGVSKC 11 Sequence 32 from Patent US 20090258815 Polyomavirus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1608 KDCVINKHHRNRCQYCRLQR 20 Sequence 31 from Patent US 20090258815 Mus musculus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1607 PPRIYPQLPSAPT 13 Sequence 30 from Patent US 20090258815 Borna disease virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1606 PRPRKIPR 8 Sequence 29 from Patent US 20090258815 Borna disease virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1605 KKKKKEEEGEGKKK 14 Sequence 28 from Patent US 20090258815 Rattus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1604 KVTKRKHDNEGSGSKRPK 18 Sequence 27 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1603 KKKRRSREK 9 Sequence 26 from Patent US 20090258815 Drosophila sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1602 KKKKRKREK 9 Sequence 25 from Patent US 20090258815 Drosophila sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1601 CYGSKNTGAKKRKIDDA 17 Sequence 24 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1600 PYLNKRKGKP 10 Sequence 23 from Patent US 20090258815 Saccharomyces cerevisiae Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1599 PPVKRERTS 9 Sequence 22 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1598 RKRRR 5 Sequence 21 from Patent US 20090258815 Rattus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1597 RGRRRRQR 8 Sequence 20 from Patent US 20090258815 Rattus sp. Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1596 KAKRQR 6 Sequence 19 from Patent US 20090258815 avian reticuloendothelios Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1595 GKKRSKA 7 Sequence 18 from Patent US 20090258815 Saccharomyces cerevisiae Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1594 PKKKRKV 7 Sequence 17 from Patent US 20090258815 Simian virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1593 KRPACTLKPECVQQLLVCSQEAKK 24 Sequence 16 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1592 RVHPYQR 7 Sequence 15 from Patent US 20090258815 Mus musculus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1591 RRMKWKK 7 Sequence 14 from Patent US 20090258815 Homo sapiens Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1590 RKKKRKVLALKAGLDI 16 Sequence 13 from Patent US 20090258815 Synthetic construct Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1589 YGRKKRRQRRRLPPLERLTLD 21 Sequence 12 from Patent US 20090258815 Synthetic construct Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1588 LPPLERLTLDRQARRNRRRRWR 22 Sequence 11 from Patent US 20090258815 Synthetic construct Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1587 RQARRNRRRRWRLPPLERLTLD 22 Sequence 10 from Patent US 20090258815 Synthetic construct Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1586 LSAQLYSSLSLD 12 Sequence 9 from Patent US 20090258815 Human T-cell lymphotropic Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1585 LPPDLRLTLD 10 Sequence 8 from Patent US 20090258815 Human immunodeficiency virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1584 LALKLAGLDI 10 Sequence 7 from Patent US 20090258815 Mus musculus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1583 LPPLERLTLD 10 Sequence 6 from Patent US 20090258815 Human immunodeficiency virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1582 YGRKKRRQRRR 11 Sequence 5 from Patent US 20090258815 Human immunodeficiency virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1581 RKKKRKV 7 Sequence 4 from Patent US 20090258815 Synthetic construct Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1580 PKKKRKV 7 Sequence 3 from Patent US 20090258815 Simian virus 40 Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1579 RKKRRQRRR 9 Sequence 2 from Patent US 20090258815 Human immunodeficiency virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1578 RQARRNRRRRWR 12 Sequence 1 from Patent US 20090258815 Human immunodeficiency virus Herpes viruse Patent Application US 2009/0258815 A1 2009-10-15 WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2 Antiviral Peptide and Antiviral Agent No cooments found in patent "Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES." Anti-Herpes viruse DRAVPa1577 RLLLRLLYGY 10 Sequence 27 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1575 RLLLRYLLGY 10 Sequence 25 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1576 RLLLRLYLGY 10 Sequence 26 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1574 RLLYRLLLGY 10 Sequence 24 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1572 RYLLRLLLGY 10 Sequence 22 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1573 RLYLRLLLGY 10 Sequence 23 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1571 RLLLRLLWGY 10 Sequence 21 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1568 RLLWRLLLGY 10 Sequence 18 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1569 RLLLRWLLGY 10 Sequence 19 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1570 RLLLRLWLGY 10 Sequence 20 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1565 RLLLRLLIGY 10 Sequence 15 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1566 RWLLRLLLGY 10 Sequence 16 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1567 RLWLRLLLGY 10 Sequence 17 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1562 RLLLRLVLGY 10 Sequence 12 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1563 RLLLRLILGY 10 Sequence 13 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1564 RLLLRLLVGY 10 Sequence 14 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1559 RLLIRLLLGY 10 Sequence 9 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1560 RLLLRVLLGY 10 Sequence 10 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1561 RLLLRILLGY 10 Sequence 11 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1557 RLILRLLLGY 10 Sequence 7 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1558 RLLVRLLLGY 10 Sequence 8 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1554 RVLLRLLLGY 10 Sequence 4 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1555 RILLRLLLGY 10 Sequence 5 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1556 RLVLRLLLGY 10 Sequence 6 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1553 RLLLRLLLGY 10 Sequence 3 from Patent US 20090215699 Synthetic construct HIV Patent Application US 2009/0215699 A1 2009-08-27 CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1 Pharmaceutically Active Antiviral Peptides No cooments found in patent "The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects." Anti-HIV DRAVPa1552 SGSWLRDDWDWECTVLTDDKTWLQSKL 27 Sequence 91 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV89), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1551 SGSWLRDDWDWECTVLTDDKTWLQSKLDYKD 31 Sequence 90 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV88), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1550 SGSWLRDVWDWICTVLTDFKTWLQSKLDYKD 31 Sequence 89 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV87), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1549 ELGFQPGLKVAQHLAYPVPDVP 22 Sequence 88 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV86), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1548 LCLAGRGLQEAEGLLLELLSEHHPLLDV 28 Sequence 87 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV85), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1547 SWLRDVWDWIC 11 Sequence 86 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV84), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1546 DVWDWICTVLTD 12 Sequence 85 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV83), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1545 LRDVWDWICT 10 Sequence 84 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV82), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1544 LRDVWDWICTVLTDFKT 17 Sequence 83 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV81), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1543 IEQGMMLAEQFKQKALGLLQTASRHAEV 28 Sequence 81 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV80), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1542 DVRCHARKAVAHINSVWKD 19 Sequence 80 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV79), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1541 QDVLKEVKAAASKVKANLLSVEE 23 Sequence 79 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV78), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1540 SGSWLRDVWDWICTVLTDFKTWLQSKLDYK 30 Sequence 77 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV77), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1539 SWLRDIWDWVCTVLSDF 17 Sequence 76 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV76), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1538 SWLYDIVNWVCTVLADF 17 Sequence 75 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV75), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1537 SWLWDVWDWVLHVLSDF 17 Sequence 74 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV74), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1536 SWLHDIWDWVCIVLSDF 17 Sequence 73 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV73), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1535 SWLRTIWDWVCSVLADF 17 Sequence 72 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV72), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1534 SWLRIIWDWVCSWSDFK 17 Sequence 71 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV71), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1533 SWLRDIWEWVLSILTDF 17 Sequence 70 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV70), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1532 SWLRDVWDWVCTILTDF 17 Sequence 69 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV69), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1531 SWLRDVWDWICTVLTDF 17 Sequence 68 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV68), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1530 SWLRDIWDWVCTVLSD 16 Sequence 67 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV67), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1529 SWLYDIVNWVCTVLAD 16 Sequence 66 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV66), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1528 SWLWDVWDWVLHVLSD 16 Sequence 65 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV65), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1527 SWLHDIWDWVCIVLSD 16 Sequence 64 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV64), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1526 SWLRTIWDWVCSVLAD 16 Sequence 63 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV63), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1525 SWLRIIWDWVCSWSDF 16 Sequence 62 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV62), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1524 SWLRDIWEWVLSILTD 16 Sequence 61 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV61), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1523 SWLRDVWDWVCTILTD 16 Sequence 60 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV60), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1522 SWLRDVWDWICTVLTD 16 Sequence 59 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV59), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1521 SWLRDIWDWVCTVLS 15 Sequence 58 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV58), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1520 SWLYDIVNWVCTVLA 15 Sequence 57 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV57), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1519 SWLWDVWDWVLHVLS 15 Sequence 56 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV56), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1518 SWLHDIWDWVCIVLS 15 Sequence 55 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV55), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1517 SWLRTIWDWVCSVLA 15 Sequence 54 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV54), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1516 SWLRIIWDWVCSWSD 15 Sequence 53 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV53), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1515 SWLRDIWEWVLSILT 15 Sequence 52 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV52), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1514 SWLRDVWDWVCTILT 15 Sequence 51 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV51), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1513 SWLRDVWDWICTVLT 15 Sequence 50 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV50), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1512 GSWLRDIWDWVCTVLSDFRVWLKSKL 26 Sequence 49 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV49), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1511 GSWLYDIVNWVCTVLADFKLWLGAKI 26 Sequence 48 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV48), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1510 GSWLWDVWDWVLHVLSDFKTCLKAKF 26 Sequence 47 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV47), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1509 GSWLHDIWDWVCIVLSDFKTWLSAKI 26 Sequence 46 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV46), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1508 GSWLRTIWDWVCSVLADFKAWLSAKI 26 Sequence 45 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV45), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1507 GSWLRIIWDWVCSWSDFKTWLSAKI 25 Sequence 44 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV44), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1506 GSWLRDIWEWVLSILTDFKNWLSAKL 26 Sequence 43 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV43), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1505 GSWLRDVWDWVCTILTDFKNWLTSKL 26 Sequence 42 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV42), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1504 GSWLRDVWDWICTVLTDFKTWLQSKL 26 Sequence 41 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV41), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1503 SGSWLRDIWDWVCTVLSDFRVWLKSKL 27 Sequence 40 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV40), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1502 SGSWLYDIVNWVCTVLADFKLWLGAKI 27 Sequence 39 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV39), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1501 SGSWLWDVWDWVLHVLSDFKTCLKAKF 27 Sequence 38 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV38), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1500 SGSWLHDIWDWVCIVLSDFKTWLSAKI 27 Sequence 37 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV37), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1499 SGSWLRTIWDWVCSVLADFKAWLSAKI 27 Sequence 36 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV36), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1498 SGSWLRIIWDWVCSWSDFKTWLSAKI 26 Sequence 35 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV35), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1497 SGSWLRDIWEWVLSILTDFKNWLSAKL 27 Sequence 34 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV34), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1496 SGSWLRDVWDWVCTILTDFKNWLTSKL 27 Sequence 33 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV33), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1495 SGSWLRDVWDWICTVLTDFKTWLQSKL 27 Sequence 32 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV32), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1494 SGSLRDIWDWICEVLSDFKTWLKA 24 Sequence 31 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV31), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1493 SWLRDIWDWVCTVLSDFRVWLKSKL 25 Sequence 30 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV30), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1492 SWLYDIVNWVCTVLADFKLWLGAKI 25 Sequence 29 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV29), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1491 SWLWDVWDWVLHVLSDFKTCLKAKF 25 Sequence 28 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV28), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1490 SWLHDIWDWVCIVLSDFKTWLSAKI 25 Sequence 27 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV27), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1489 SWLRTIWDWVCSVLADFKAWLSAKI 25 Sequence 26 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV26), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1488 SWLRIIWDWVCSWSDFKTWLSAKI 24 Sequence 25 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV25), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1487 SWLRDIWEWVLSILTDFKNWLSAKL 25 Sequence 24 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV24), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1486 SWLRDVWDWVCTILTDFKNWLTSKL 25 Sequence 23 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV23), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1485 SWLRDVWDWICTVLTDFKTWLQSKL 25 Sequence 22 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV22), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1484 WLRDIWDWVCTVLSDFRVWLKSKL 24 Sequence 21 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV21), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1483 WLYDIVNWVCTVLADFKLWLGAKI 24 Sequence 20 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV20), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1482 WLWDVWDWVLHVLSDFKTCLKAKF 24 Sequence 19 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV19), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1481 WLHDIWDWVCIVLSDFKTWLSAKI 24 Sequence 18 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV18), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1480 WLRTIWDWVCSVLADFKAWLSAKI 24 Sequence 17 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV17), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1479 WLRIIWDWVCSVVSDFKTWLSAKI 24 Sequence 16 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV16), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1478 WLRDIWEWVLSILTDFKNWLSAKL 24 Sequence 15 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV15), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1477 WLRDVWDWVCTILTDFKNWLTSKL 24 Sequence 14 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV14), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1476 WLRDVWDWICTVLTDFKTWLQSKL 24 Sequence 13 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV13), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1475 LRDIWDWICEVLSDFKTWLKA 21 Sequence 12 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV12), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1474 SWLRDIWDWICEVL 14 Sequence 11 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV11), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." DRAVPe01079 Anti-HCV DRAVPa1472 SWLYDIVNWVCTVC 14 Sequence 9 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV9), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1473 SWLRDIWDWVCTVC 14 Sequence 10 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV10), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1470 SWLHDIWDWVCIVC 14 Sequence 7 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV7), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1471 SWLWDVWDWVLHVL 14 Sequence 8 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV8), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1468 SWLRIIWDWVCSWC 14 Sequence 5 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV5), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1469 SWLRTIWDWVCSVC 14 Sequence 6 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV6), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1466 SWLRDVWDWVCTIL 14 Sequence 3 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV3), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1467 SWLRDIWEWVLSIL 14 Sequence 4 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV4), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses." "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1465 SWLRDVWDWICTVL 14 Sequence 2 from Patent US 20090105151 Hepatitis C virus HCV Patent Application US 2009/0105151 A1 2009-04-23 WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2 Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents "The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV2), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. " "The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner." Anti-HCV DRAVPa1464 PGDVYANGLVA 11 Sequence 32 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1462 RRKKAAVA 8 Sequence 30 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1463 PGYAGAVVNDL 11 Sequence 31 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1461 RRKKAAVAVVP 11 Sequence 29 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1460 RRKKAAVAVVPAVL 14 Sequence 28 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1458 RRKKLLAP 8 Sequence 26 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1459 RRKKAAVALLPAVLLAL 17 Sequence 27 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01188 Anti-HSV DRAVPa1457 RRKKLLALLAP 11 Sequence 25 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1456 RRKKPAVLLALLAP 14 Sequence 24 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01196 Anti-HSV DRAVPa1455 RRKKALLPAVLLALLAP 17 Sequence 23 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01193 Anti-HSV DRAVPa1453 RRKKPAVLLA 10 Sequence 20 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1454 RRKKPAVLLALLALLA 16 Sequence 22 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1452 RRKKAVAVAVPAVLLALLAP 20 Sequence 19 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1451 RRKKAAVALLP 11 Sequence 18 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01190 Anti-HSV DRAVPa1449 RRKK 4 Sequence 16 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1450 RRKKLAALPLVLAAPLAVLA 20 Sequence 17 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1448 DPKGDPKGVTVTVTVTVTGKGDPKPD 26 Sequence 13 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1447 GWTLNSAGYLLGKINLKALAALAKKIL 27 Sequence 12 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1446 YGRKKRRQRRRPGDVYANGLVA 22 Sequence 11 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=67 ¦ÌM)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1445 YGRKKRRQRRRPGYAGAVVNDL 22 Sequence 10 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=26 ¦ÌM)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1443 RQIKIWFPNRRMKWKK 16 Sequence 8 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=7 ¦ÌM)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1444 RQIKIFFPNRRMKFKK 16 Sequence 9 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=40 ¦ÌM)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1442 RQIKIWFPNRRMKWKKPGYAGAVVNDL 27 Sequence 7 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=9-12 ¦ÌM)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1441 KLALKLALKALKAALKLA 18 Sequence 5 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=11 ¦ÌM)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1440 RRKKPAVLLALLA 13 Sequence 4 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1439 RRKKAAVALLAVLLALLAPP 20 Sequence 3 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." Anti-HSV DRAVPa1437 QQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ 41 Sequence 48 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" The peptide shows antiviral activity against HIV IIIB.(IC50=0.89 ¦Ìg/ml) "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1438 RRKKAAVALLPAVLLALLAP 20 Sequence 1 from Patent US 20050130884 Synthetic construct HSV Patent Application US 2005/0130884 A1 2005-06-16 WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7 Pharmacologically active antiviral peptides and methods of their use "The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=15-26 ¦ÌM)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01185 Anti-HSV DRAVPa1436 QARQLLSGIVQQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ 51 Sequence 47 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" The peptide shows antiviral activity against HIV IIIB.(IC50=0.61 ¦Ìg/ml) "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1434 QQQNNLLRAIEAQQHLLQLTVWGIKQLAARILAVERYLKDQ 41 Sequence 45 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1435 QQQNNLLRAIEAQQHALQLTVWGIKQLQARILAVERYLKDQ 41 Sequence 46 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1433 QQQNNLLRAIEAQQHLLQLTVWGIAQLQARILAVERYLKDQ 41 Sequence 44 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1432 QQQNNLLRAIEAQQHLLQLTVFGIKQLQARILAVERYLKDQ 41 Sequence 43 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=1.34 ¦Ìg/ml, IC90=3.81 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1430 QARQLVSGLVQQQNNILRALEATQHLVQLLVWGVKQLQARVLALERYIK 49 Sequence 41 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=3.892 ¦Ìg/ml, IC90=14.53 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1431 QIRQLLSGIVQQQNNLLRAIEAIQHLLQLIVWGIKQLQARILAVERYLK 49 Sequence 42 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=13.605 ¦Ìg/ml, IC90=33.56 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1429 QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGVKQLQARILAVERYLKDQ 51 Sequence 40 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.41 ¦Ìg/ml, IC90=1.84 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1427 QARQLLSGIVQQQNNLLRAIEATQHAVQALVWGVKQLQARVLALERYIKDQ 51 Sequence 38 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.18 ¦Ìg/ml, IC90=0.88 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1428 QARQLVSGLVQQQNNILRALEAQQHALQATVWGIKQLQARVLALERYIKDQ 51 Sequence 39 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.26 ¦Ìg/ml, IC90=1.20 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1426 QARQLVSGLVQQQNNILRALEATQHAVQALVWGVRQLQARVLALERYIK 49 Sequence 37 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" The peptide shows antiviral activity against HIV IIIB.(IC50<0.78 ¦Ìg/ml) "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1425 QIRQLLSGIVQQQNNLLRAIEAIQHALQAIVWGIKQLQARILAVERYLK 49 Sequence 36 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.73 ¦Ìg/ml, IC90=3.03 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1423 QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLKDQ 51 Sequence 34 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.19 ¦Ìg/ml, IC90=0.62 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1424 QARQLVSGLVQQQNNILRALEATQHAVQALVWGVKQLQARVLALERYIK 49 Sequence 35 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.14 ¦Ìg/ml, IC90=0.69 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1422 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL 36 Sequence 33 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." DRAVPe01974 Anti-HIV DRAVPa1420 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVFGIRQLQARILAVERYLK 49 Sequence 31 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.93 ¦Ìg/ml, IC90=3.06 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1421 QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLK 49 Sequence 32 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.59 ¦Ìg/ml, IC90=1.90 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1419 QQQNNLLRAIEAQQHLLQLTVAGIKQLQARILAVERYLKDQ 41 Sequence 30 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=0.37 ¦Ìg/ml, IC90=1.00 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1418 QQQNNLLRAIEAQQHLLQLTAWGIKQLQARILAVERYLKDQ 41 Sequence 29 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=2.81 ¦Ìg/ml, IC90=5.86 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1416 QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 41 Sequence 27 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=4.69 ¦Ìg/ml, IC90=23.24 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1417 RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 34 Sequence 28 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1415 SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 45 Sequence 26 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1413 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 51 Sequence 24 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=3.73 ¦Ìg/ml, IC90=12.301 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1414 SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 36 Sequence 25 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1412 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK 49 Sequence 23 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" "The peptide shows antiviral activity against HIV IIIB.(IC50=4.69 ¦Ìg/ml, IC90=23.24 ¦Ìg/ml)" "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1410 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 42 Sequence 21 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1411 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY 47 Sequence 22 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1409 LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG 36 Sequence 20 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1407 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI 38 Sequence 18 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1408 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR 44 Sequence 19 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1406 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG 37 Sequence 17 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1404 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV 35 Sequence 15 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1405 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW 36 Sequence 16 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1403 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 34 Sequence 14 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1401 MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 35 Sequence 12 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1402 MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV 36 Sequence 13 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1400 SMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 36 Sequence 11 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1399 RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL 36 Sequence 10 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1397 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI 50 Sequence 8 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1398 ARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQ 36 Sequence 9 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1396 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV 40 Sequence 7 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1394 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLL 36 Sequence 5 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1395 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL 38 Sequence 6 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1393 GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI 54 Sequence 4 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1391 NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 38 Sequence 2 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1392 GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 43 Sequence 3 from Patent US 20040091855 Synthetic construct HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1389 YQEWERKVDFLEENITALLEEAQIQQEKNMYELQKL 36 Sequence 80 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1390 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQLLGI 59 Sequence 1 from Patent US 20040091855 Human immunodeficiency virus HIV Patent Application US 2004/0091855 A1 2004-05-13 US 2004/0091855 A1 "Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom" No comments found in patent "Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers." Anti-HIV DRAVPa1386 EALLRALQE 9 Sequence 77 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1387 WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF 39 Sequence 78 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." DRAVPe00254 Anti-HIV DRAVPa1388 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT 39 Sequence 79 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1383 AARIEALLRALQE 13 Sequence 74 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1384 ARIEALLRALQE 12 Sequence 75 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1385 RIEALLRALQE 11 Sequence 76 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1380 TTWEAWDRAIAEYA 14 Sequence 71 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1381 TYWEAWDRAIAEY 13 Sequence 72 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1382 EL 2 Sequence 73 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1377 TTWEAWDRAIAEYAARI 17 Sequence 68 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1378 TTWEAWDRAIAEYAAR 16 Sequence 69 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1379 TTWEAWDRAIAEYAA 15 Sequence 70 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1374 TTWEAWDRAIAEYAARIEALLR 22 Sequence 65 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1375 TTWEAWDRAIAEYAARIEALL 21 Sequence 66 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1376 TTWEAWDRAIAEYAARIEA 19 Sequence 67 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1371 EQQEKNEAALREL 13 Sequence 62 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1372 TTWEAWDRAIAEYAARIEALLRALQ 25 Sequence 63 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1373 TTWEAWDRAIAEYAARIEALLRAL 24 Sequence 64 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1368 RIEALLRALQEQQEKNEAALRE 22 Sequence 59 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1369 QEQQEKNEAALREL 14 Sequence 60 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1370 LQEQQEKNEAALREL 15 Sequence 61 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1365 AIAEYAARIEALLRAAQEQQEKLEAALREL 30 Sequence 56 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1366 TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRE 37 Sequence 57 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1367 AARIEALLRALQEQQEKNEAALRE 24 Sequence 58 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1362 EYAARIEALLRAAQEQQEKLEAALREL 27 Sequence 53 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1363 AEYAARIEALLRAAQEQQEKLEAALREL 28 Sequence 54 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1364 IAEYAARIEALLRAAQEQQEKLEAALREL 29 Sequence 55 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1359 ALLRAAQEQQEKLEAALRE 19 Sequence 50 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1360 ALLRAAQEQQEKLEAALREL 20 Sequence 51 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with amide C-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1361 YAARIEALLRAAQEQQEKLEAALREL 26 Sequence 52 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1357 LRAAQEQQEKLEAALRE 17 Sequence 48 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1358 LRAALQEQQEKLEAALREL 19 Sequence 49 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with amide C-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1354 AEYAARIEALLRAAQE 16 Sequence 45 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1355 IAEYAARIEALLRAAQE 17 Sequence 46 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1356 AIAEYAARIEALLRAAQE 18 Sequence 47 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1351 QQEKLEAALRE 11 Sequence 42 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1352 QQEKLEAALREL 12 Sequence 43 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with amide C-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1353 EYAARIEALLRAAQE 15 Sequence 44 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1348 AIAEYAARIEALLRALQEQQEKNEAALREL 30 Sequence 39 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1349 TTWEAWDRAIAEYAARIEALLRALQE 26 Sequence 40 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1350 YAARIEALLRAAQE 14 Sequence 41 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1345 EYAARIEALLRALQEQQEKNEAALREL 27 Sequence 36 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1346 AEYAARIEALLRALQEQQEKNEAALREL 28 Sequence 37 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1347 IAEYAARIEALLRALQEQQEKNEAALREL 29 Sequence 38 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1342 ALLRALQEQQEKNEAALRE 19 Sequence 33 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1343 ALLRALQEQQEKNEAALREL 20 Sequence 34 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with amide C-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1344 YAARIEALLRALQEQQEKNEAALREL 26 Sequence 35 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1339 LRALQEQQEKNEAALRE 17 Sequence 30 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1340 LRALQEQQEKNEAALREL 18 Sequence 31 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with amide C-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1341 TTWEAWDRAIAEYAARIE 18 Sequence 32 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with acetyl N-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1336 TTWEAWDR 8 Sequence 27 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with acetyl N-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1337 AIAEYAARIEALLRALQE 18 Sequence 28 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1338 TTWEAWDRAIAEYAARIEAL 20 Sequence 29 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with acetyl N-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1333 AEYAARIEALLRALQE 16 Sequence 24 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1334 TTWEAWDRA 9 Sequence 25 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with acetyl N-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1335 IAEYAARIEALLRALQE 17 Sequence 26 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1330 TTWEAWDRAIA 11 Sequence 21 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with acetyl N-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1331 EYAARIEALLRALQE 15 Sequence 22 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1332 TTWEAWDRAI 10 Sequence 23 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with acetyl N-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1327 YAARIEALLRALQE 14 Sequence 18 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1328 QQEKNEAALRE 11 Sequence 19 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1329 QQEKNEAALREL 12 Sequence 20 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with amide C-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1325 TTWEAWDRAIAEYAARIEALLRAAQEQQEKIEAALREL 38 Sequence 15 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1326 TTWEAWDRAIAE 12 Sequence 17 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide was modified with acetyl N-terminus. "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1322 TTWEAWDRAIAEYAARIEALIRAIQEQQEKLEAALREL 38 Sequence 12 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1323 TTWEAWDRAIAEYAARIEALIRALQEQQEKIEAALREL 38 Sequence 13 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1324 TTWEAWDRAIAEYAARIEALLRAIQEQQEKNEAALREL 38 Sequence 14 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1319 TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL 38 Sequence 9 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 ¦Ìg/ml) and HIV-Res(IC50<0.10 ¦Ìg/ml). "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1320 TTWEAWDRAIAEYAARIEALLRAAQEQQEKLEAALREL 38 Sequence 10 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 ¦Ìg/ml) and HIV-Res(IC50<0.10 ¦Ìg/ml). "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1321 TTWEAWDRAIAEYAARIEALIRALQEQQEKLEAALREL 38 Sequence 11 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1316 TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL 38 Sequence 6 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 ¦Ìg/ml) and HIV-Res(IC50>0.10 ¦Ìg/ml). "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." DRAVPe00262 Anti-HIV DRAVPa1317 TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL 38 Sequence 7 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 ¦Ìg/ml) and HIV-Res(IC50>0.10 ¦Ìg/ml). "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." DRAVPe00265 Anti-HIV DRAVPa1318 TTWEAWDRAIAEYAARIEALLRAAQEQQEKNEAALREL 38 Sequence 8 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 ¦Ìg/ml). "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1314 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL 36 Sequence 4 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." DRAVPe01974 Anti-HIV DRAVPa1315 TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL 38 Sequence 5 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 ¦Ìg/ml) and HIV-Res(IC50<0.10 ¦Ìg/ml). "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." DRAVPe00792 Anti-HIV DRAVPa1311 WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 64 Sequence 1 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." Anti-HIV DRAVPa1312 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 2 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." DRAVPe00520 Anti-HIV DRAVPa1313 MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL 36 Sequence 3 from Patent US 20100261876 A1 Synthetic construct HIV Patent Application US 2010/0261876 A1 2010-10-14 CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2 Novel Methods of Synthesis for Therapeutic Antiviral Peptides No comments found in patent "Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides." DRAVPe00255 Anti-HIV DRAVPa1309 TYICEVEDQKEE 12 Sequence 10 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1310 XPXLX 5 Sequence 11 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides "X residues at position 1 and 5 are any amino acid, and can vary from 0 residues to about 100 residues at reach position." This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1308 LKIEDSDTYICEVEDQKEE 19 Sequence 9 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1306 KWLDAFYKDVAKELEKAF 18 Sequence 7 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1307 IKILGNQGSTLTKGPYSK 18 Sequence 8 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1304 ACYCRIPACIAGERRYGTCIYQGRLWAFCC 30 Sequence 5 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. DRAVPe00299 Anti-HIV DRAVPa1305 DWLKAFYDKVAEKLKEAF 18 Sequence 6 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. DRAVPe01095 Anti-HIV DRAVPa1303 ASTTTNYT 8 Sequence 4 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1301 TKPKTKPR 8 Sequence 2 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1302 AKTKPRQQ 8 Sequence 3 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1299 GTHPSSSAGLKNDLLEN 17 Sequence 58 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1300 TKPKTKPK 8 Sequence 1 from Patent US 5447915 A Synthetic construct HIV Granted Patent US 5447915 A 1995-09-05 CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A Terminally blocked antiviral peptides No comments found in patent This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. Anti-HIV DRAVPa1297 KREITFHGAKEISLS 15 Sequence 56 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1298 EQIADSQHRSHRQMV 15 Sequence 57 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1295 LTVPSERGLQRRR 13 Sequence 54 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1296 ALNGNGDPNNMDKAVKLY 18 Sequence 55 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1293 CXTCEQIADSQHXSHRQMV 19 Sequence 52 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 2 and 13 represent NMe-Ala and NMe-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1294 CXTCEQIADSQHXSHXQMV 19 Sequence 53 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 2 represents NMe-Ala and 'X' at position 13 and 16 indicates NMe-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1291 CATCEQIADSQHXSHRQMV 19 Sequence 50 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 13 represents Nme-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1292 CATCEQIADSQHRSHXQMV 19 Sequence 51 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 16 represents NMe-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1289 CXTCEQIADSQHXSHXQMV 19 Sequence 48 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 2 represents D-Ala and 'X' at position 13 and 16 indicates D-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1290 CXTCEQIADSQHRSHRQMV 19 Sequence 49 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 2 represents NMe-Ala. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1288 CXTCEQIADSQHXSHRQMV 19 Sequence 47 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 2 and 13 represent D-Ala and D-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1286 CATCEQIADSQHXSHRQMV 19 Sequence 45 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 13 represents D-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1287 CATCEQIADSQHRSHXQMV 19 Sequence 46 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 16 represents D-Arg. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1284 CATCEQIADSQHRSHRQMI 19 Sequence 43 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1285 CXTCEQIADSQHRSHRQMV 19 Sequence 44 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The 'X' at position 2 represents D-Ala. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1282 CATCEQIADSQHRSHRNMV 19 Sequence 41 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1283 CATCEQIADSQHRSHRQML 19 Sequence 42 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1280 CATCEQIADSNHRSHRQMV 19 Sequence 39 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1281 CATCEQIADSQHRTHRQMV 19 Sequence 40 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1278 CATCEQIAESQHRSHRQMV 19 Sequence 37 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1279 CATCEQIADTQHRSHRQMV 19 Sequence 38 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1276 CATCEQLADSQHRSHRQMV 19 Sequence 35 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1277 CATCEQVADSQHRSHRQMV 19 Sequence 36 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1274 CATCDQIADSQHRSHRQMV 19 Sequence 33 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1275 CATCENIADSQHRSHRQMV 19 Sequence 34 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1272 CATCEQIADSQHKSHKQMV 19 Sequence 31 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1273 CASCEQIADSQHRSHRQMV 19 Sequence 32 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1270 CATCEQIADSQHKSHRQMV 19 Sequence 29 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1271 CATCEQIADSQHRSHKQMV 19 Sequence 30 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1268 CATCEQIADSQHRSHRQAV 19 Sequence 27 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1269 CATCEQIADSQHRSHRQMA 19 Sequence 28 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1267 CATCEQIADSQHRSHRAMV 19 Sequence 26 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1265 CATCEQIADSQHRAHRQMV 19 Sequence 24 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1266 CATCEQIADSQHRSHAQMV 19 Sequence 25 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1263 CATCEQIADSAHRSHRQMV 19 Sequence 22 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1264 CATCEQIADSQHASHRQMV 19 Sequence 23 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1261 CATCEQIAASQHRSHRQMV 19 Sequence 20 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1262 CATCEQIADAQHRSHRQMV 19 Sequence 21 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1259 CATCEAIADSQHRSHRQMV 19 Sequence 18 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1260 CATCEQAADSQHRSHRQMV 19 Sequence 19 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1257 CAACEQIADSQHRSHRQMV 19 Sequence 16 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1258 CATCAQIADSQHRSHRQMV 19 Sequence 17 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1256 CATCEQIADSQHRSHRQMV 19 Sequence 15 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1255 CATCEQIADSQHRSHRQMV 19 Sequence 14 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The peptide was modified with acetyl N-terminus and amide C-terminus. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1254 CATCEQIADSQHRHRQMV 18 Sequence 13 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents The peptide was modified with acetyl N-terminus. Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1253 CATCEQIADSQHRHRQMV 18 Sequence 12 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1252 CACEQIADSQHRSHRQMV 18 Sequence 11 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1251 CTCEQIADSQHRSHRQMV 18 Sequence 10 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1250 CATCADSQHRSHRQMV 16 Sequence 9 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1249 CATCIADSQHRSHRQMV 17 Sequence 8 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1248 CATCQIADSQHRSHRQMV 18 Sequence 7 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1247 CATCEQIADSQHRSH 15 Sequence 6 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1246 CATCEQIADSQHRSHR 16 Sequence 5 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1245 CATCEQIADSQHRSHRQ 17 Sequence 4 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1244 CATCEQIADSQHRSHRQM 18 Sequence 3 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1243 CATCEQIADSQHRSHRQMV 19 Sequence 2 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1242 CATCEQIADSQHRSHRQMV 19 Sequence 1 from Patent US 5616327 Synthetic construct influenza virus Granted Patent US 5616327 A 1997-04-01 CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2 M-protein peptides of influenza virus as antiviral agents No comments found in patent Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations. Anti-influenza virus DRAVPa1241 APGDEPAPP 9 Sequence 12 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=115 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1240 EETRRMLHRAFDTLA 15 Sequence 11 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=32.5 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1239 AGATAEETA 9 Sequence 10 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=88.5 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1238 GATAEETA 8 Sequence 9 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=240 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1237 AGATAEETAA 10 Sequence 8 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=56.6 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1236 AGATAEETAY 10 Sequence 7 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=37.5 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1235 AAAPGDEPAPP 11 Sequence 6 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=90 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1234 AAPGDEPAPP 10 Sequence 5 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=152 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1233 APGDEPAPP 9 Sequence 4 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=188 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1232 APGDEPAPPY 10 Sequence 3 from Patent US 5859187 A Synthetic construct HSV Granted Patent US 5859187 A 1999-01-12 IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A Antiviral peptides The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=161 ¦ÌM). Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. Anti-HSV DRAVPa1231 QVNEKINQSLAFIRKSDELLHNVNAGKST 29 Sequence 232 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1230 ISQVNEKINQSLAFIRKSDELLHNVNAGKST 31 Sequence 231 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1229 FDASISQVNEKINQSLAFIRKSDEL 25 Sequence 230 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1228 FDASISQVNEKINQSLAFIRKSDELLH 27 Sequence 229 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1227 FDASISQVNEKINQSLAFIRKSDELLHNV 29 Sequence 228 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1226 FDASISQVNEKINQSLAFIRKSDELLHNVNA 31 Sequence 227 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1225 DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT 35 Sequence 226 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00912 Anti-HIV DRAVPa1224 FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST 35 Sequence 225 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00911 Anti-HIV DRAVPa1223 EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS 35 Sequence 224 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00910 Anti-HIV DRAVPa1222 DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK 35 Sequence 223 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00909 Anti-HIV DRAVPa1221 SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG 35 Sequence 222 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00908 Anti-HIV DRAVPa1220 PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA 35 Sequence 221 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00907 Anti-HIV DRAVPa1219 FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN 35 Sequence 220 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00906 Anti-HIV DRAVPa1218 VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV 35 Sequence 219 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00905 Anti-HIV DRAVPa1217 LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN 35 Sequence 218 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00904 Anti-HIV DRAVPa1216 PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH 35 Sequence 217 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00903 Anti-HIV DRAVPa1215 DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL 35 Sequence 216 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00902 Anti-HIV DRAVPa1214 YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL 35 Sequence 215 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00901 Anti-HIV DRAVPa1213 FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE 35 Sequence 214 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00900 Anti-HIV DRAVPa1212 INFYDPLVFPSDEFDASISQVNEKINQSLAFIRKS 35 Sequence 213 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00898 Anti-HIV DRAVPa1211 IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRK 35 Sequence 212 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00897 Anti-HIV DRAVPa1210 DEFDASISQVNEKINQSLAFIRKSDELL 28 Sequence 211 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1209 VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV 35 Sequence 210 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1208 PGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTSTGPCRTCMTT 57 Sequence 209 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1207 PLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSP 46 Sequence 208 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1206 SENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDLLNF 37 Sequence 207 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1205 SSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDL 35 Sequence 206 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1204 LQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHED 45 Sequence 205 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1203 LLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSI 35 Sequence 204 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1202 ASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDS 45 Sequence 203 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1201 SELEIKRYKNRVASRKCRAKFQLLQHYREVAAAKSSENDRLRLLL 45 Sequence 202 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1200 MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWG 63 Sequence 201 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1199 LSNLLQISNNSDEWLEALEIEHEKWKLTQWQSYEQF 36 Sequence 200 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1198 LLDNFESTWEQSKELWEQQEISIQNLHKSALQEYWN 36 Sequence 199 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1197 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNSF 36 Sequence 198 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1196 YTSLIHSLIEESQNQQEKNEQELLELDKWASPWNWF 36 Sequence 197 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1195 YTSLIHSLIEESQNQQEKNEQELLELDKPASLWNWF 36 Sequence 196 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1194 YTSLIHSLIEESQNQQEKNEQELLEFDKWASLWNWF 36 Sequence 195 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1193 YTSLIHSLIEESQNQQEKLEQELLELDKWASLWNWF 36 Sequence 194 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1192 YTSLIHSLIEESQNLQEKNEQELLELDKWASLWNWF 36 Sequence 193 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1191 YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF 36 Sequence 192 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1190 YTSLIQSLIEESQNQQEKNEQQLLELDKWASLWNWF 36 Sequence 191 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1189 YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF 36 Sequence 190 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1188 YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA 36 Sequence 189 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1187 YTSLIHSLIQQSQNQQQKNQQQLLQLDKWASLWNWF 36 Sequence 188 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1186 YTSLIHSLIQESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 187 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1185 YTSLIHSLIEQSQNQQEKNEQELLELDKWASLWNWF 36 Sequence 186 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1184 YTSLIHSLIEESQNQQEKNEQELLELNKWASLWNWF 36 Sequence 185 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1183 YTSLIHSLIEESQQQQEKNEQELLELDKWASLWNWF 36 Sequence 184 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1182 YTSLIQSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 183 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1181 YTSLIHSLIEESQNQQEKNQQELLQLDKWASLWNWF 36 Sequence 182 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1180 YTSLIHSLIEESQNQQEKNEQELLQLDKWASLWNWF 36 Sequence 181 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1179 YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF 36 Sequence 180 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1178 YTSLIHSLIEESQNQQEKNEQELLELDKWASLANWF 36 Sequence 179 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1177 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNAF 36 Sequence 178 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1176 CGGYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 39 Sequence 177 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1175 LELKKWASLWNWF 13 Sequence 176 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1174 LKLDKWASLWNWF 13 Sequence 175 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1173 LELDKAASLWNWF 13 Sequence 174 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1172 LELDKWASAWNWF 13 Sequence 173 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1171 LELDKWASLWNWA 13 Sequence 172 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1170 LELDKWASLWNAF 13 Sequence 171 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1169 LELDKWASLFNFF 13 Sequence 170 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1168 LELDKWASLANAF 13 Sequence 169 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1167 CLELDKWASLWNFFC 15 Sequence 168 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1166 CLELDKWASLANWFC 15 Sequence 167 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1165 CLELDKWASLWNWFC 15 Sequence 166 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1164 FWNWLSAWKDLELYPGSLELDKWASLWNWF 30 Sequence 165 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1163 RMKQLEDKVEELLSKNYHLENELELDKWASLWNWF 35 Sequence 164 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1162 FWNWLSAWKDLELKSLLEEVKDELQKMR 28 Sequence 163 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1161 RMKQLEDKVEELLSKLELDKWASLWNWF 28 Sequence 162 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1160 EAAAREAAAREAAARLELDKWASLWNWF 28 Sequence 161 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1159 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWLIKIFI 49 Sequence 160 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1158 WMEWDREINNYTSLIGSLIEESQNQQEKNEQELLE 35 Sequence 159 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1157 NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEEQNQQEKNEQELLELDKWASLWNWF 57 Sequence 158 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1156 TSITLQVRLPLLTRLLNTQIYRVDSISYNIQNREWY 36 Sequence 157 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1155 YSELTNIFGDNIGSLQEKGIKLQGIASLYRTNITEI 36 Sequence 156 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1154 DQQIKQYKRLLDRLIIPLYDGLRQKDVIVSNQESN 35 Sequence 155 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1153 RMKQLEDKVEELLSKLEWIRRSNQKLDSI 29 Sequence 154 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1152 IDISIELNKAKSDLEESKEWIKKSNQKLDSIGNWH 35 Sequence 153 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1151 EWIRRSNQKLDSI 13 Sequence 152 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1150 LKEAIRDTNKAVQSVQSSIGNLIVAIKS 28 Sequence 151 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1149 AVQSVQSSIGNLIVAIKSVQDYVNKEIV 28 Sequence 150 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1148 IRDTNKAVQSVQSSIGNLIVAIKSVQDY 28 Sequence 149 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1147 AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA 35 Sequence 148 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1146 AAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSS 35 Sequence 147 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1145 ATSAQITAAVALVEAKQARSDIEKLKEA 28 Sequence 146 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1144 FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST 35 Sequence 145 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00911 Anti-HIV DRAVPa1143 ASISQVNEKINQSLAFIRKSDELLHNVNAGKST 33 Sequence 144 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1142 FDASISQVNEKINQSLAFIRKSDELLHNVNAGK 33 Sequence 143 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1141 SLAFIRKSDELLHNVNAGKST 21 Sequence 142 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1140 FDASISQVNEKINQSLAFI 19 Sequence 141 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1139 AFIRKSDELLHNVNAGKST 19 Sequence 140 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1138 RMKQLEDKVEELLSKLAFIRKSDELLHNV 29 Sequence 139 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1137 PIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR 35 Sequence 138 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1136 SISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVS 36 Sequence 137 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1135 NDQKKLMSNNVQIVRQQSYSIMSIIKEE 28 Sequence 136 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1134 VLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSK 35 Sequence 135 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50=328 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1133 ASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGV 37 Sequence 134 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1132 LLSTNKAVVSLSNGVSVLTSKVLDLKNY 28 Sequence 133 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1131 VLHLEGEVNKIKSALLSTNKAVVSLSNG 28 Sequence 132 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1130 LLSTNKAVVSLSNGVSVLTSKVLDLKNY 28 Sequence 131 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1129 VVSLSNGVSVLTSKVLDLKNYIDKQLL 27 Sequence 130 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1128 AVSKGYLSALRTGWYTSVITIELSNIKENKXNGTDA 36 Sequence 129 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1127 KENKXNGTDAKVKLIKQELDKYKNAVTELQLLMQS 35 Sequence 128 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1126 SNIKENKXNGTDAKVKLIKQELDKYKNAVTELQLL 35 Sequence 127 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1125 SVITIELSNIKENKXNGTDAKVKLIKQELDKYKNA 35 Sequence 126 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1124 TSVITIELSNIKENKXNGTDAKVKLIKQELDKYKN 35 Sequence 125 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1123 YTSVITIELSNIKENKXNGTDAKVKLIKQELDKYK 35 Sequence 124 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1122 AFIRKSDELLHNV 13 Sequence 123 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50=26 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1121 VSKGYSALRTGWYTSVITIELSNIKEN 27 Sequence 122 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group. The antiviral activity of peptide on RSV(IC50=165 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1120 IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 42 Sequence 121 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group. The antiviral activity of peptide on RSV(IC50>500 ¦Ìg/ml)." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1119 TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQKLNSWDVFGNWF 47 Sequence 120 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1118 LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK 34 Sequence 119 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1117 PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED 35 Sequence 118 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00936 Anti-HIV DRAVPa1116 YTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT 56 Sequence 101 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1115 GTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP 70 Sequence 100 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1114 GEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT 53 Sequence 99 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1113 ASGVAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL 54 Sequence 98 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1112 YTSVITIELSNIKENKCNGAKVKLIKQELDKYKNAVTELQLLMQST 46 Sequence 97 from Patent US 6228983 B1 Synthetic construct RSV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-RSV DRAVPa1111 NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 38 Sequence 89 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1110 IEKTNEKFHQIEKEFSEVEGRIQDLEKY 28 Sequence 88 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1109 EQKLISEEDLLEKRREQLKHKLEQLRNS 28 Sequence 87 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1108 IARLEEKVKTLKAQNSELASTANMLREQ 28 Sequence 86 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1107 TDTLQAETDQLEDEKSALQTEIANLLKE 28 Sequence 85 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1106 MKQLEDKVEELLSKNYHLENEVARLKKL 28 Sequence 84 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1105 LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK 34 Sequence 83 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1104 SLERLDVGTNLGNAIAKLEAKELLESSDQILRSM 34 Sequence 82 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1103 PISLERLDVGTNLGNAIAKLEAKELLESSDQILR 34 Sequence 81 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1102 PPISLERLDVGTNLGNAIAKLEAKELLESSDQIL 34 Sequence 80 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1101 GPPISLERLDVGTNLGNAIAKLEAKELLESSDQI 34 Sequence 79 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1100 LGPPISLERLDVGTNLGNAIAKLEAKELLESSDQ 34 Sequence 78 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1099 DLGPPISLERLDVGTNLGNAIAKLEAKELLESSD 34 Sequence 77 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1098 IDLGPPISLERLDVGTNLGNAIAKLEAKELLESS 34 Sequence 76 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1097 RIDLGPPISLERLDVGTNLGNAIAKLEAKELLES 34 Sequence 75 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1096 HRIDLGPPISLERLDVGTNLGNAIAKLEAKELLE 34 Sequence 74 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1095 LHRIDLGPPISLERLDVGTNLGNAIAKLEAKELL 34 Sequence 73 from Patent US 6228983 B1 Synthetic construct MeV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-MeV DRAVPa1094 FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN 35 Sequence 72 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1093 DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG 35 Sequence 71 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1092 VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF 35 Sequence 70 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1091 KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV 35 Sequence 69 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1090 RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD 35 Sequence 68 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1089 ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW 35 Sequence 67 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1088 WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS 35 Sequence 66 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1087 EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN 35 Sequence 65 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1086 QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL 35 Sequence 64 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1085 WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK 35 Sequence 63 from Patent US 6228983 B1 Synthetic construct SIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-SIV DRAVPa1084 AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV 35 Sequence 62 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1083 LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK 35 Sequence 61 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1082 KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN 35 Sequence 60 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1081 SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ 35 Sequence 59 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1080 RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV 35 Sequence 58 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1079 ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS 35 Sequence 57 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1078 QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK 35 Sequence 56 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1077 KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI 35 Sequence 55 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1076 AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA 35 Sequence 54 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1075 EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV 35 Sequence 53 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1074 VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI 35 Sequence 52 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1073 LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL 35 Sequence 51 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1072 AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI 35 Sequence 50 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1071 TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS 35 Sequence 49 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HPIV3 DRAVPa1070 ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT 35 Sequence 48 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00935 Anti-HPIV3 DRAVPa1069 IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST 35 Sequence 47 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00934 Anti-HPIV3 DRAVPa1068 SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS 35 Sequence 46 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00933 Anti-HPIV3 DRAVPa1067 ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS 35 Sequence 45 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00932 Anti-HPIV3 DRAVPa1066 DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ 35 Sequence 44 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00931 Anti-HPIV3 DRAVPa1065 IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH 35 Sequence 43 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00929 Anti-HPIV3 DRAVPa1064 PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW 35 Sequence 42 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00928 Anti-HPIV3 DRAVPa1063 DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN 35 Sequence 41 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00927 Anti-HPIV3 DRAVPa1062 LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG 35 Sequence 40 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00926 Anti-HPIV3 DRAVPa1061 ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI 35 Sequence 39 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00925 Anti-HPIV3 DRAVPa1060 VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS 35 Sequence 38 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00924 Anti-HPIV3 DRAVPa1059 SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD 35 Sequence 37 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00923 Anti-HPIV3 DRAVPa1058 NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL 35 Sequence 36 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00922 Anti-HPIV3 DRAVPa1057 NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK 35 Sequence 35 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00921 Anti-HPIV3 DRAVPa1056 LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ 35 Sequence 34 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00920 Anti-HPIV3 DRAVPa1055 TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN 35 Sequence 33 from Patent US 6228983 B1 Synthetic construct HPIV3 Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00919 Anti-HPIV3 DRAVPa1054 ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ 33 Sequence 32 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1053 IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK 33 Sequence 31 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1052 KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID 33 Sequence 30 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1051 NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI 33 Sequence 29 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1050 VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY 33 Sequence 28 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1049 EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN 33 Sequence 27 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1048 GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK 33 Sequence 26 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1047 LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD 33 Sequence 25 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1046 KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS 33 Sequence 24 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1045 SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT 33 Sequence 23 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1044 VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL 33 Sequence 22 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1043 AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV 33 Sequence 21 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1042 VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS 33 Sequence 20 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1041 ALGVATSAQITAAVALVEAKQARSDIEKLKEAIR 34 Sequence 19 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1040 ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS 35 Sequence 18 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00918 Anti-HIV DRAVPa1039 FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL 37 Sequence 17 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1038 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 48 Sequence 16 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities "The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group." "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1037 QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ 38 Sequence 10 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1036 LQARILAVERYLKDQQQ 17 Sequence 9 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1035 CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 41 Sequence 8 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1034 LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL 36 Sequence 7 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1033 LEANISKSLEQAQIQQEKNMYELQKLNSWDIFGNWF 36 Sequence 6 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1032 YTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWF 36 Sequence 5 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1031 YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF 36 Sequence 4 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1030 YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 3 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1029 SSESFTLLEQWNNWKLQLAEQWLEQINEKHYLEDIS 36 Sequence 2 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." Anti-HIV DRAVPa1028 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 1 from Patent US 6228983 B1 Synthetic construct HIV Granted Patent US 6228983 B1 2001-05-08 WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62 Human respiratory syncytial virus peptides with antifusogenic and antiviral activities No comments found in patent "The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides." DRAVPe00520 Anti-HIV DRAVPa1027 PGDVYANGLVA 11 Sequence 44 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1026 PGYAGAVVNDL 11 Sequence 43 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1025 GRKKRRQXXRC 11 Sequence 42 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The 'X' at position 8 and 9 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1024 GRKKRRQXXRC 11 Sequence 41 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The 'X' at position 8 and 9 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1023 GRXXRRQRRRC 11 Sequence 40 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The 'X' at position 3 and 4 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1022 GRKKRRQRRRC 11 Sequence 39 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01935 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1021 GRKKRRQRRRC 11 Sequence 38 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01935 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1020 GRKKRRQRRR 10 Sequence 37 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01573 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1019 GRKKRRQRRR 10 Sequence 36 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01573 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1018 GRKKRRQRRRC 11 Sequence 35 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01935 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1017 LAVLAPGRKKRRQRRRC 17 Sequence 34 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1016 LVLAAPLAVLAPGRKKRRQRRRC 23 Sequence 33 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1015 LAALPLVLAAPLAVLAPGRKKRRQRRRC 28 Sequence 32 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1014 YGRKKRRQRRRPLAALPLVLAAPLAVLA 28 Sequence 31 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1013 GRKKRRQRRRPLAALPLVLAAPLAVLA 27 Sequence 30 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1012 RRKKAAVA 8 Sequence 29 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1011 RRKKAAVAVVP 11 Sequence 28 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1010 RRKKAAVAVVPAVL 14 Sequence 27 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1009 RRKKAAVALLPAVLLAL 17 Sequence 26 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01188 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1008 RRKKLLAP 8 Sequence 25 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1007 RRKKLLALLAP 11 Sequence 24 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1006 RRKKPAVLLALLAP 14 Sequence 23 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01196 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1005 RRKKALLPAVLLALLAP 17 Sequence 22 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01193 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1004 RRKKPAVLLALLALLA 16 Sequence 21 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1003 RRKKPAVLLA 10 Sequence 20 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1002 RRKKAVAVAVPAVLLALLAP 20 Sequence 19 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1001 RRKKAAVALLP 11 Sequence 18 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01190 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa1000 RRKKLAALPLVLAAPLAVLA 20 Sequence 17 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0999 RRKK 4 Sequence 16 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0998 DPKGDPKGVTVTVTVTVTGKGDPKPD 26 Sequence 13 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0997 GWTLNSAGYLLGKINLKALAALAKKIL 27 Sequence 12 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0996 YGRKKRRQRRRPGDVYANGLVA 22 Sequence 11 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=67 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0995 YGRKKRRQRRRPGYAGAVVNDL 22 Sequence 10 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=26 ¦Ìm) and antifree virus activity(IC50=8 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0994 RQIKIFFPNRRMKFKK 16 Sequence 9 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=40 ¦Ìm) and antifree virus activity(IC50=34 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0993 RQIKIWFPNRRMKWKK 16 Sequence 8 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=7 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0992 RQIKIWFPNRRMKWKKPGYAGAVVNDL 27 Sequence 7 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=9-12 ¦Ìm) and antifree virus activity(IC50=6 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0991 KLALKLALKALKAALKLA 18 Sequence 6 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=23 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0990 KLALKLALKALKAALKLA 18 Sequence 5 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=11 ¦Ìm) and antifree virus activity(IC50=4.5 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0989 RRKKPAVLLALLA 13 Sequence 4 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0988 RRKKAAVALLAVLLALLAPP 20 Sequence 3 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0987 RRKKAAVALLPAVLLALLAP 20 Sequence 2 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=15 ¦Ìm) and antifree virus activity(IC50=21 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01185 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0986 RRKKAAVALLPAVLLALLAP 20 Sequence 1 from Patent US 7432045 B2 Synthetic construct "HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus" Granted Patent US 7432045 B2 2008-10-07 WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2 Method of inhibiting influenza infection with antiviral peptides "The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=15-26 ¦Ìm)." "This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections." DRAVPe01185 "Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus" DRAVPa0985 LTWQEWDREINNYTSLIYSLIEESQNQQEENEQELL 36 Sequence 114 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0984 SLEQIWNNMTWMEWEREIDNYTSLIYSLI 29 Sequence 99 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0983 EWEREIDNYTSLIYSLIEESQNQQEKNEQE 30 Sequence 98 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0982 NNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE 36 Sequence 97 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0981 KSLEQIWNNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE 43 Sequence 96 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0980 LIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT 36 Sequence 95 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0979 SLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI 36 Sequence 94 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0978 TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN 36 Sequence 93 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0977 NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW 36 Sequence 92 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0976 WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKW 36 Sequence 91 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0975 EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK 36 Sequence 90 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0974 MEWDREINNYTSLIHSLIEESQNQQEKNEQELLED 35 Sequence 89 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0973 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL 36 Sequence 88 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." DRAVPe01974 Anti-HIV DRAVPa0972 TWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLE 36 Sequence 87 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0971 MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL 36 Sequence 86 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." DRAVPe00255 Anti-HIV DRAVPa0970 NMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEL 36 Sequence 85 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0969 NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQE 36 Sequence 84 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0968 WNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ 36 Sequence 83 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0967 IWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNE 36 Sequence 82 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0966 QIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKN 36 Sequence 81 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0965 EQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEK 36 Sequence 80 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0964 LEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQE 36 Sequence 79 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0963 SLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQ 36 Sequence 78 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0962 KSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQ 36 Sequence 77 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0961 NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQN 36 Sequence 76 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0960 NASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLI 36 Sequence 75 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0959 QQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ 41 Sequence 74 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0958 QARQLLSGIVQQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ 51 Sequence 73 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0957 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVFGIRQLQARILAVERYLK 49 Sequence 72 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0956 QQQNNLLRAIEAQQHLLQLTVFGIKQLQARILAVERYLKDQ 41 Sequence 71 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0955 QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGVKQLQARILAVERYLKDQ 51 Sequence 70 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0954 QARQLVSGLVQQQNNILRALEAQQHALQATVWGIKQLQARVLALERYIKDQ 51 Sequence 69 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0953 QARQLLSGIVQQQNNLLRAIEATQHAVQALVWGVKQLQARVLALERYIKDQ 51 Sequence 68 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0952 QARQLVSGLVQQQNNILRALEATQHAVQALVWGVRQLQARVLALERYIK 49 Sequence 67 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0951 QIRQLLSGIVQQQNNLLRAIEAIQHALQAIVWGIKQLQARILAVERYLK 49 Sequence 66 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0950 QARQLVSGLVQQQNNILRALEATQHAVQALVWGVKQLQARVLALERYIK 49 Sequence 65 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0949 QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLKDQ 51 Sequence 64 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0948 QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLK 49 Sequence 63 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0947 QQQNNLLRAIEAQQHLLQLTVAGIKQLQARILAVERYLKDQ 41 Sequence 62 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0946 QQQNNLLRAIEAQQHLLQLTAWGIKQLQARILAVERYLKDQ 41 Sequence 61 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0945 WQEWEQKITALLEQAQIQQEKIEYELQKLIEWEWF 35 Sequence 60 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0944 WQEWEQKITALLEQAQIQQEKNEYELQKLAEWAGLWAWF 39 Sequence 59 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0943 WQEWEQKITALLEQAQIQQEKNEYELQKLDKWAGLWEWF 39 Sequence 58 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0942 WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWNWF 39 Sequence 57 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0941 WQEWEREITALLEQAQIQQEKIEYELQKLDEWEWF 35 Sequence 56 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0940 WQEWEREITALLEQAQIQQEKNEYELQKLIEWEWF 35 Sequence 55 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0939 WQEWEREITALLEQAQIQQEKIEYELQKLIEWEWF 35 Sequence 54 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0938 WQEWDREITALLEQAQIQQEKNEYELQKLDEWEWF 35 Sequence 53 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0937 WQEWDREITALLEQAQIQQEKNEYELQKLDEWASLWEWF 39 Sequence 52 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0936 WQEWDREITALLEQAQIQQEKNEYELQKLDKWASLWNWF 39 Sequence 51 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0935 WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKLEWEW 40 Sequence 50 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0934 WQEWDREISNYTSLITALLEQAQIQQEKNEYELQKLDEWASLWEWF 46 Sequence 49 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0933 WNWFITALLEQAQIQQEKNEYELQKLDKWASLWNWF 36 Sequence 48 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0932 NNMTWQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF 50 Sequence 47 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0931 WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF 46 Sequence 46 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0930 NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK 42 Sequence 45 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0929 MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 48 Sequence 44 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0928 DREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 42 Sequence 43 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0927 WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKL 36 Sequence 42 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0926 YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF 36 Sequence 41 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0925 YTSLIYSLLEKSQIQQEKNEQELLELDKWASLWNWF 36 Sequence 40 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0924 YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF 36 Sequence 39 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0923 YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 38 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0922 LSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAV 39 Sequence 37 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0921 CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC 44 Sequence 36 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0920 NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC 41 Sequence 35 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0919 NNLLRAIEAQQHLLQLTVWGIKQLQARILAV 31 Sequence 34 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0918 CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 41 Sequence 33 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0917 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL 36 Sequence 32 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." DRAVPe01974 Anti-HIV DRAVPa0916 RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 34 Sequence 31 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0915 QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 41 Sequence 30 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0914 SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 45 Sequence 29 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0913 SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 36 Sequence 28 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0912 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 51 Sequence 27 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0911 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK 49 Sequence 26 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0910 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY 47 Sequence 25 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0909 QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 42 Sequence 24 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0908 LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG 36 Sequence 23 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0907 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR 44 Sequence 22 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0906 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI 38 Sequence 21 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0905 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG 37 Sequence 20 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0904 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW 36 Sequence 19 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0903 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV 35 Sequence 18 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0902 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 34 Sequence 17 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0901 MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV 36 Sequence 16 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0900 MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 35 Sequence 15 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0899 SMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 36 Sequence 14 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0898 RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL 36 Sequence 13 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0897 ARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQ 36 Sequence 12 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0896 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI 50 Sequence 11 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0895 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV 40 Sequence 10 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0894 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL 38 Sequence 9 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0893 GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLL 36 Sequence 8 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0892 GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI 54 Sequence 7 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0891 GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT 43 Sequence 6 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0890 WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF 39 Sequence 5 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." DRAVPe00254 Anti-HIV DRAVPa0889 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 4 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." DRAVPe00520 Anti-HIV DRAVPa0888 NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 38 Sequence 3 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0887 WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 64 Sequence 2 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0886 TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGI 60 Sequence 1 from Patent US 7556813 B2 Synthetic construct HIV Granted Patent US 7556813 B2 2009-07-07 CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides No comments found in patent "Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer." Anti-HIV DRAVPa0885 WEEWDREINNYTKLIHELIEESQNQQEENEQELLX 35 Sequence 15 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 35 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0884 WEEWDREINNYTXLIHELIEESQNQQEENEQELL 34 Sequence 14 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0883 WQEWEQKITALIEQAQIQQEKNEYELQKLDKWASLWEWFX 40 Sequence 13 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 40 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=15.7 nM against HIV-1 and TC50>25000 nM against PBMC)" "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0882 WQEWEQKITALLXQAQIQQEKNEYELQKLDKWASLWEWF 39 Sequence 12 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=7.78 nM against HIV-1 and TC50>25000 nM against PBMC)" "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0881 WEEWDREINNYTELIHELIEESQNQQEKNEQELLX 35 Sequence 11 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 35 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=9.09 nM against HIV-1 and TC50>25000 nM against PBMC)" "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0880 WEEWDREINNYTXLIHELIEESQNQQEKNEWELL 34 Sequence 10 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=3.94 nM against HIV-1 and TC50>25000 nM against PBMC)" "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0879 SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELLX 45 Sequence 9 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 45 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0878 SLEQIWNNMTWEEWDREINNYTXLIHELIEESQNQQEKNEQELL 44 Sequence 8 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The 'X' at position 23 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0877 WEEWDREINNYTKLIHELIEESQNQQEENEQELL 34 Sequence 7 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0876 WQEWERKVDFLEENITALLEEAQIQQEKNMYELQ 34 Sequence 6 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0875 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL 34 Sequence 5 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." DRAVPe00519 "Anti-HIV, Anti-SIV" DRAVPa0874 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 4 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." DRAVPe00520 "Anti-HIV, Anti-SIV" DRAVPa0873 WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF 39 Sequence 3 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection." "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." DRAVPe00254 "Anti-HIV, Anti-SIV" DRAVPa0872 WEEWDREINNYTKLIHELIEESQNQQEKNEQELL 34 Sequence 2 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=1.41 nM against HIV-1 and TC50=15900 nM against PBMC)" "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0871 SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELL 44 Sequence 1 from Patent US 7575750 B2 Synthetic construct "HIV, SIV" Granted Patent US 7575750 B2 2009-08-18 WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118 Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity "The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=0.93 nM against HIV-1 and TC50=14300 nM against PBMC)" "This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections." "Anti-HIV, Anti-SIV" DRAVPa0870 NNLLRAIEAQQHMLQLTVWQIKQLQARILAVERYLKDQ 38 Sequence 545 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0869 NNLLRAIQAQQHLLQLTVWQIKQLQARILAVERYLKDQ 38 Sequence 544 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0868 NNLLRAIDAQQHLLQLTVWQIKQLQARILAVERYLKDQ 38 Sequence 543 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0867 SNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 38 Sequence 542 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0866 YTSLIHSLLEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 541 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0865 YTSLIHTLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 540 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0864 YTSLIHNLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 539 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0863 YTSLIHRLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 538 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0862 YTSLIYSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 537 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0861 YTSIIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 536 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0860 YTNLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 535 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0859 YTGLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 534 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0858 KEAIRD 6 Sequence 533 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0857 LKEAIRD 7 Sequence 532 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0856 KLKEAIRD 8 Sequence 531 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0855 EKLKEAIRD 9 Sequence 530 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0854 IEKLKEAIRD 10 Sequence 529 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0853 DIEKLKEAIRD 11 Sequence 528 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0852 SDIEKLKEAIRD 12 Sequence 527 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0851 RSDIEKLKEAIRD 13 Sequence 526 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0850 ARSDIEKLKEAIRD 14 Sequence 525 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0849 QARSDIEKLKEAIRD 15 Sequence 524 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0848 KQARSDIEKLKEAIRD 16 Sequence 523 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0847 AKQARSDIEKLKEAIRD 17 Sequence 522 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0846 EAKQARSDIEKLKEAIRD 18 Sequence 521 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0845 VEAKQARSDIEKLKEAIRD 19 Sequence 520 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0844 LVEAKQARSDIEKLKEAIRD 20 Sequence 519 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0843 ALVEAKQARSDIEKLKEAIRD 21 Sequence 518 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0842 VALVEAKQARSDIEKLKEAIRD 22 Sequence 517 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0841 AVALVEAKQARSDIEKLKEAIRD 23 Sequence 516 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0840 AAVALVEAKQARSDIEKLKEAIRD 24 Sequence 515 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0839 TAAVALVEAKQARSDIEKLKEAIRD 25 Sequence 514 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0838 ITAAVALVEAKQARSDIEKLKEAIRD 26 Sequence 513 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0837 QITAAVALVEAKQARSDIEKLKEAIRD 27 Sequence 512 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0836 AQITAAVALVEAKQARSDIEKLKEAIRD 28 Sequence 511 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0835 SAQITAAVALVEAKQARSDIEKLKEAIRD 29 Sequence 510 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0834 TSAQITAAVALVEAKQARSDIEKLKEAIRD 30 Sequence 509 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0833 ATSAQITAAVALVEAKQARSDIEKLKEAIRD 31 Sequence 508 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0832 VATSAQITAAVALVEAKQARSDIEKLKEAIRD 32 Sequence 507 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0831 GVATSAQITAAVALVEAKQARSDIEKLKEAIRD 33 Sequence 506 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0830 LGVATSAQITAAVALVEAKQARSDIEKLKEAIRD 34 Sequence 505 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0829 ALGVAT 6 Sequence 504 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0828 ALGVATS 7 Sequence 503 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0827 ALGVATSA 8 Sequence 502 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0826 ALGVATSAQ 9 Sequence 501 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0825 ALGVATSAQI 10 Sequence 500 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0824 ALGVATSAQIT 11 Sequence 499 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0823 ALGVATSAQITA 12 Sequence 498 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0822 ALGVATSAQITAA 13 Sequence 497 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0821 ALGVATSAQITAAV 14 Sequence 496 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0820 ALGVATSAQITAAVA 15 Sequence 495 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0819 ALGVATSAQITAAVAL 16 Sequence 494 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0818 ALGVATSAQITAAVALV 17 Sequence 493 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0817 ALGVATSAQITAAVALVE 18 Sequence 492 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0816 ALGVATSAQITAAVALVEA 19 Sequence 491 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0815 ALGVATSAQITAAVALVEAK 20 Sequence 490 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0814 ALGVATSAQITAAVALVEAKQ 21 Sequence 489 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0813 ALGVATSAQITAAVALVEAKQA 22 Sequence 488 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0812 ALGVATSAQITAAVALVEAKQAR 23 Sequence 487 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0811 ALGVATSAQITAAVALVEAKQARS 24 Sequence 486 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0810 ALGVATSAQITAAVALVEAKQARSD 25 Sequence 485 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0809 ALGVATSAQITAAVALVEAKQARSDI 26 Sequence 484 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0808 ALGVATSAQITAAVALVEAKQARSDIE 27 Sequence 483 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0807 ALGVATSAQITAAVALVEAKQARSDIEK 28 Sequence 482 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0806 ALGVATSAQITAAVALVEAKQARSDIEKL 29 Sequence 481 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0805 ALGVATSAQITAAVALVEAKQARSDIEKLK 30 Sequence 480 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0804 ALGVATSAQITAAVALVEAKQARSDIEKLKE 31 Sequence 479 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0803 ALGVATSAQITAAVALVEAKQARSDIEKLKEA 32 Sequence 478 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0802 ALGVATSAQITAAVALVEAKQARSDIEKLKEAI 33 Sequence 477 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0801 ALGVATSAQITAAVALVEAKQARSDIEKLKEAIR 34 Sequence 476 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0799 KEWIRRS 7 Sequence 474 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0800 EWIRRS 6 Sequence 475 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0798 SKEWIRRS 8 Sequence 473 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0797 ESKEWIRRS 9 Sequence 472 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0796 EESKEWIRRS 10 Sequence 471 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0795 LEESKEWIRRS 11 Sequence 470 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0793 SDLEESKEWIRRS 13 Sequence 468 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0794 DLEESKEWIRRS 12 Sequence 469 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0792 KSDLEESKEWIRRS 14 Sequence 467 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0790 KAKSDLEESKEWIRRS 16 Sequence 465 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0791 AKSDLEESKEWIRRS 15 Sequence 466 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0789 NKAKSDLEESKEWIRRS 17 Sequence 464 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0788 LNKAKSDLEESKEWIRRS 18 Sequence 463 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0786 IELNKAKSDLEESKEWIRRS 20 Sequence 461 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0787 ELNKAKSDLEESKEWIRRS 19 Sequence 462 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0785 SIELNKAKSDLEESKEWIRRS 21 Sequence 460 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0784 ISIELNKAKSDLEESKEWIRRS 22 Sequence 459 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0783 DISIELNKAKSDLEESKEWIRRS 23 Sequence 458 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0782 IDISIELNKAKSDLEESKEWIRRS 24 Sequence 457 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0781 PIDISIELNKAKSDLEESKEWIRRS 25 Sequence 456 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0780 DPIDISIELNKAKSDLEESKEWIRRS 26 Sequence 455 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0779 LDPIDISIELNKAKSDLEESKEWIRRS 27 Sequence 454 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0778 ALDPIDISIELNKAKSDLEESKEWIRRS 28 Sequence 453 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0776 SVALDPIDISIELNKAKSDLEESKEWIRRS 30 Sequence 451 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0777 VALDPIDISIELNKAKSDLEESKEWIRRS 29 Sequence 452 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0775 NSVALDPIDISIELNKAKSDLEESKEWIRRS 31 Sequence 450 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0774 NNSVALDPIDISIELNKAKSDLEESKEWIRRS 32 Sequence 449 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0773 LNNSVALDPIDISIELNKAKSDLEESKEWIRRS 33 Sequence 448 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0772 TLNNSVALDPIDISIELNKAKSDLEESKEWIRRS 34 Sequence 447 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0771 ITLNNS 6 Sequence 446 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0770 ITLNNSV 7 Sequence 445 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0769 ITLNNSVA 8 Sequence 444 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0768 ITLNNSVAL 9 Sequence 443 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0767 ITLNNSVALD 10 Sequence 442 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0766 ITLNNSVALDP 11 Sequence 441 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0764 ITLNNSVALDPID 13 Sequence 439 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0765 ITLNNSVALDPI 12 Sequence 440 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0763 ITLNNSVALDPIDI 14 Sequence 438 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0762 ITLNNSVALDPIDIS 15 Sequence 437 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0761 ITLNNSVALDPIDISI 16 Sequence 436 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0760 ITLNNSVALDPIDISIE 17 Sequence 435 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0759 ITLNNSVALDPIDISIEL 18 Sequence 434 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0758 ITLNNSVALDPIDISIELN 19 Sequence 433 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0757 ITLNNSVALDPIDISIELNK 20 Sequence 432 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0756 ITLNNSVALDPIDISIELNKA 21 Sequence 431 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0755 ITLNNSVALDPIDISIELNKAK 22 Sequence 430 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0754 ITLNNSVALDPIDISIELNKAKS 23 Sequence 429 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0752 ITLNNSVALDPIDISIELNKAKSDL 25 Sequence 427 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0753 ITLNNSVALDPIDISIELNKAKSD 24 Sequence 428 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0751 ITLNNSVALDPIDISIELNKAKSDLE 26 Sequence 426 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0750 ITLNNSVALDPIDISIELNKAKSDLEE 27 Sequence 425 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0749 ITLNNSVALDPIDISIELNKAKSDLEES 28 Sequence 424 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0748 ITLNNSVALDPIDISIELNKAKSDLEESK 29 Sequence 423 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0747 ITLNNSVALDPIDISIELNKAKSDLEESKE 30 Sequence 422 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0746 ITLNNSVALDPIDISIELNKAKSDLEESKEW 31 Sequence 421 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0745 ITLNNSVALDPIDISIELNKAKSDLEESKEWI 32 Sequence 420 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0744 ITLNNSVALDPIDISIELNKAKSDLEESKEWIR 33 Sequence 419 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0743 ITLNNSVALDPIDISIELNKAKSDLEESKEWIRR 34 Sequence 418 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0742 ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS 35 Sequence 417 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00918 Anti-HPV 3 DRAVPa0741 KSDELL 6 Sequence 416 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0740 RKSDELL 7 Sequence 415 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0738 FIRKSDELL 9 Sequence 413 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0739 IRKSDELL 8 Sequence 414 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0737 AFIRKSDELL 10 Sequence 412 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0736 LAFIRKSDELL 11 Sequence 411 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0735 SLAFIRKSDELL 12 Sequence 410 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0734 QSLAFIRKSDELL 13 Sequence 409 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0733 NQSLAFIRKSDELL 14 Sequence 408 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0732 INQSLAFIRKSDELL 15 Sequence 407 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0731 KINQSLAFIRKSDELL 16 Sequence 406 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0730 EKINQSLAFIRKSDELL 17 Sequence 405 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0729 NEKINQSLAFIRKSDELL 18 Sequence 404 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0727 QVNEKINQSLAFIRKSDELL 20 Sequence 402 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0728 VNEKINQSLAFIRKSDELL 19 Sequence 403 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0726 SQVNEKINQSLAFIRKSDELL 21 Sequence 401 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0725 ISQVNEKINQSLAFIRKSDELL 22 Sequence 400 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0724 SISQVNEKINQSLAFIRKSDELL 23 Sequence 399 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0723 ASISQVNEKINQSLAFIRKSDELL 24 Sequence 398 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0722 DASISQVNEKINQSLAFIRKSDELL 25 Sequence 397 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0721 FDASISQVNEKINQSLAFIRKSDELL 26 Sequence 396 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0720 EFDASISQVNEKINQSLAFIRKSDELL 27 Sequence 395 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0719 DEFDASISQVNEKINQSLAFIRKSDELL 28 Sequence 394 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0718 SDEFDASISQVNEKINQSLAFIRKSDELL 29 Sequence 393 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0717 PSDEFDASISQVNEKINQSLAFIRKSDELL 30 Sequence 392 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0716 FPSDEFDASISQVNEKINQSLAFIRKSDELL 31 Sequence 391 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0714 LVFPSDEFDASISQVNEKINQSLAFIRKSDELL 33 Sequence 389 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0715 VFPSDEFDASISQVNEKINQSLAFIRKSDELL 32 Sequence 390 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0713 PLVFPSDEFDASISQVNEKINQSLAFIRKSDELL 34 Sequence 388 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0712 DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL 35 Sequence 387 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00902 Anti-RSV DRAVPa0711 YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL 36 Sequence 386 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0710 FYDPLV 6 Sequence 385 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0709 FYDPLVF 7 Sequence 384 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0708 FYDPLVFP 8 Sequence 383 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0707 FYDPLVFPS 9 Sequence 382 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0706 FYDPLVFPSD 10 Sequence 381 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0705 FYDPLVFPSDE 11 Sequence 380 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0703 FYDPLVFPSDEFD 13 Sequence 378 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0704 FYDPLVFPSDEF 12 Sequence 379 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0702 FYDPLVFPSDEFDA 14 Sequence 377 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0701 FYDPLVFPSDEFDAS 15 Sequence 376 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0700 FYDPLVFPSDEFDASI 16 Sequence 375 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0699 FYDPLVFPSDEFDASIS 17 Sequence 374 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0698 FYDPLVFPSDEFDASISQ 18 Sequence 373 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0697 FYDPLVFPSDEFDASISQV 19 Sequence 372 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0696 FYDPLVFPSDEFDASISQVN 20 Sequence 371 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0695 FYDPLVFPSDEFDASISQVNE 21 Sequence 370 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0694 FYDPLVFPSDEFDASISQVNEK 22 Sequence 369 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0693 FYDPLVFPSDEFDASISQVNEKI 23 Sequence 368 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0691 FYDPLVFPSDEFDASISQVNEKINQ 25 Sequence 366 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0692 FYDPLVFPSDEFDASISQVNEKIN 24 Sequence 367 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0690 FYDPLVFPSDEFDASISQVNEKINQS 26 Sequence 365 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0689 FYDPLVFPSDEFDASISQVNEKINQSL 27 Sequence 364 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0688 FYDPLVFPSDEFDASISQVNEKINQSLA 28 Sequence 363 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0687 FYDPLVFPSDEFDASISQVNEKINQSLAF 29 Sequence 362 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0686 FYDPLVFPSDEFDASISQVNEKINQSLAFI 30 Sequence 361 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0685 FYDPLVFPSDEFDASISQVNEKINQSLAFIR 31 Sequence 360 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0684 FYDPLVFPSDEFDASISQVNEKINQSLAFIRK 32 Sequence 359 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0683 FYDPLVFPSDEFDASISQVNEKINQSLAFIRKS 33 Sequence 358 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0682 FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSD 34 Sequence 357 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0681 FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE 35 Sequence 356 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00900 Anti-RSV DRAVPa0680 FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL 36 Sequence 355 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0679 FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL 37 Sequence 354 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0678 LLMQST 6 Sequence 353 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0676 LQLLMQST 8 Sequence 351 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0677 QLLMQST 7 Sequence 352 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0675 ELQLLMQST 9 Sequence 350 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0673 VTELQLLMQST 11 Sequence 348 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0674 TELQLLMQST 10 Sequence 349 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0672 AVTELQLLMQST 12 Sequence 347 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0671 NAVTELQLLMQST 13 Sequence 346 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0669 YKNAVTELQLLMQST 15 Sequence 344 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0670 KNAVTELQLLMQST 14 Sequence 345 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0668 KYKNAVTELQLLMQST 16 Sequence 343 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0666 LDKYKNAVTELQLLMQST 18 Sequence 341 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0667 DKYKNAVTELQLLMQST 17 Sequence 342 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0665 ELDKYKNAVTELQLLMQST 19 Sequence 340 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0663 KQELDKYKNAVTELQLLMQST 21 Sequence 338 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0664 QELDKYKNAVTELQLLMQST 20 Sequence 339 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0661 LIKQELDKYKNAVTELQLLMQST 23 Sequence 336 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0662 IKQELDKYKNAVTELQLLMQST 22 Sequence 337 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0660 KLIKQELDKYKNAVTELQLLMQST 24 Sequence 335 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0659 VKLIKQELDKYKNAVTELQLLMQST 25 Sequence 334 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0657 AKVKLIKQELDKYKNAVTELQLLMQST 27 Sequence 332 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0658 KVKLIKQELDKYKNAVTELQLLMQST 26 Sequence 333 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0656 DAKVKLIKQELDKYKNAVTELQLLMQST 28 Sequence 331 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0654 GTDAKVKLIKQELDKYKNAVTELQLLMQST 30 Sequence 329 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0655 TDAKVKLIKQELDKYKNAVTELQLLMQST 29 Sequence 330 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0653 NGTDAKVKLIKQELDKYKNAVTELQLLMQST 31 Sequence 328 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0652 CNGTDAKVKLIKQELDKYKNAVTELQLLMQST 32 Sequence 327 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0650 NKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 34 Sequence 325 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0651 KCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 33 Sequence 326 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0649 KENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 36 Sequence 324 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0647 NIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 38 Sequence 322 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0648 IKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 37 Sequence 323 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0646 SNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 39 Sequence 321 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0645 LSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 40 Sequence 320 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0643 IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 42 Sequence 318 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0644 ELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 41 Sequence 319 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0642 TIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 43 Sequence 317 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0641 ITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 44 Sequence 316 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0639 SVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 46 Sequence 314 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0640 VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 45 Sequence 315 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0638 TSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 47 Sequence 313 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0636 YTSVITI 7 Sequence 311 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0637 YTSVIT 6 Sequence 312 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0635 YTSVITIE 8 Sequence 310 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0634 YTSVITIEL 9 Sequence 309 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0632 YTSVITIELSN 11 Sequence 307 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0633 YTSVITIELS 10 Sequence 308 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0631 YTSVITIELSNI 12 Sequence 306 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0629 YTSVITIELSNIKE 14 Sequence 304 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0630 YTSVITIELSNIK 13 Sequence 305 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0628 YTSVITIELSNIKEN 15 Sequence 303 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0626 YTSVITIELSNIKENKC 17 Sequence 301 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0627 YTSVITIELSNIKENK 16 Sequence 302 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0625 YTSVITIELSNIKENKCN 18 Sequence 300 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0624 YTSVITIELSNIKENKCNG 19 Sequence 299 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0622 YTSVITIELSNIKENKCNGTD 21 Sequence 297 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0623 YTSVITIELSNIKENKCNGT 20 Sequence 298 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0621 YTSVITIELSNIKENKCNGTDA 22 Sequence 296 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0619 YTSVITIELSNIKENKCNGTDAKV 24 Sequence 294 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0620 YTSVITIELSNIKENKCNGTDAK 23 Sequence 295 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0618 YTSVITIELSNIKENKCNGTDAKVK 25 Sequence 293 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0617 YTSVITIELSNIKENKCNGTDAKVKL 26 Sequence 292 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0615 YTSVITIELSNIKENKCNGTDAKVKLIK 28 Sequence 290 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0616 YTSVITIELSNIKENKCNGTDAKVKLI 27 Sequence 291 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0614 YTSVITIELSNIKENKCNGTDAKVKLIKQ 29 Sequence 289 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0613 YTSVITIELSNIKENKCNGTDAKVKLIKQE 30 Sequence 288 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0612 YTSVITIELSNIKENKCNGTDAKVKLIKQEL 31 Sequence 287 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0611 YTSVITIELSNIKENKCNGTDAKVKLIKQELD 32 Sequence 286 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0610 YTSVITIELSNIKENKCNGTDAKVKLIKQELDK 33 Sequence 285 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0609 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKY 34 Sequence 284 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0608 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYK 35 Sequence 283 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0607 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKN 36 Sequence 282 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0606 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNA 37 Sequence 281 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0605 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV 38 Sequence 280 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0604 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVT 39 Sequence 279 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0602 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTEL 41 Sequence 277 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0603 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTE 40 Sequence 278 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0601 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQ 42 Sequence 276 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0600 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQL 43 Sequence 275 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0599 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLL 44 Sequence 274 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0597 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQ 46 Sequence 272 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0598 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLM 45 Sequence 273 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0596 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQS 47 Sequence 271 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0595 VFTNWL 6 Sequence 270 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0593 WDVFTNWL 8 Sequence 268 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0594 DVFTNWL 7 Sequence 269 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0592 SWDVFTNWL 9 Sequence 267 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0591 NSWDVFTNWL 10 Sequence 266 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0590 LNSWDVFTNWL 11 Sequence 265 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0589 KLNSWDVFTNWL 12 Sequence 264 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0587 LQKLNSWDVFTNWL 14 Sequence 262 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0588 QKLNSWDVFTNWL 13 Sequence 263 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0586 ELQKLNSWDVFTNWL 15 Sequence 261 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0585 YELQKLNSWDVFTNWL 16 Sequence 260 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0584 MYELQKLNSWDVFTNWL 17 Sequence 259 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0582 KNMYELQKLNSWDVFTNWL 19 Sequence 257 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0583 NMYELQKLNSWDVFTNWL 18 Sequence 258 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0581 EKNMYELQKLNSWDVFTNWL 20 Sequence 256 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0580 QEKNMYELQKLNSWDVFTNWL 21 Sequence 255 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0579 QQEKNMYELQKLNSWDVFTNWL 22 Sequence 254 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0578 IQQEKNMYELQKLNSWDVFTNWL 23 Sequence 253 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0576 AQIQQEKNMYELQKLNSWDVFTNWL 25 Sequence 251 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0577 QIQQEKNMYELQKLNSWDVFTNWL 24 Sequence 252 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0575 QAQIQQEKNMYELQKLNSWDVFTNWL 26 Sequence 250 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0574 EQAQIQQEKNMYELQKLNSWDVFTNWL 27 Sequence 249 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0573 LEQAQIQQEKNMYELQKLNSWDVFTNWL 28 Sequence 248 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0572 SLEQAQIQQEKNMYELQKLNSWDVFTNWL 29 Sequence 247 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0570 SQSLEQAQIQQEKNMYELQKLNSWDVFTNWL 31 Sequence 245 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0571 QSLEQAQIQQEKNMYELQKLNSWDVFTNWL 30 Sequence 246 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0569 ISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL 32 Sequence 244 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0568 NISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL 33 Sequence 243 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0567 ANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL 34 Sequence 242 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0565 LEANIS 6 Sequence 240 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0566 EANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL 35 Sequence 241 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0564 LEANISQ 7 Sequence 239 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0563 LEANISQS 8 Sequence 238 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0562 LEANISQSL 9 Sequence 237 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0561 LEANISQSLE 10 Sequence 236 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0559 LEANISQSLEQA 12 Sequence 234 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0560 LEANISQSLEQ 11 Sequence 235 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0558 LEANISQSLEQAQ 13 Sequence 233 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0557 LEANISQSLEQAQI 14 Sequence 232 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0556 LEANISQSLEQAQIQ 15 Sequence 231 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0554 LEANISQSLEQAQIQQE 17 Sequence 229 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0555 LEANISQSLEQAQIQQ 16 Sequence 230 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0553 LEANISQSLEQAQIQQEK 18 Sequence 228 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0552 LEANISQSLEQAQIQQEKN 19 Sequence 227 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0551 LEANISQSLEQAQIQQEKNM 20 Sequence 226 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0550 LEANISQSLEQAQIQQEKNMY 21 Sequence 225 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0548 LEANISQSLEQAQIQQEKNMYEL 23 Sequence 223 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0549 LEANISQSLEQAQIQQEKNMYE 22 Sequence 224 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0547 LEANISQSLEQAQIQQEKNMYELQ 24 Sequence 222 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0546 LEANISQSLEQAQIQQEKNMYELQK 25 Sequence 221 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0545 LEANISQSLEQAQIQQEKNMYELQKL 26 Sequence 220 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0544 LEANISQSLEQAQIQQEKNMYELQKLN 27 Sequence 219 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0542 LEANISQSLEQAQIQQEKNMYELQKLNSW 29 Sequence 217 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0543 LEANISQSLEQAQIQQEKNMYELQKLNS 28 Sequence 218 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0541 LEANISQSLEQAQIQQEKNMYELQKLNSWD 30 Sequence 216 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0540 LEANISQSLEQAQIQQEKNMYELQKLNSWDV 31 Sequence 215 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0539 LEANISQSLEQAQIQQEKNMYELQKLNSWDVF 32 Sequence 214 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0538 LEANISQSLEQAQIQQEKNMYELQKLNSWDVFT 33 Sequence 213 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0536 LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNW 35 Sequence 211 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0537 LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTN 34 Sequence 212 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0535 RYLKDQ 6 Sequence 210 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0534 ERYLKDQ 7 Sequence 209 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0533 VERYLKDQ 8 Sequence 208 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0531 LAVERYLKDQ 10 Sequence 206 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0532 AVERYLKDQ 9 Sequence 207 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0530 ILAVERYLKDQ 11 Sequence 205 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0529 RILAVERYLKDQ 12 Sequence 204 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0528 ARILAVERYLKDQ 13 Sequence 203 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0526 LQARILAVERYLKDQ 15 Sequence 201 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0527 QARILAVERYLKDQ 14 Sequence 202 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0525 QLQARILAVERYLKDQ 16 Sequence 200 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0524 KQLQARILAVERYLKDQ 17 Sequence 199 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0523 IKQLQARILAVERYLKDQ 18 Sequence 198 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0522 QIKQLQARILAVERYLKDQ 19 Sequence 197 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0520 VWQIKQLQARILAVERYLKDQ 21 Sequence 195 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0521 WQIKQLQARILAVERYLKDQ 20 Sequence 196 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0519 TVWQIKQLQARILAVERYLKDQ 22 Sequence 194 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0518 LTVWQIKQLQARILAVERYLKDQ 23 Sequence 193 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0517 QLTVWQIKQLQARILAVERYLKDQ 24 Sequence 192 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0516 LQLTVWQIKQLQARILAVERYLKDQ 25 Sequence 191 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0514 HLLQLTVWQIKQLQARILAVERYLKDQ 27 Sequence 189 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0515 LLQLTVWQIKQLQARILAVERYLKDQ 26 Sequence 190 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0513 QHLLQLTVWQIKQLQARILAVERYLKDQ 28 Sequence 188 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0512 QQHLLQLTVWQIKQLQARILAVERYLKDQ 29 Sequence 187 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0511 AQQHLLQLTVWQIKQLQARILAVERYLKDQ 30 Sequence 186 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0509 IEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 32 Sequence 184 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0510 EAQQHLLQLTVWQIKQLQARILAVERYLKDQ 31 Sequence 185 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0508 AIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 33 Sequence 183 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0507 RAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 34 Sequence 182 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0506 LRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 35 Sequence 181 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0505 LLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 36 Sequence 180 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0503 NNLLRA 6 Sequence 178 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0504 NLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 37 Sequence 179 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0502 NNLLRAI 7 Sequence 177 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0500 NNLLRAIEA 9 Sequence 175 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0501 NNLLRAIE 8 Sequence 176 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0499 NNLLRAIEAQ 10 Sequence 174 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0498 NNLLRAIEAQQ 11 Sequence 173 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0496 NNLLRAIEAQQHL 13 Sequence 171 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0497 NNLLRAIEAQQH 12 Sequence 172 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0495 NNLLRAIEAQQHLL 14 Sequence 170 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0493 NNLLRAIEAQQHLLQL 16 Sequence 168 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0494 NNLLRAIEAQQHLLQ 15 Sequence 169 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0492 NNLLRAIEAQQHLLQLT 17 Sequence 167 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0491 NNLLRAIEAQQHLLQLTV 18 Sequence 166 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0489 NNLLRAIEAQQHLLQLTVWQ 20 Sequence 164 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0490 NNLLRAIEAQQHLLQLTVW 19 Sequence 165 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0488 NNLLRAIEAQQHLLQLTVWQI 21 Sequence 163 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0486 NNLLRAIEAQQHLLQLTVWQIKQ 23 Sequence 161 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0487 NNLLRAIEAQQHLLQLTVWQIK 22 Sequence 162 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0485 NNLLRAIEAQQHLLQLTVWQIKQL 24 Sequence 160 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0484 NNLLRAIEAQQHLLQLTVWQIKQLQ 25 Sequence 159 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0482 NNLLRAIEAQQHLLQLTVWQIKQLQAR 27 Sequence 157 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0483 NNLLRAIEAQQHLLQLTVWQIKQLQA 26 Sequence 158 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0481 NNLLRAIEAQQHLLQLTVWQIKQLQARI 28 Sequence 156 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0480 NNLLRAIEAQQHLLQLTVWQIKQLQARIL 29 Sequence 155 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0478 NNLLRAIEAQQHLLQLTVWQIKQLQARILAV 31 Sequence 153 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0479 NNLLRAIEAQQHLLQLTVWQIKQLQARILA 30 Sequence 154 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0477 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVE 32 Sequence 152 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0476 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVER 33 Sequence 151 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0474 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYL 35 Sequence 149 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0475 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERY 34 Sequence 150 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0473 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLK 36 Sequence 148 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0472 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKD 37 Sequence 147 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0470 ASLWNWF 7 Sequence 145 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0471 SLWNWF 6 Sequence 146 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0469 WASLWNWF 8 Sequence 144 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0468 KWASLWNWF 9 Sequence 143 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0466 LDKWASLWNWF 11 Sequence 141 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0467 DKWASLWNWF 10 Sequence 142 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0465 ELDKWASLWNWF 12 Sequence 140 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0464 LELDKWASLWNWF 13 Sequence 139 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0462 ELLELDKWASLWNWF 15 Sequence 137 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0463 LLELDKWASLWNWF 14 Sequence 138 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0461 QELLELDKWASLWNWF 16 Sequence 136 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0460 EQELLELDKWASLWNWF 17 Sequence 135 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0458 KNEQELLELDKWASLWNWF 19 Sequence 133 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0459 NEQELLELDKWASLWNWF 18 Sequence 134 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0457 EKNEQELLELDKWASLWNWF 20 Sequence 132 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0456 QEKNEQELLELDKWASLWNWF 21 Sequence 131 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0454 NQQEKNEQELLELDKWASLWNWF 23 Sequence 129 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0455 QQEKNEQELLELDKWASLWNWF 22 Sequence 130 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0453 QNQQEKNEQELLELDKWASLWNWF 24 Sequence 128 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0452 SQNQQEKNEQELLELDKWASLWNWF 25 Sequence 127 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0450 EESQNQQEKNEQELLELDKWASLWNWF 27 Sequence 125 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0451 ESQNQQEKNEQELLELDKWASLWNWF 26 Sequence 126 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0449 IEESQNQQEKNEQELLELDKWASLWNWF 28 Sequence 124 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0448 LIEESQNQQEKNEQELLELDKWASLWNWF 29 Sequence 123 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0446 HSLIEESQNQQEKNEQELLELDKWASLWNWF 31 Sequence 121 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0447 SLIEESQNQQEKNEQELLELDKWASLWNWF 30 Sequence 122 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0445 IHSLIEESQNQQEKNEQELLELDKWASLWNWF 32 Sequence 120 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0444 LIHSLIEESQNQQEKNEQELLELDKWASLWNWF 33 Sequence 119 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0442 TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 35 Sequence 117 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0443 SLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 34 Sequence 118 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0441 YTSLIH 6 Sequence 116 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0440 YTSLIHS 7 Sequence 115 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0438 YTSLIHSLI 9 Sequence 113 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0439 YTSLIHSL 8 Sequence 114 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0437 YTSLIHSLIE 10 Sequence 112 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0436 YTSLIHSLIEE 11 Sequence 111 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0434 YTSLIHSLIEESQ 13 Sequence 109 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0435 YTSLIHSLIEES 12 Sequence 110 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0433 YTSLIHSLIEESQN 14 Sequence 108 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0432 YTSLIHSLIEESQNQ 15 Sequence 107 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0431 YTSLIHSLIEESQNQQ 16 Sequence 106 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0429 YTSLIHSLIEESQNQQEK 18 Sequence 104 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0430 YTSLIHSLIEESQNQQE 17 Sequence 105 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0428 YTSLIHSLIEESQNQQEKN 19 Sequence 103 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0427 YTSLIHSLIEESQNQQEKNE 20 Sequence 102 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0425 YTSLIHSLIEESQNQQEKNEQE 22 Sequence 100 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0426 YTSLIHSLIEESQNQQEKNEQ 21 Sequence 101 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0424 YTSLIHSLIEESQNQQEKNEQEL 23 Sequence 99 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0423 YTSLIHSLIEESQNQQEKNEQELL 24 Sequence 98 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0421 YTSLIHSLIEESQNQQEKNEQELLEL 26 Sequence 96 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0422 YTSLIHSLIEESQNQQEKNEQELLE 25 Sequence 97 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0420 YTSLIHSLIEESQNQQEKNEQELLELD 27 Sequence 95 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0419 YTSLIHSLIEESQNQQEKNEQELLELDK 28 Sequence 94 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00675 Anti-HIV DRAVPa0417 YTSLIHSLIEESQNQQEKNEQELLELDKWA 30 Sequence 92 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0418 YTSLIHSLIEESQNQQEKNEQELLELDKW 29 Sequence 93 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0416 YTSLIHSLIEESQNQQEKNEQELLELDKWAS 31 Sequence 91 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0415 YTSLIHSLIEESQNQQEKNEQELLELDKWASL 32 Sequence 90 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0413 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWN 34 Sequence 88 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0414 YTSLIHSLIEESQNQQEKNEQELLELDKWASLW 33 Sequence 89 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0412 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW 35 Sequence 87 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0411 LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK 34 Sequence 86 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0409 PISLERLDVGTNLGNAIAKLEAKELLESSDQILR 34 Sequence 84 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0410 SLERLDVGTNLGNAIAKLEAKELLESSDQILRSM 34 Sequence 85 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0408 PPISLERLDVGTNLGNAIAKLEAKELLESSDQIL 34 Sequence 83 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0407 GPPISLERLDVGTNLGNAIAKLEAKELLESSDQI 34 Sequence 82 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0405 DLGPPISLERLDVGTNLGNAIAKLEAKELLESSD 34 Sequence 80 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0406 LGPPISLERLDVGTNLGNAIAKLEAKELLESSDQ 34 Sequence 81 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0404 IDLGPPISLERLDVGTNLGNAIAKLEAKELLESS 34 Sequence 79 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0403 RIDLGPPISLERLDVGTNLGNAIAKLEAKELLES 34 Sequence 78 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0401 LHRIDLGPPISLERLDVGTNLGNAIAKLEAKELL 34 Sequence 76 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0402 HRIDLGPPISLERLDVGTNLGNAIAKLEAKELLE 34 Sequence 77 from Patent US 7582301 B1 Synthetic construct MeV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-MeV DRAVPa0400 LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK 34 Sequence 75 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0399 PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED 35 Sequence 74 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00936 Anti-HIV DRAVPa0397 DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG 35 Sequence 72 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0398 FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN 35 Sequence 73 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0396 VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF 35 Sequence 71 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0395 KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV 35 Sequence 70 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0393 ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW 35 Sequence 68 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0394 RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD 35 Sequence 69 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0392 WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS 35 Sequence 67 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0391 EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN 35 Sequence 66 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0390 QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL 35 Sequence 65 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0388 TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQKLNSWDVFGNWF 47 Sequence 63 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0389 WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK 35 Sequence 64 from Patent US 7582301 B1 Synthetic construct SIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-SIV DRAVPa0387 AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV 35 Sequence 62 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0386 LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK 35 Sequence 61 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0384 SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ 35 Sequence 59 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0385 KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN 35 Sequence 60 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0383 RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV 35 Sequence 58 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0382 ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS 35 Sequence 57 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0380 KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI 35 Sequence 55 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0381 QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK 35 Sequence 56 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0379 AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA 35 Sequence 54 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0378 EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV 35 Sequence 53 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0376 LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL 35 Sequence 51 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0377 VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI 35 Sequence 52 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0375 AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI 35 Sequence 50 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0374 TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS 35 Sequence 49 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HPV 3 DRAVPa0372 IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST 35 Sequence 47 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00934 Anti-HPV 3 DRAVPa0373 ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT 35 Sequence 48 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00935 Anti-HPV 3 DRAVPa0371 SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS 35 Sequence 46 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00933 Anti-HPV 3 DRAVPa0370 ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS 35 Sequence 45 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00932 Anti-HPV 3 DRAVPa0368 IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH 35 Sequence 43 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00929 Anti-HPV 3 DRAVPa0369 DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ 35 Sequence 44 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00931 Anti-HPV 3 DRAVPa0367 PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW 35 Sequence 42 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00928 Anti-HPV 3 DRAVPa0366 DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN 35 Sequence 41 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00927 Anti-HPV 3 DRAVPa0365 LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG 35 Sequence 40 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00926 Anti-HPV 3 DRAVPa0363 VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS 35 Sequence 38 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00924 Anti-HPV 3 DRAVPa0364 ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI 35 Sequence 39 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00925 Anti-HPV 3 DRAVPa0362 SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD 35 Sequence 37 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00923 Anti-HPV 3 DRAVPa0361 NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL 35 Sequence 36 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00922 Anti-HPV 3 DRAVPa0359 LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ 35 Sequence 34 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00920 Anti-HPV 3 DRAVPa0360 NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK 35 Sequence 35 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00921 Anti-HPV 3 DRAVPa0358 TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN 35 Sequence 33 from Patent US 7582301 B1 Synthetic construct HPV 3 Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00919 Anti-HPV 3 DRAVPa0357 YTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT 56 Sequence 32 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0356 GTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP 70 Sequence 31 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0355 ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ 33 Sequence 30 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0354 IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK 33 Sequence 29 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0353 KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID 33 Sequence 28 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0352 NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI 33 Sequence 27 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0351 VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY 33 Sequence 26 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0350 EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN 33 Sequence 25 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0349 GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK 33 Sequence 24 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0348 LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD 33 Sequence 23 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0347 KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS 33 Sequence 22 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0346 SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT 33 Sequence 21 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0345 VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL 33 Sequence 20 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0344 AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV 33 Sequence 19 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0343 VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS 33 Sequence 18 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0342 VITIELSNIKENKMNGDAKVKLIKQELDKYKNAV 34 Sequence 17 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0341 VITIELSNIKENKCNGDAKVKLIKQELDKYKNAV 34 Sequence 16 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0340 TSVITIELSNIKENKCNGDAKVKLIKQELDKYKN 34 Sequence 15 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0339 YTSVITIELSNIKENKCNGDAKVKLIKQELDKYK 34 Sequence 14 from Patent US 7582301 B1 Synthetic construct RSV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-RSV DRAVPa0338 YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST 48 Sequence 13 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0337 GEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT 53 Sequence 12 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0336 ASGVAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL 54 Sequence 11 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0335 YTSVITIELSNIKENKCNGAKVKLIKQELDKYKNAVTELQLLMQST 46 Sequence 10 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0334 QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ 38 Sequence 9 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0333 CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ 41 Sequence 8 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0332 LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL 36 Sequence 7 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0331 LEANISKSLEQAQIQQEKNMYELQKLNSWDIFGNWF 36 Sequence 6 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0330 YTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWF 36 Sequence 5 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0329 YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF 36 Sequence 4 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0328 YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 3 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0327 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ 38 Sequence 2 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides "The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107." "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." Anti-HIV DRAVPa0326 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF 36 Sequence 1 from Patent US 7582301 B1 Synthetic construct HIV Granted Patent US 7582301 B1 2009-09-01 CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2## Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides No comments found in patent "Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component." DRAVPe00520 Anti-HIV DRAVPa0325 RXXWEQWWDX 10 Sequence 20 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase "The 'X' at position 3 indicates Thr,Val or Ile, the 'X' at position 2 indicates Glu or Asp,and the 'X' at position 10 indicates Asn or Asp." "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0324 RETWETWWAD 10 Sequence 19 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0323 KETWEVWWTE 10 Sequence 18 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0322 KETWDTWWTE 10 Sequence 17 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0321 KETWEXWWXX 10 Sequence 16 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase "The 'X' at position 6 indicates Thr or Ala, the 'X' at position 10 indicates Glu or Asp,and the 'X' at position 9 indicates Thr,Ala,Val or Ile." "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0320 KETWEAWWTD 10 Sequence 15 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0319 KETWEXWWME 10 Sequence 14 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase The 'X' at position 6 indicates Thr or Ala. "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0318 KETWEXWWTX 10 Sequence 13 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase "The 'X' at position 6 indicates Thr or Ala, and the 'X' at position 10 indicates Glu or Asp." "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0317 RETWDQWWTD 10 Sequence 12 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0316 REIWEQWWDN 10 Sequence 11 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0315 KETWETWWAE 10 Sequence 10 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0314 KETWETWWIE 10 Sequence 9 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0313 KETWEAWWME 10 Sequence 8 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0312 KETWEAWWTE 10 Sequence 7 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0311 GALFLGFLGAAKETWETWWTE 21 Sequence 6 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0310 RGTKALTEVIPLTED 15 Sequence 5 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0309 GFLGAAGSTMGAWSQKETWETWWTE 25 Sequence 4 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0308 GFLGAA 6 Sequence 3 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0307 GALFLGFLGAAGSTMGAWSQPKSKRKV 27 Sequence 2 from Patent US 7790171 B1 Synthetic construct HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0306 KETWETWWTE 10 Sequence 1 from Patent US 7790171 B1 Synthetic construct(residues 395-404 of HIV-1 BH10 HIV Granted Patent US 7790171 B1 2010-09-07 WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1 Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase No comments found in patent "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa0305 CCCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 39 Sequence 126 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0304 GGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 37 Sequence 125 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0303 CCCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL 39 Sequence 124 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0302 GGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL 37 Sequence 123 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0301 CCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 46 Sequence 122 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0300 GGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 44 Sequence 121 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0299 CCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL 38 Sequence 120 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0298 IEKKIEEIEEKIEEIEK 17 Sequence 119 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0297 IEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL 34 Sequence 118 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0296 IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARILGGCC 38 Sequence 117 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0295 CCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 38 Sequence 116 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0294 IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 34 Sequence 115 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0293 IEKKIEEIEKKIEEIEK 17 Sequence 114 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0292 IEKKIEAIEK 10 Sequence 113 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0291 IEKKIEAIEKKIEAIEKKIEAIEK 24 Sequence 112 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0290 CCCGGIEEKIEEIEELLQLTVWGIKQLQARIL 32 Sequence 111 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0289 GGGIEEKIEEIEELLQLTVWGIKQLQARIL 30 Sequence 110 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0288 CCGGIEEKIEEIEELLQLTVWGIKQLQARIL 31 Sequence 109 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0287 IEEKIEEIEELLQLTVWGIKQLQARIL 27 Sequence 108 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0286 IEEKIEEIEE 10 Sequence 107 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0285 GGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL 37 Sequence 106 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0284 CCCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL 39 Sequence 105 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0283 GGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL 44 Sequence 104 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0282 CCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL 46 Sequence 103 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0281 CCGGIEKKIEAIEKLLQLTVWGIKQLQARIL 31 Sequence 102 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0280 IEKKIEAIEKLLQLTVWGIKQLQARIL 27 Sequence 101 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0279 CCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL 38 Sequence 100 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0278 IEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL 34 Sequence 99 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0277 CCGGIEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL 45 Sequence 98 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0276 IEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL 41 Sequence 97 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0275 CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQIKKEIEAI 47 Sequence 96 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0274 CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQ 41 Sequence 95 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0273 LLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI 40 Sequence 94 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0272 CCGGLLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI 44 Sequence 93 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0271 IKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK 34 Sequence 92 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0270 IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARILGGCC 38 Sequence 91 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0269 CCGGIKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL 38 Sequence 90 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0268 IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL 34 Sequence 89 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0267 IKKKIEAIEKLIQLIVWGIKQIQARILGGCC 31 Sequence 88 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0266 CCGGIKKKIEAIEKLIQLIVWGIKQIQARIL 31 Sequence 87 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0265 IKKKIEAIEKLIQLIVWGIKQIQARIL 27 Sequence 86 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0264 LIQLIVWGIKQIQARIL 17 Sequence 85 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0263 ASQLL 5 Sequence 84 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0262 IKKKIEAIEKLLQLTVWGIKQLQARILGGCC 31 Sequence 83 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0261 GGCC 4 Sequence 82 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0260 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIA 41 Sequence 81 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0259 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQAAIL 41 Sequence 80 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0258 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLAARIL 41 Sequence 79 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0257 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALQARIL 41 Sequence 78 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0256 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIAQLQARIL 41 Sequence 77 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0255 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVAGIKQLQARIL 41 Sequence 76 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0254 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTAWGIKQLQARIL 41 Sequence 75 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0253 IKKEIEAIKKEQEAIKKKIEAIEKLLQATVWGIKQLQARIL 41 Sequence 74 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0252 IKKEIEAIKKEQEAIKKKIEAIEKLLALTVWGIKQLQARIL 41 Sequence 73 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0251 IKKEIEAIKKEQEAIKKKIEAIEKALQLTVWGIKQLQARIL 41 Sequence 72 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0250 GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA 46 Sequence 71 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0249 GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA 46 Sequence 70 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0248 GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 46 Sequence 69 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0247 GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL 46 Sequence 68 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0246 ERVVQNVSYIAQTQDQFTHLFRNINNRLNVLHRRVS 36 Sequence 67 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0245 NHTFEVENSTLNGMDLIERQIKILYAMILQTHADVQ 36 Sequence 66 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0244 ATHQETIEKVTEALKINNLRLVTLEHQVLVIGLKVE 36 Sequence 65 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0243 QTLANATAAQQDALEATYAMVQHVAKGVRILEARVA 36 Sequence 64 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0242 QSLANATAAQQNVLEATYAMVQHVAKGVRILEARVA 36 Sequence 63 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0241 AGIVQQQQQLLDVVKRQQELLRLTVWGTKNLQTRVS 36 Sequence 62 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0240 CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKALAAAIA 38 Sequence 61 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0239 LLQLTVWGIKALAAAIA 17 Sequence 60 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0238 IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILAVERYLK 41 Sequence 59 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0237 IKKEIEAIKKEQEAIKKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 55 Sequence 58 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0236 IKKEIEAIKKEQEAIKKEIEAQQHLLQLTVWGIKQLQARIL 41 Sequence 57 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0235 RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARILAVERYLK 52 Sequence 56 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0234 IEKKIEEIEKKIEEIEKKIEEIEEKLLQLTVWGIKQLQARILAVERYLK 49 Sequence 55 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0233 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK 48 Sequence 54 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0232 ARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK 48 Sequence 53 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0231 SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK 43 Sequence 52 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0230 IEAQQHLLQLTVWGIKQLQARILAVERYLK 30 Sequence 51 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0229 LLQLTVWGIKQLQARILAVERYLK 24 Sequence 50 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0228 AVERYLK 7 Sequence 49 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0227 IEAQQHLLQLTVWGIKQLQARIL 23 Sequence 48 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0226 IKKKIEAIEK 10 Sequence 45 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0225 LLQLTVWGIKQLQARIL 17 Sequence 44 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0224 IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILGGCC 38 Sequence 43 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0223 CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL 38 Sequence 42 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0222 IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL 34 Sequence 41 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0221 IKKEIEAIKKEQEAIKK 17 Sequence 40 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0220 KIEEIESKIKKIENEIARIKK 21 Sequence 39 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0219 KIEEIESKQKKIENEIARIKKL 22 Sequence 38 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0218 KIKKIENEIARIKKL 15 Sequence 37 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0217 KQKKIENEIAAIKKL 15 Sequence 36 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0216 RMKQIEDKIEEIESKQKKIENEIARIKKL 29 Sequence 35 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0215 IEKKIEE 7 Sequence 34 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0214 IEKKIEA 7 Sequence 33 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0213 IEKKIEEIEKKIEEIEKKIEEIEK 24 Sequence 32 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0212 IKKEIEAIKKEQEAIKKKIEAIEK 24 Sequence 31 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0211 RMKQIEDKIEEILSKQYHIENEIARIKKLIGER 33 Sequence 30 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0210 YGGIEKKIEAIEKKIEAIEKKIEAIEKKIEA 31 Sequence 29 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0209 CCGG 4 Sequence 28 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0208 CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKALAAAIA 49 Sequence 27 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0207 CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL 49 Sequence 26 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0206 RMKQIEDKIEEIESKQKKIENEIARIKKLISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 66 Sequence 25 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." DRAVPe00815 Anti-HIV DRAVPa0205 RMKQIEDKIEEIESKQKKIENEIARIKKLIEAQQHLLQLTVWGIKQLQARIL 52 Sequence 24 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." DRAVPe00814 Anti-HIV DRAVPa0204 RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL 45 Sequence 23 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." DRAVPe00812 Anti-HIV DRAVPa0203 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWDIKQLQARIL 41 Sequence 22 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0202 SGGCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL 48 Sequence 21 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0201 CCGGIKKKIEAIEKLLQLTVWGIKQLQARIL 31 Sequence 20 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0200 IEKKIEEIEKKIEEIEKKIEEIEEKISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 62 Sequence 19 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0199 CCGGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 66 Sequence 18 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0198 GKGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 65 Sequence 17 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0197 IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 62 Sequence 16 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." DRAVPe00818 Anti-HIV DRAVPa0196 CCGGIEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL 52 Sequence 15 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0195 IEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL 48 Sequence 14 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0194 CCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL 52 Sequence 13 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0193 GCCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL 53 Sequence 12 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=0.316 nM). "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0192 GGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL 50 Sequence 11 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=2.173 nM). "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0191 IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL 48 Sequence 10 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." DRAVPe00817 Anti-HIV DRAVPa0190 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL 41 Sequence 1 from Patent US 7811577 B2 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=1.7 nM; HIV Bal:IC50=3.2 nM).The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." DRAVPe00816 Anti-HIV DRAVPa0188 KNIYRPDKFLQCVKNPEDSSCTSEI 25 Sequence 22 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0189 GKGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL 44 Sequence 3 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0187 SGPGTTKRFPETVLACVKYTEIH 23 Sequence 21 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0186 NTRKSIIGPGRAFYTTGQIIGDIRQAH 27 Sequence 20 from Patent US 8080633 Human immunodeficiency virus(HIV-1 subtype B gp120 HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0185 RWRQQWSGPGTTKRFPETVLARCVKYTEIH 30 Sequence 19 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0184 GPGTTK 6 Sequence 18 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0182 RWRQQWSGPGTTKRFPETVLARCVKYTEIH 30 Sequence 16 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0183 RQQWSGPGTTKRFPETVLARCVKYTEIH 28 Sequence 17 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0181 SGPGTTKRFPETVLARCVKYTEIH 24 Sequence 15 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0180 RWRQTWSGPGTTK 13 Sequence 14 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0179 RQTWSGPGTTKRFPETVLARCVKYTEIH 28 Sequence 13 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0178 RWRQTWSGPGTTKRFPETVLARCVKYTEIH 30 Sequence 12 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0177 KRPGNKTVVPITLMSGLVFHSQPINRPRQAW 31 Sequence 11 from Patent US 8080633 Human immunodeficiency virus(HIV-2) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0175 RPGVQEIIGPMAWYSMGLNNSRAY 24 Sequence 9 from Patent US 8080633 Human immunodeficiency virus(HIV subgroup O) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0176 RPGNNTRGQIGPGMTFYNIENIVGDTRA 28 Sequence 10 from Patent US 8080633 Simian immunodeficiency virus(SIV cpz) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0174 TRPGNNTGGQVQIGPAMTFYNIEKIVGDRQAY 32 Sequence 8 from Patent US 8080633 Human immunodeficiency virus(HIV subgroup N) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0173 TRPSNNTRTSRIGPGRVFYKTGDIIGDIRKAY 32 Sequence 7 from Patent US 8080633 Human immunodeficiency virus(HIV sub E) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0172 TRPYNRQRTPIGLGQALYTTRYTTRIIGQAY 31 Sequence 6 from Patent US 8080633 Human immunodeficiency virus(HIV sub D) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0171 TRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAH 33 Sequence 5 from Patent US 8080633 Human immunodeficiency virus(HIV sub C) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0170 TRPNNNTRRSIRIGPGQAFYATGDIIGDIRQAH 33 Sequence 4 from Patent US 8080633 Human immunodeficiency virus(HIV sub A) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0169 TRPNNNTRKSIIGPGRAFYTTGQIIGDIRQAH 32 Sequence 3 from Patent US 8080633 Human immunodeficiency virus(HIV sub B) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0167 RWRQTWSGPGTTKRFPETVLARCVKYTEIH 30 Sequence 1 from Patent US 8080633 Homo sapiens HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0168 NTRKSHIGPGRAFYTTGIIGDIRQAH 26 Sequence 2 from Patent US 8080633 Human immunodeficiency virus(HIV gp120 299-324) HIV Granted Patent US 8080633 B2 2011-12-20 WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1 Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. Anti-HIV DRAVPa0166 GICRCICGRRICRCICGR 18 Sequence 140 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." DRAVPe01560 "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0165 RYICRCICGRGICRCICG 18 Sequence 139 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." DRAVPe01563 "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0164 GICRCICGRYICRCICGR 18 Sequence 138 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." DRAVPe01562 "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0163 GICYCICGKGICRCICGR 18 Sequence 137 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0162 RXICGXXIC 9 Sequence 136 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The 'X' at position 2 and 6 indicates Arg or Lys, and the 'X' at position 7 indicates Arg, Lys or Gly.The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0161 GVCRCICGRGVCRCICGR 18 Sequence 135 from Patent US 2009/0264344 A1 Orangutan "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0160 GVCRCICGRGVCRCICRR 18 Sequence 134 from Patent US 2009/0264344 A1 Orangutan "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0159 GICRCICGRRICRCICGK 18 Sequence 133 from Patent US 2009/0264344 A1(Retrocyclin 2F) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0158 GICKCICGRRICRCICGR 18 Sequence 132 from Patent US 2009/0264344 A1(Retrocyclin 2E) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0157 GICRCICGRRICKCICGR 18 Sequence 131 from Patent US 2009/0264344 A1(Retrocyclin 2D) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0156 GICRCICGRKICRCICGR 18 Sequence 130 from Patent US 2009/0264344 A1(Retrocyclin 2C) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0155 GICRCICGKKICRCICGR 18 Sequence 129 from Patent US 2009/0264344 A1(Retrocyclin 2B) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0154 GICRCICGKRICRCICGR 18 Sequence 128 from Patent US 2009/0264344 A1(Retrocyclin 2A) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0153 GICKCICGKGICKCICGR 18 Sequence 127 from Patent US 2009/0264344 A1(K Retrocyclin-1) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0152 GICRCICGKGICRCYCGR 18 Sequence 126 from Patent US 2009/0264344 A1(RC101/103 hybrid) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0151 CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL 45 Sequence 2 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=0.04 nM; HIV Bal:IC50=0.34 nM;HIV 89.6:IC50=8 nM;HIV SHIV89.6p:IC50=6.9 Nm;HIV MN-1:IC50=0.9 nM;HIV NL43:IC50=0.1 nM).The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0150 RCLCVLRIC 9 Sequence 119 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0149 RCLCVLRVC 9 Sequence 118 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0148 RCLCTLRIC 9 Sequence 117 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0147 RCLCTLRVC 9 Sequence 116 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0146 RCLCGLRIC 9 Sequence 115 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0145 RCLCGLRVC 9 Sequence 114 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0144 RCICVLRFC 9 Sequence 113 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0143 RCICVLRVC 9 Sequence 112 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0142 RCICTLRFC 9 Sequence 111 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0141 RCICTLRVC 9 Sequence 110 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0140 RCICRLRFC 9 Sequence 109 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0139 RCICRLRVC 9 Sequence 108 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0138 RCICGRRIC 9 Sequence 107 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0137 RCLCVRRVC 9 Sequence 106 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0136 RCLCVLRIC 9 Sequence 105 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0135 RCLCTRRFC 9 Sequence 104 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0134 RCLCGRRVC 9 Sequence 103 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0133 RCLCTLRIC 9 Sequence 102 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0132 RCLCRRRFC 9 Sequence 101 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0131 RCLCRRRVC 9 Sequence 100 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0130 RCLCRLRIC 9 Sequence 99 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0129 RCICGLRVC 9 Sequence 98 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0128 RCICGLRFC 9 Sequence 97 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0127 RCICGRRFC 9 Sequence 96 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0126 RCICVRRVC 9 Sequence 95 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0125 RCICRLRIC 9 Sequence 94 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0124 RCICVLRFC 9 Sequence 93 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0123 RCICTLRIC 9 Sequence 92 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0122 RCICTRRFC 9 Sequence 91 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0121 RCICTRRVC 9 Sequence 90 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0120 RCICRRRFC 9 Sequence 89 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0119 RCICRRRVC 9 Sequence 88 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0118 RCLCGRRFC 9 Sequence 87 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0117 RCLCGRRVC 9 Sequence 86 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0116 RCLCGLRVC 9 Sequence 85 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0115 RCLCVRRIC 9 Sequence 84 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0114 RCLCTRRIC 9 Sequence 83 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0113 RCLCRRRVC 9 Sequence 82 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0112 RCICGRRFC 9 Sequence 81 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0111 RCICGRRVC 9 Sequence 80 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0110 RCICGLRIC 9 Sequence 79 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0109 RCICVRRIC 9 Sequence 78 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0108 RCICTRRIC 9 Sequence 77 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0107 RCICRRRIC 9 Sequence 76 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0106 RCLCGRRIC 9 Sequence 75 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0105 RCICGRRIC 9 Sequence 74 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0104 IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA 41 Sequence 4 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity No comments found in patent "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0103 CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA 45 Sequence 5 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0102 IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 41 Sequence 6 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0101 CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL 45 Sequence 7 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0100 IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA 41 Sequence 8 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0099 CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA 45 Sequence 9 from Patent US 7811577 B2 Synthetic construct HIV Granted Patent US 7811577 B2 2010-12-12 WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2 Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity The peptide was modified with acetyl N-terminus and amide C-terminus. "Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process." Anti-HIV DRAVPa0098 RCLCVLGIC 9 Sequence 64 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0097 RCLCVLGVC 9 Sequence 63 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0096 RCLCTLGIC 9 Sequence 62 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0095 RCLCTLGVC 9 Sequence 61 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0094 RCLCGLGIC 9 Sequence 60 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0093 RCLCGLGVC 9 Sequence 59 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0092 RCICVLGFC 9 Sequence 58 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0091 RCICVLGVC 9 Sequence 57 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0090 RCICTLGFC 9 Sequence 56 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0089 RCICTLGVC 9 Sequence 55 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0088 RCICRLGFC 9 Sequence 54 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0087 RCICRLGVC 9 Sequence 53 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0086 RCICGRGIC 9 Sequence 52 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0085 RCLCVRGVC 9 Sequence 51 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0084 RCLCVLGIC 9 Sequence 50 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0083 RCLCTRGFC 9 Sequence 49 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0082 RCLCTRGVC 9 Sequence 48 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0081 RCLCTLGIC 9 Sequence 47 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0080 RCLCRRGFC 9 Sequence 46 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0079 RCLCRRGVC 9 Sequence 45 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0078 RCLCRLGIC 9 Sequence 44 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0077 RCICGLGVC 9 Sequence 43 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0076 RCICGLGFC 9 Sequence 42 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0075 RCICGRGFC 9 Sequence 41 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0074 RCICVRGVC 9 Sequence 40 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0073 RCICRLGIC 9 Sequence 39 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0072 RCICVLGFC 9 Sequence 38 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0071 RCICTLGIC 9 Sequence 37 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0070 RCICTRGFC 9 Sequence 36 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0069 RCICTRGVC 9 Sequence 35 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0068 RCICRRGFC 9 Sequence 34 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0067 RCICRRGVC 9 Sequence 33 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0066 RCLCGRGFC 9 Sequence 32 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0065 RCLCGRGVC 9 Sequence 31 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0064 RCLCGLGVC 9 Sequence 30 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0063 RCLCVRGIC 9 Sequence 29 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0062 RCLCTRGIC 9 Sequence 28 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0061 RCLCRRGVC 9 Sequence 27 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0060 RCICGRGFC 9 Sequence 26 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0059 RCICGRGVC 9 Sequence 25 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0058 RCICGLGIC 9 Sequence 24 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0057 RCICVRGIC 9 Sequence 23 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0056 RCICTRGIC 9 Sequence 22 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0055 RCICRRGIC 9 Sequence 21 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0054 RCLCGRGIC 9 Sequence 20 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0053 RCICGRGIC 9 Sequence 19 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0052 MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGADDQGMAHSFTRPENAALPLSESARGLRCLCRRGVCQLL 76 Sequence 17 from Patent US 2009/0264344 A1 Macaca mulatta "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0051 MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGTDDQGMAHSFTWPENAALPLSESAKGLRCICTRGFCRLL 76 Sequence 15 from Patent US 2009/0264344 A1 Macaca mulatta "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0050 MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD 97 Sequence 13 from Patent US 2009/0264344 A1(human defensin 4) Homo sapiens "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0049 AQAEPLQARADEAAAQEQPGADDQEMAHAFTWHESAALPLSDSARGLRCICGRGICRLL 59 Sequence 12 from Patent US 2009/0264344 A1 Homo sapiens "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides "The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity." "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0048 RGCICRCIGRGCICRCIG 18 Sequence 10 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0047 GICICICGRGICYCICGR 18 Sequence 9 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0046 GICICICGYGICRCICGR 18 Sequence 8 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0045 GICYCICGRGICRCICGR 18 Sequence 7 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0044 GICRCICGRGYCRCICGR 18 Sequence 6 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0043 GYCRCICGRGICRCICGR 18 Sequence 5 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0042 GICRCICGRGICRCYCGR 18 Sequence 4 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0041 GICRCYCGRGICRCICGR 18 Sequence 3 from Patent US 2009/0264344 A1 Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0040 GICRCICGKGICRCICGR 18 Sequence 2 from Patent US 2009/0264344 A1(RC-101) Synthetic construct "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." DRAVPe01561 "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0039 GICRCICGRGICRCICGR 18 Sequence 1 from Patent US 2009/0264344 A1 Homo sapiens "HIV-1,HSV-1,HSV-2" Patent Application US 2009/0264344 A1 2009-10-22 US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2 Retrocyclins: Antiviral and Antimicrobial Peptides The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. The mean IC50 value of RC-101 for the seven subtype B strains was <1.25 ¦Ìg/ml (<660 nM). "Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens." DRAVPe01559 "Anti-HIV-1,Anti-HSV-1,Anti-HSV-2" DRAVPa0038 MEHFRWG 7 Sequence 1 from Patent US 7244710(¦Á-MSH [4-10]) Homo sapiens "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0037 HFRWGKPV 8 Sequence 2 from Patent US 7244710(¦Á-MSH [6-13]) Homo sapiens "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0036 SYSMEHFRWGKPV 13 Sequence 3 from Patent US 7244710(¦Á-MSH [1-13]) Homo sapiens "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0035 VPKCCKPV 8 Sequence 4 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0034 CKPV 4 Sequence 5 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0033 VPKXCKPV 8 Sequence 6 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), the 'X' at position 4 indicates Penicillamine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0032 VPKXXKPV 8 Sequence 7 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), the 'X' at position 4 and 5 indicates Penicillamine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0031 VPKCCKPV 8 Sequence 8 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), and the Cys at position 4 and 5 refers to Omocysteine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0030 VPKCCKPV 8 Sequence 9 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0029 VPKCXKPV 8 Sequence 10 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0028 VPKCCKPV 8 Sequence 11 from Patent US 7244710 Synthetic construct "Herpesvirus,HIV" Granted Patent US 7244710 B2 2007-07-17 FR 1456903 A##ES 323291 A1##SU 622426 A3 Treatment Of Ophthalmic Infections Using Antimicrobial Peptides "The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription." "The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (¦Á-MSH) include ¦Á-MSH (1¨C13) which is SYSMEHFRWGKPV, ¦Á-MSH (4¨C10) which is MEHFRWG, ¦Á-MSH (6¨C13) which is HFRWGKPV, ¦Á-MSH (11¨C13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter." "Herpesvirus,Anti-HIV" DRAVPa0027 IPLRGAFINGRWDSQCHRFSNGAIAAA 27 Sequence 27 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0026 IPLRGAFINGRWDSQCHRFSNGAAACA 27 Sequence 26 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0025 IPLRGAFINGRWDSQCHRFSNAAIACA 27 Sequence 25 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0024 IPLRGAFINGRWDSQCHRFSAGAIACA 27 Sequence 24 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0023 IPLRGAFINGRWDSQCHRFANGAIACA 27 Sequence 23 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0022 IPLRGAFINGRWDSQCHRASNGAIACA 27 Sequence 22 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0021 IPLRGAFINGRWDSQCHAFSNGAIACA 27 Sequence 21 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0020 IPLRGAFINGRWDSQCARFSNGAIACA 27 Sequence 20 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0019 IPLRGAFINGRWDSQAHRFSNGAIACA 27 Sequence 19 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0018 IPLRGAFINGRWDSACHRFSNGAIACA 27 Sequence 18 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0017 IPLRGAFINGRWDAQCHRFSNGAIACA 27 Sequence 17 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0016 IPLRGAFINGRWASQCHRFSNGAIACA 27 Sequence 16 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0015 IPLRGAFINGRADSQCHRFSNGAIACA 27 Sequence 15 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0014 IPLRGAFINGAWDSQCHRFSNGAIACA 27 Sequence 14 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0013 IPLRGAFINARWDSQCHRFSNGAIACA 27 Sequence 13 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0012 IPLRGAFIAGRWDSQCHRFSNGAIACA 27 Sequence 12 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0011 IPLRGAFANGRWDSQCHRFSNGAIACA 27 Sequence 11 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0010 IPLRGAAINGRWDSQCHRFSNGAIACA 27 Sequence 10 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0009 IPLRAAFINGRWDSQCHRFSNGAIACA 27 Sequence 9 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0008 IPLAGAFINGRWDSQCHRFSNGAIACA 27 Sequence 8 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0007 IPARGAFINGRWDSQCHRFSNGAIACA 27 Sequence 7 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0006 IALRGAFINGRWDSQCHRFSNGAIACA 27 Sequence 6 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0005 APLRGAFINGRWDSQCHRFSNGAIACA 27 Sequence 5 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0004 SFITKLKDVAIGVAKGAGLGILKTLTCKLDNSCA 34 Sequence 4 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0003 SFVTKLKDVAIGVAKGAGLGILKTLTCKLDNSCA 34 Sequence 3 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0002 SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC 37 Sequence 2 from Patent US 20190367567 Synthetic construct H1N1 Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." H1N1 DRAVPa0001 IPLRGAFINGRWDSQCHRFSNGAIACA 27 Sequence 1 from Patent US 20190367567(Urumin) Synthetic construct "H1N1,H1N2" Patent Application US 2019/0367567 A1 2019-12-05 WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4 Peptides and Uses for Managing Viral Infections The peptide exhibits no toxicity to human red blood cells.IC50=2.5-5 ¦ÌM tested by graded concentrations of Urumin (0.6-320 ¦ÌM) against PR8 virus by plaque assay. "It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same." "H1N1,H1N2" DRAVPa1674 AQEVKXWMTXTLLVA 15 Sequence 4 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=4.29 ¡À 0.62 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>116 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1675 AQAVKXWMTXTLLVA 15 Sequence 5 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=2.36 ¡À 0.33 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50=30.2 ¡À 4.32 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1676 AQEVKXWMTXTLLVAKKK 18 Sequence 6 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=6.29 ¡À 0.54 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50=13.24 ¡À 0.5 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1677 AQKVEXWMTXTLLVA 15 Sequence 7 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=5.15 ¡À 0.76 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>112 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1678 AQAVKXWMTXTLLVENA 17 Sequence 8 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=2.95 ¡À 0.33 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>102 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1679 AQAVKXWMTXTLLKANAE 18 Sequence 9 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=17.4 ¡À 0.90 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>48 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1680 EQLVWXKMTXALAVT 15 Sequence 10 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50>56 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>112 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1681 AQEVKNWMTE TLLVA 15 Sequence 11 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides No cooments found in patent Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1682 AQAVKNWMTXTLLXA 15 Sequence 12 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=4.6 ¡À 0.40 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50=67.3 ¡À 4.4 ¦ÌM).The 'X' at position 10 and 14 indicates (S)-a-2-(2'-pentenyl)alanine, X(10) and X(14) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1683 AQAWKXWATXTLLVAE 16 Sequence 13 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=3.7 ¡À 0.06 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>106 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1684 AQAVKXWMEXTLKVAE 16 Sequence 14 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50>52.7 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>105.4 ¦ÌM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1685 AQAVKXWMTETLXVA 15 Sequence 15 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=7.97 ¡À 1.03 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>140.4 ¦ÌM).The 'X' at position 6 and 13 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(13) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1686 AQAWKXWATETLXVAN 16 Sequence 16 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=9.3 ¡À 1.6 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>130 ¦ÌM).The 'X' at position 6 and 13 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(13) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1687 IAQAKVEXWMTXTLLVAN 18 Sequence 17 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides "The peptide shows antiviral activity against HIV-1 IIIB(IC50=7.2 ¡À 1.2 ¦ÌM) and exhibits cytotoxicity against MT-2 cells(CC50>124.4 ¦ÌM).The 'X' at position 8 and 12 indicates (S)-a-2-(2'-pentenyl)alanine, X(8) and X(12) are cross-linked by hydrocarbon stapling." Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1688 AQAVKNWMTETLLVA 15 Sequence 19 from Patent US 20090281041 Synthetic construct HIV Patent Application US 2009/0281041 A1 2009-11-12 CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2 Antiviral Cell-Penetrating Peptides No cooments found in patent Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. Anti-HIV DRAVPa1689 RRKKAAVALLPAVLLALLAP 20 Sequence 1 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 95 ¡À 2% inhibition against influenza virus at 10 ¦ÌM.(EC50= 2.6 ¡À 1.0 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01185 Anti-influenza virus DRAVPa1690 RRKKAAVALLPAVLLALLA 19 Sequence 2 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94 ¡À 2% inhibition against influenza virus at 10 ¦ÌM.(EC50=0.5 ¡À 0.3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01186 Anti-influenza virus DRAVPa1691 RRKKAAVALLPAVLLALL 18 Sequence 3 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 95 ¡À 2% inhibition against influenza virus at 10 ¦ÌM.(EC50= 0.6 ¡À 0.3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01187 Anti-influenza virus DRAVPa1692 RRKKAAVALLPAVLLAL 17 Sequence 4 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 89 ¡À 3% inhibition against influenza virus at 10 ¦ÌM.(EC50= 3.8 ¡À 1.9 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01188 Anti-influenza virus DRAVPa1693 RRKKAAVALLPAVLLA 16 Sequence 5 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 96 ¡À 3% inhibition against influenza virus at 10 ¦ÌM.(EC50= 2.8 ¡À 1.1 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01189 Anti-influenza virus DRAVPa1694 RRKKAAVALLPAVLL 15 Sequence 6 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1695 RRKKAAVALLPAVL 14 Sequence 7 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1696 RRKKAAVALLPAV 13 Sequence 8 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1697 RRKKAAVALLPA 12 Sequence 9 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1698 RRKKAAVALLP 11 Sequence 10 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 4 ¡À 8% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01190 Anti-influenza virus DRAVPa1699 RRKKAAVALL 10 Sequence 11 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1700 RRKKAAVAL 9 Sequence 12 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1701 RRKKAAVA 8 Sequence 13 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1702 RRKKAAV 7 Sequence 14 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1703 RRKKAA 6 Sequence 15 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1704 RRKKA 5 Sequence 16 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1705 RRKK 4 Sequence 17 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1706 RRKKAVALLPAVLLALLAP 19 Sequence 18 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94 ¡À 6% inhibition against influenza virus at 10 ¦ÌM.(EC50= 0.8 ¡À 0.3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01191 Anti-influenza virus DRAVPa1707 RRKKVALLPAVLLALLAP 18 Sequence 19 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94 ¡À 4% inhibition against influenza virus at 10 ¦ÌM.(EC50= 0.5 ¡À 0.4 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01192 Anti-influenza virus DRAVPa1708 RRKKALLPAVLLALLAP 17 Sequence 20 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94 ¡À 3% inhibition against influenza virus at 10 ¦ÌM.(EC50= 0.7¡À 0.3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01193 Anti-influenza virus DRAVPa1709 RRKKLLPAVLLALLAP 16 Sequence 21 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94¡À 4% inhibition against influenza virus at 10 ¦ÌM.(EC50=0.8 ¡À 0.3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01194 Anti-influenza virus DRAVPa1710 RRKKLPAVLLALLAP 15 Sequence 22 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94 ¡À 4% inhibition against influenza virus at 10 ¦ÌM.(EC50= 0.9 ¡À 0.3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01195 Anti-influenza virus DRAVPa1711 RRKKVLLALLAP 12 Sequence 23 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 90 ¡À 4% inhibition against influenza virus at 10 ¦ÌM.(EC50=4.0 ¡À 0.8 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01198 Anti-influenza virus DRAVPa1712 RRKKLLALLAP 11 Sequence 24 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1713 RRKKALLAP 9 Sequence 25 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1714 RRKKLLAP 8 Sequence 26 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1715 RRKKLAP 7 Sequence 27 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1716 RRKKAP 6 Sequence 28 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1717 RRKKP 5 Sequence 29 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1718 RRKKAALLVLAALAVLA 17 Sequence 30 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1719 RRKKLAALPLVLAAPLAVLA 20 Sequence 31 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1720 RRKKVALLAVLLALLA 16 Sequence 32 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94 ¡À 4% inhibition against influenza virus at 10 ¦ÌM.(EC50= 0.5 ¡À 0.5 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01200 Anti-influenza virus DRAVPa1721 RRKKAAVALLAVLLALLA 18 Sequence 43 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 95 ¡À 2% inhibition against influenza virus at 10 ¦ÌM.(EC50=1.6 ¡À 1.2 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01199 Anti-influenza virus DRAVPa1722 RRKKLLAVLLALLA 14 Sequence 44 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 95 ¡À 2% inhibition against influenza virus at 10 ¦ÌM.(EC50= 3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01202 Anti-influenza virus DRAVPa1723 RRKKLAVLLALLA 13 Sequence 45 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 94 ¡À 0% inhibition against influenza virus at 10 ¦ÌM.(EC50= 3 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." DRAVPe01203 Anti-influenza virus DRAVPa1724 RRKKAAAAAAAAA 13 Sequence 49 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 87.5% inhibition against influenza virus at 10 ¦ÌM.(EC50~7 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1725 RKKLAVLLALLA 12 Sequence 50 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 75% inhibition against influenza virus at 10 ¦ÌM.(EC50=8 ¦ÌM) "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1726 RKAVLLALLA 10 Sequence 51 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 50% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1727 KLAVLLALLA 10 Sequence 52 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 25% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1728 KKLAVLLALLA 11 Sequence 53 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1729 EEDDLAVLLALLA 13 Sequence 54 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1730 RRKKLAVAAALLA 13 Sequence 55 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1731 RRKKLAVLLAAAA 13 Sequence 56 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus 0% inhibition against influenza virus at 10 ¦ÌM. "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1732 EEDD 4 Sequence 61 from Patent US 20100041604 Synthetic construct Influenza Virus Patent Application US 2010/0041604 A1 2010-02-18 CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2 Novel Antiviral Peptides Against Influenza Virus No comments found in patent "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa1733 CVHAYRS 7 Sequence 1 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1734 CVHAYRA 7 Sequence 2 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1735 CVHAFRS 7 Sequence 3 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1736 CVHAFRA 7 Sequence 4 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1737 CVHSYRS 7 Sequence 5 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1738 CVHSYRA 7 Sequence 6 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1739 CVHSFRS 7 Sequence 7 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1740 CVHSFRA 7 Sequence 8 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1741 CVHTYRS 7 Sequence 9 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1742 CVHTYRA 7 Sequence 10 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1743 CVHTFRS 7 Sequence 11 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1744 CVHTFRA 7 Sequence 12 from Patent US 7476649 B2 Sos scrofus(pig) "Infuenza Virus,Vaccinia Virus,HIV" Granted Patent US 7476649 B2 2009-01-13 "WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936" Antiproliferative and antiviral proteins and peptides "The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents." "Anti-influenza virus,Anti-vaccinia virus,Anti-HIV" DRAVPa1745 NGAICWGPCPTAFRQIGNCGHFKVRCCKIR 30 P9 Synthetic construct SARS-CoV-2 Patent Application US20230165936 A1 2023-06-01 WO/2021/185071£¬CN115379849£¬EP4121087 Compositions of anti-viral peptides and methods of use thereof "Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus." DRAVPe01761 Anti-SARS-CoV-2 DRAVPa1746 NGAICWGPCPTAFRQIGNCGRFRVRCCRIR 30 P9R Synthetic construct SARS-CoV-2 Patent Application US20230165936 A1 2023-06-01 WO/2021/185071£¬CN115379849£¬EP4121087 Compositions of anti-viral peptides and methods of use thereof "Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus." DRAVPe01763 Anti-SARS-CoV-2 DRAVPa1747 PAEPYTTVTTQNTASQTMS 19 PS19 Synthetic construct ASFV Granted Patent US 8592552 B2 2013-11-26 "WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE" ?Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8 New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8. Anti-ASFV DRAVPa1748 RRRRRRRRPAEPYTTVTTQNTASQTMS 27 RS27 Synthetic construct ASFV Granted Patent US 8592552 B2 2013-11-26 "WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE" ?Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8 New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8. Anti-ASFV DRAVPa1749 SLVSSDESSSGSSHSSGEHS 20 SS20 Synthetic construct ASFV Granted Patent US 8592552 B2 2013-11-26 "WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE" ?Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8 New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8. Anti-ASFV DRAVPa1750 RRRRRRRRSLVSSDESSSGSSHSSGEHS 28 RS28 Synthetic construct ASFV Granted Patent US 8592552 B2 2013-11-26 "WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE" ?Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8 New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8. Anti-ASFV DRAVPa1751 RRRRRRRRHPAEPGSTVTTQNTASQTMS 28 COVA1 Synthetic construct ASFV Granted Patent US 8592552 B2 2013-11-26 "WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE" ?Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8 New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8. Anti-ASFV DRAVPa1752 RRRRRRRRHPTESGSTVTTQNSAAQTMS 28 PEP1 Synthetic construct ASFV Granted Patent US 8592552 B2 2013-11-26 "WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE" ?Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8 New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC10. Anti-ASFV DRAVPa1753 KYKETDLLILFKDDYFAKKNEERK 24 Sequence 1 from Patent US20090233868 A1 Human La protein HCV Patent Application US20090233868 A1 2009-09-17 WO/2006/117805£¬IN520/CHE/2005£¬EP1877431£¬US20110091966£¬CA2606668 Small antiviral peptides against hepatitis C virus "Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication." Anti-HCV DRAVPa1754 KYKETDL 7 Sequence 2 from Patent US20090233868 A1 Human La protein ?HCV Patent Application US20090233868 A1 2009-09-17 WO/2006/117805£¬IN520/CHE/2005£¬EP1877431£¬US20110091966£¬CA2606668 Small antiviral peptides against hepatitis C virus "Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication." Anti-HCV DRAVPa1755 KIKRWR 6 Sequence 10 from Patent CN104072579 B Synthetic construct HIV Granted Patent CN104072579 B 2017-01-25 CN104072579 B Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide "The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses." Anti-HIV DRAVPa1756 KIWWK 5 Sequence 2 from Patent CN104072579 B Synthetic construct HIV Granted Patent CN104072579 B 2017-01-25 CN104072579 B Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide "The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses." Anti-HIV DRAVPa1757 KKWK 4 Sequence 13 from Patent CN104072579 B Synthetic construct H5N1 Granted Patent CN104072579 B 2017-01-25 CN104072579 B Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide "The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses." Anti-H5N1 DRAVPa1758 KWK 3 Sequence 12 from Patent CN104072579 B Synthetic construct H5N1 Granted Patent CN104072579 B 2017-01-25 CN104072579 B Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide "The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses." Anti-H5N1 DRAVPa1759 CNDFRSKTC 9 Sequence 1 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N2 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1760 NDFRSKT 7 Sequence 2 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N3 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1761 QHSTKWF 7 Sequence 3 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N4 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1762 LPYAAKH 7 Sequence 4 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N5 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1763 ILGDKVG 7 Sequence 5 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N6 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1764 LPYGSKH 7 Sequence 6 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N7 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1765 ILGYKVG 7 Sequence 7 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N8 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1766 HPQFLSL 7 Sequence 8 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N9 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1767 GLYNHPQ 7 Sequence 9 from Patent US20110135676 B2 Synthetic construct AIV Granted Patent US20110135676 B2 2014-11-11 "WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061" Antiviral peptide against avian influenza virus H9N10 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-AIV DRAVPa1768 KETWETWWTE 10 Sequence 1 from Patent US20110064793 A1 Synthetic construct HIV Patent Application US20110064793 A1 2011-03-17 "WO/2002/015661,US7790171,EP1311538,AU2001292153,AT420103" INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF HIV INFECTIONS "The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections." Anti-HIV DRAVPa1769 SPMLVAYD 8 Sequence 2 from Patent US20110064793 A1 Synthetic construct influenza virus Granted Patent US11304989 B2 2022-04-19 "WO/2019/069307,EP3691672,CN111163792" Peptides for use in the treatment of viral infections "Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent." Anti-influenza virus DRAVPa1770 HVKGKHLCP 9 Sequence 3 from Patent US20110064793 A1 Synthetic construct influenza virus Granted Patent US11304989 B3 2022-04-19 "WO/2019/069307,EP3691672,CN111163792" Peptides for use in the treatment of viral infections "Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent." Anti-influenza virus DRAVPa1771 HKGLDSAV 8 Sequence 4 from Patent US20110064793 A1 Synthetic construct influenza virus Granted Patent US11304989 B4 2022-04-19 "WO/2019/069307,EP3691672,CN111163792" Peptides for use in the treatment of viral infections "Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent." Anti-influenza virus DRAVPa1772 YVNQTDIY 8 Sequence 5 from Patent US20110064793 A1 Synthetic construct influenza virus Granted Patent US11304989 B5 2022-04-19 "WO/2019/069307,EP3691672,CN111163792" Peptides for use in the treatment of viral infections "Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent." Anti-influenza virus DRAVPa1773 SNGTIIHVK 9 Sequence 6 from Patent US20110064793 A1 Synthetic construct influenza virus Granted Patent US11304989 B6 2022-04-19 "WO/2019/069307,EP3691672,CN111163792" Peptides for use in the treatment of viral infections "Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent." Anti-influenza virus DRAVPa1774 WNFFDWFSGLMSWFGGPLKLY 21 Sequence 5 from Patent US20150337015 B2 Synthetic construct RVFV Granted Patent US20150337015 B2 2017-01-31 WO/2014/123614 ?Antiviral rift valley fever virus peptides and methods of use "The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus." Anti-RVFV DRAVPa1775 WNFFDWFSGLMSWFGGPLK 19 Sequence 6 from Patent US20150337015 B2 Synthetic construct RVFV Granted Patent US20150337015 B2 2017-01-31 WO/2014/123614 ?Antiviral rift valley fever virus peptides and methods of use "The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus." Anti-RVFV DRAVPa1776 WNFFDWFSGLMSWFGGPLKTI 21 Sequence 7 from Patent US20150337015 B2 Synthetic construct RVFV Granted Patent US20150337015 B2 2017-01-31 WO/2014/123614 ?Antiviral rift valley fever virus peptides and methods of use "The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus." Anti-RVFV DRAVPa1777 SWNFFDWFSGLMSWFGGPLK 20 Sequence 8 from Patent US20150337015 B2 Synthetic construct RVFV Granted Patent US20150337015 B2 2017-01-31 WO/2014/123614 ?Antiviral rift valley fever virus peptides and methods of use "The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus." Anti-RVFV DRAVPa1778 SGSWNFFDWFSGLMSWFGG 19 Sequence 9 from Patent US20150337015 B2 Synthetic construct RVFV Granted Patent US20150337015 B2 2017-01-31 WO/2014/123614 ?Antiviral rift valley fever virus peptides and methods of use "The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus." Anti-RVFV DRAVPa1779 SGSWNFFDWFSGLMSWFGGPL 21 Sequence 10 from Patent US20150337015 B2 Synthetic construct RVFV Granted Patent US20150337015 B2 2017-01-31 WO/2014/123614 ?Antiviral rift valley fever virus peptides and methods of use "The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus." Anti-RVFV DRAVPa1780 YQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFESIENSQALVDQSNKILNSAEKGNTGF 67 Sequence 1 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1781 PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGF 78 Sequence 2 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1782 YQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNV 34 Sequence 3 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1783 PVSSSFDPIKFPEDQFNVALDQVFESIENSQAL 33 Sequence 4 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1784 ALDQVFESIENSQALVDQSNKILNSAEKGNTGF 33 Sequence 5 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1785 YQLSKVEGEQHVIKGRPVSSSFDPIKFP 28 Sequence 6 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1786 EDQFNVALDQVFESIEEDQFNVALDQVFESIEEKGNTGF 39 Sequence 7 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1787 KFPEDQFNVALDQVFESIENSQALVDQSNKILNSAEK 37 Sequence 8 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1788 EDQFNVALDQVFESIENSQALVDQSNKILNSAEK 34 Sequence 9 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1789 PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN 36 Sequence 10 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1790 DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID 37 Sequence 11 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1791 RLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGF 36 Sequence 12 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1792 NIQKEIDRLNEVAKNLNESLIDLQEL 26 Sequence 13 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1793 LNESLIDLQELGKYEQYIKWPWYVWLGF 28 Sequence 14 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1794 QELGKYEQYIKWPWYVWLGF 20 Sequence 15 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1795 YEQYIKWPWYVWLGF 15 Sequence 16 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1796 YEQYIKWPWYVWLG 14 Sequence 17 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1797 YIKWPWYVWL 10 Sequence 18 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1798 PELDSFKEELDKYFKNHTSP 20 Sequence 19 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1799 PNLPDFKEELDQWFKNQTSVAPDLSLDYINVTLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVW 73 Sequence 20 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1800 PNLPDFKEELDQWFKNQTSVAPDLSLD 27 Sequence 21 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1801 YINVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKW 42 Sequence 22 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1802 QVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKW 33 Sequence 23 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1803 QEAIKVLNQSYINLKDIGTYEYYVKWPW 28 Sequence 24 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1804 QSYINLKDIGTYEYYVKWPW 20 Sequence 25 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1805 YEYYVKWPWYVW 12 Sequence 26 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1806 QDAIKKLNESYINLKEVGTYEMYVKWPWYVW 31 Sequence 27 from Patent US20040229219 A1 Mouse hepatitis virus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1807 FLGFLG 6 Sequence 28 from Patent US20040229219 A1 Human immunodeficiency virus type 1 SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1808 TTTS 4 Sequence 29 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1809 ELDKY 5 Sequence 30 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1810 ELDKW 5 Sequence 31 from Patent US20040229219 A1 Human immunodeficiency virus type 1 SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1811 PEL 3 Sequence 32 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1812 PDFKE 5 Sequence 33 from Patent US20040229219 A1 Mouse hepatitis virus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1813 FKEELDK 7 Sequence 34 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1814 KWPWYVWL 8 Sequence 35 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1815 QALVDQ 6 Sequence 36 from Patent US20040229219 A1 Human metapneumovirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1816 GRKKRRQRRRP 11 Sequence 38 from Patent US20040229219 A1 Human immunodeficiency virus type 1 SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1817 ELRVRLASHLRKLRKRLLRDADD 23 Sequence 39 from Patent US20040229219 A1 Homo sapiens SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1818 RIQDAIK 7 Sequence 40 from Patent US20040229219 A1 Mouse hepatitis virus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1819 RLNEVAK 7 Sequence 41 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1820 ENQKQIANQFNKAISQIQESL 21 Sequence 42 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1821 KVQDVVNQNAQALNTLVKQL 20 Sequence 43 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1822 KYEQYIKWPWYVW 13 Sequence 44 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1823 TYEMYVKWPWYVW 13 Sequence 45 from Patent US20040229219 A1 Mouse hepatitis virus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1824 TYEYYVKWPWYVW 13 Sequence 46 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1825 YEWKWIYWYPVKQ 13 Sequence 47 from Patent US20040229219 A1 Synthetic construct SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1826 PNLPDFKEELDQWFKNQTSVAPDLSLDYINVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVWLLICLAGVA 83 Sequence 48 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1827 PNPPDFKEELDKWFKNQTSIAPDLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKEVGTYEMYVKWPWYVWLLIGLAGVA 85 Sequence 49 from Patent US20040229219 A1 Mouse hepatitis virus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1828 PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIA 84 Sequence 50 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1829 WTFGAGAALQIPFAMQMAY 19 Sequence 51 from Patent US20040229219 A1 Human coronavirus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1830 RIQDAIKKLNESYINLKEVGTYEMYVKWPWYVWLLI 36 Sequence 52 from Patent US20040229219 A1 Mouse hepatitis virus SARS Patent Application US20040229219 A1 2004-11-18 WO/2005/007078 Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) "The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus." Anti-SARS DRAVPa1831 HGVSGHGQHGVHG 13 Sequence 1 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 3 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1832 GVSGHGQHGVHG 12 Sequence 12 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 4 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1833 VSGHGQHGVH 10 Sequence 14 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 5 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1834 SGHGQHGV 8 Sequence 15 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 6 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1835 PSLTGHGFHGVYD 13 Sequence 16 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 7 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1836 FIVSAHGDHGV 11 Sequence 17 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 8 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1837 THGQHGV 7 Sequence 18 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 9 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1838 HGHGVHG 7 Sequence 19 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 10 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1839 LASLHGQHGV 10 Sequence 20 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 11 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1840 CVVTGHGSHGVFV 13 Sequence 2 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 12 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1841 ISGHGQHGVP 10 Sequence 3 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 13 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1842 CGHGNHGVH 9 Sequence 4 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 14 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1843 IVARIHGQNHGL 12 Sequence 5 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 15 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1844 HGSDGHGVQHG 11 Sequence 6 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 16 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1845 FGHGHGV 7 Sequence 7 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 17 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1846 HGNHGVLA 7 Sequence 8 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 18 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1847 HGDSGHGQHGVD 12 Sequence 9 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 19 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1848 HGHGVPL 7 Sequence 10 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 20 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1849 SGHGAVHGVM 10 Sequence 11 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 21 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1850 YAMSGHGHGVFI 12 Sequence 13 from Patent US20170058000 B2 Synthetic construct H3N2 Granted Patent US20170058000 B2 2018-11-13 "WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014" Bioactive peptide complexes "The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 22 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target." Anti-H3N2 DRAVPa1851 GEKKRRETVEREGG 14 Sequence 1 from Patent US20160346383 B2 Synthetic construct encephalomyocarditis virus Granted Patent US20160346383 B2 2017-06-20 "WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089" Ezrin-derived peptides and pharmaceutical compositions thereof "The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1 EKKRRETVERE X2X3, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof." Anti-encephalomyocarditis virus DRAVPa1852 TEKKRRETVEREKE 14 Sequence 2 from Patent US20160346383 B2 human ezrin protein encephalomyocarditis virus Granted Patent US20160346383 B2 2017-06-20 "WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089" Ezrin-derived peptides and pharmaceutical compositions thereof "The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1 EKKRRETVERE X2X4, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof." Anti-encephalomyocarditis virus DRAVPa1853 TEKKR 5 Sequence 3 from Patent US20160346383 B2 human ezrin protein encephalomyocarditis virus Granted Patent US20160346383 B2 2017-06-20 "WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089" Ezrin-derived peptides and pharmaceutical compositions thereof "The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1 EKKRRETVERE X2X5, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof." Anti-encephalomyocarditis virus DRAVPa1854 RETVEREKE 9 Sequence 4 from Patent US20160346383 B2 human ezrin protein encephalomyocarditis virus Granted Patent US20160346383 B2 2017-06-20 "WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089" Ezrin-derived peptides and pharmaceutical compositions thereof "The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1 EKKRRETVERE X2X6, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof." Anti-encephalomyocarditis virus DRAVPa1855 DKEWILQKIYEIMRRLDEEG 20 Sequence 1 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-19." Anti-SARS-CoV-2 DRAVPa1856 DKEWILQKIYEIMRLLDELG 20 Sequence 4 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-20." Anti-SARS-CoV-2 DRAVPa1857 DKEWILQKIYEIMRKLDEDG 20 Sequence 6 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-21." Anti-SARS-CoV-2 DRAVPa1858 DKEWILQKIYEIMRRLDEEGHAEASMRVSDLIYEFMKKD 39 Sequence 53 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-22." Anti-SARS-CoV-2 DRAVPa1859 DKEWILQKIYEIMRRLDEEGHGEASLRVSDLIYEFMKKD 39 Sequence 54 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-23." Anti-SARS-CoV-2 DRAVPa1860 DKEWILQKIYEIMRKLDEDGHAEASMRVSDLIYEFMKKD 39 Sequence 52 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-24." Anti-SARS-CoV-2 DRAVPa1861 DKEWILQKIYEIMRRLDEEGHGEASLRVSDLIYEFMKRD 39 Sequence 55 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-25." Anti-SARS-CoV-2 DRAVPa1862 DKEWILQKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD 39 Sequence 58 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-26." Anti-SARS-CoV-2 DRAVPa1863 DKLWILQKIYEIMVRLDEEGHGEASLMVSDLIYEFMKRD 39 Sequence 60 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-27." Anti-SARS-CoV-2 DRAVPa1864 DKEWILYKIYEIMVRLDEEGHGEASLMVSDLIYEFMKRD 39 Sequence 62 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-28." Anti-SARS-CoV-2 DRAVPa1865 DKLWILQKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD 39 Sequence 64 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-29." Anti-SARS-CoV-2 DRAVPa1866 DKEWILYKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD 39 Sequence 66 from Patent US20240309059 A1 Synthetic construct SARS-COV-2 Patent Application US20240309059 A1 2024-09-19 "WO/2023/282281,JPWO2023282281,EP4368631" "PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT" "Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-30." Anti-SARS-CoV-2 DRAVPa1867 WEEWDKKIEEYTKKIEELIKKSONOOIDL 29 Sequence 66 from Patent US20240309059 A1 Synthetic construct HIV Patent Application CN106543273?A 2017-03-29 Polypeptide for inhibiting HIV infection and medicinal application thereof "The invention belongs to the field of biological medicine and relates to an anti-HIV infection peptide, in particular to a polypeptide shown by a formula 1 CP_I(L)_D_I (L), its derivatives, its stereoisomers, or its salts free of physiological toxicity. CP in the formula represents a C-terminal polypeptide derived from HIV-1 gp41 and having HIV-1 inhibiting activity, L represents leucine, I represents isoleucine, and D represents aspartic acid. Variable amino acid is added to the carbon terminal of the C-terminal polypeptide having the HIV-1 inhibiting activity to obtain a longer polypeptide, so that the polypeptide has remarkable strengthened antiviral activity. The invention further relates to a drug composition containing the polypeptide shown by the formula 1, its derivatives, its stereoisomers or its salts free of physiological toxicity and application in preparation of drugs for treating or preventing related diseases caused by HIV infection, especially acquired immune deficiency syndrome." Anti-HIV DRAVPa1868 MTWEEWDKKIEEYTKKIEELIKKSONOOIDL 31 Sequence 66 from Patent US20240309059 A1 Synthetic construct HIV Patent Application CN106543273?A 2017-03-29 Polypeptide for inhibiting HIV infection and medicinal application thereof "The invention belongs to the field of biological medicine and relates to an anti-HIV infection peptide, in particular to a polypeptide shown by a formula 1 CP_I(L)_D_I (L), its derivatives, its stereoisomers, or its salts free of physiological toxicity. CP in the formula represents a C-terminal polypeptide derived from HIV-1 gp41 and having HIV-1 inhibiting activity, L represents leucine, I represents isoleucine, and D represents aspartic acid. Variable amino acid is added to the carbon terminal of the C-terminal polypeptide having the HIV-1 inhibiting activity to obtain a longer polypeptide, so that the polypeptide has remarkable strengthened antiviral activity. The invention further relates to a drug composition containing the polypeptide shown by the formula 1, its derivatives, its stereoisomers or its salts free of physiological toxicity and application in preparation of drugs for treating or preventing related diseases caused by HIV infection, especially acquired immune deficiency syndrome." Anti-HIV DRAVPa1869 RVTQMNLNDRLASLYDKV 18 Sequence 1 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N1" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 20 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N1" DRAVPa1870 RATQMNLNDRLASLYDKV 18 Sequence 6 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N2" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N2" DRAVPa1871 RVTAMNLNDRLASLYDKV 18 Sequence 7 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N3" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 22 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N3" DRAVPa1872 RVTQANLNDRLASLYDKV 18 Sequence 8 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N4" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 23 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N4" DRAVPa1873 RVTQMNANDRLASLYDKV 18 Sequence 9 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N5" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 24 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N5" DRAVPa1874 RVTQMNLNARLASLYDKV 18 Sequence 10 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N6" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 25 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N6" DRAVPa1875 RVTQMNLNDRLVSLYDKV 18 Sequence 11 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N7" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 26 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N7" DRAVPa1876 RVTQMNLNDRLASLYAKV 18 Sequence 12 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N8" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 27 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N8" DRAVPa1877 RVTQMNLNDRLASLYDAV 18 Sequence 13 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N9" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 28 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N9" DRAVPa1878 NDRLASLYDKV 11 Sequence 14 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N10" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 29 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N10" DRAVPa1879 NLNDRLASLYDKV 13 Sequence 15 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N11" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 30 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N11" DRAVPa1880 RVTQMNLADRLASLYDKV 18 Sequence 16 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N12" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 31 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N12" DRAVPa1881 RVTQMNLNDALASLYDKV 18 Sequence 17 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N13" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 32 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N13" DRAVPa1882 RVTQMNLNDRLAALYDKV 18 Sequence 18 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N14" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 33 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N14" DRAVPa1883 RVTQMNLNDRLASLYDKV 18 Sequence 19 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N15" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 34 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N15" DRAVPa1884 RVTQMNLNDRAASLYDKV 18 Sequence 21 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N16" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 35 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N16" DRAVPa1885 RVTQMNLNDRLASLADKV 18 Sequence 22 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N17" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 36 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N17" DRAVPa1886 GRKKRRQRRRPPQACWMSPRHLGTC 25 Sequence 23 from Patent CN116964073 A Synthetic construct "SARS-CoV-2,MERS-CoV,BCoV,H1N18" Patent Application CN116964073 A 2023-10-27 "WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603" Peptides for treating respiratory tract infections of viral origin "A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 37 and an antiviral drug." "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N18" DRAVPa1887 DIFCDWWRWVISVLDSVK 18 Sequence 1 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1888 DVVSIWFKWIDCLWDSVR 18 Sequence 2 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1889 RLVKSIWDWFCIVVDSWD? 18 Sequence 3 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1890 DVWCSWVSWVIKLFRDID 18 Sequence 4 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1891 DWVDCFWSWLIKVIDRVS 18 Sequence 5 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1892 SVVCDWWDVIIKWFDRLS 18 Sequence 6 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1893 DWVSKFWRILICVWDSVD 18 Sequence 7 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1894 DVVDDWWSVLCKWFRIIS 18 Sequence 8 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1895 RVFCIVWDWVKSWIDDLS 18 Sequence 9 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1896 SWVDSFWDWLIRVIKCVD 18 Sequence 10 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1897 DVVDIVLRWICSWWSDFK 18 Sequence 11 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1898 RVIDCWVDWWSIVFKSLD 18 Sequence 12 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1899 SVFCSLWRWVIDWVDDIK 18 Sequence 13 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1900 KLVDSIWSWFICVVRDWD 18 Sequence 14 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1901 DVFCIWIDWVKSLWRDVS 18 Sequence 15 from Patent WO2024054009A1 Synthetic construct dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1902 ?DWLRIIWWWVCSVVSDFK 18 Sequence 16 from Patent WO2024054009A1 HCV dengue virus Patent Application WO2024054009A1 2024-03-14 "KR20220114326A, KR2023013277W" NOVEL ANTIVIRAL PEPTIDE "The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide." Anti-dengue virus DRAVPa1903 NDFRSKT 7 Sequence 1 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088370A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1904 TKSRFDN 7 Sequence 2 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088371A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1905 CNDFRSKTC 9 Sequence 3 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088372A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." DRAVPe00458 Anti-influenza virus DRAVPa1906 CTKSRFDNC 9 Sequence 4 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088373A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1907 RRKKCTWARFINC 13 Sequence 17 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088374A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1908 RRKKCTWCRFINC 13 Sequence 18 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088375A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1909 RRKKCTWDRFINC 13 Sequence 19 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088376A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1910 RRKKCTWERFINC 13 Sequence 20 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088377A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1911 RRKKCTWFRFINC 13 Sequence 21 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088378A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1912 RRKKCTWGRFINC 13 Sequence 22 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088379A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1913 RRKKCTWHRFINC 13 Sequence 23 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088380A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1914 RRKKCTWIRFINC 13 Sequence 24 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088381A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1915 RRKKCTWKRFINC 13 Sequence 25 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088382A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1916 RRKKCTWLRFINC 13 Sequence 26 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088383A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1917 RRKKCTWMRFINC 13 Sequence 27 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088384A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1918 RRKKCTWNRFINC 13 Sequence 28 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088385A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1919 RRKKCTWPRFINC 13 Sequence 29 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088386A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1920 RRKKCTWQRFINC 13 Sequence 30 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088387A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1921 RRKKCTWRRFINC 13 Sequence 31 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088388A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1922 RRKKCTWSRFINC 13 Sequence 32 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088389A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1923 RRKKCTWTRFINC 13 Sequence 33 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088390A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1924 RRKKCTWVRFINC 13 Sequence 34 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088391A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1925 RRKKCTWWRFINC 13 Sequence 35 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088392A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1926 RRKKCTWYRFINC 13 Sequence 36 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088393A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1927 RRKKCTWFAFINC 13 Sequence 37 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088394A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1928 RRKKCTWFCFINC 13 Sequence 38 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088395A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1929 RRKKCTWFDFINC 13 Sequence 39 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088396A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1930 RRKKCTWFEFINC 13 Sequence 40 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088397A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1931 RRKKCTWFFFINC 13 Sequence 41 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088398A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1932 RRKKCTWFGFINC 13 Sequence 42 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088399A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1933 RRKKCTWFHFINC 13 Sequence 43 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088400A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1934 RRKKCTWFIFINC 13 Sequence 44 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088401A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1935 RRKKCTWFKFINC 13 Sequence 45 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088402A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1936 RRKKCTWFLFINC 13 Sequence 46 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088403A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1937 RRKKCTWFMFINC 13 Sequence 47 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088404A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1938 RRKKCTWFNFINC 13 Sequence 48 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088405A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1939 RRKKCTWFPFINC 13 Sequence 49 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088406A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1940 RRKKCTWFQFINC 13 Sequence 50 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088407A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1941 RRKKCWWFTWIAC 13 Sequence 51 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088408A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1942 RRKKCTWFSFINC 13 Sequence 52 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088409A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1943 RRKKCTWFTFINC 13 Sequence 53 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088410A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1944 RRKKCTWFVFINC 13 Sequence 54 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088411A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1945 RRKKCTWFWFINC 13 Sequence 55 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088412A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1946 RRKKCTWFYFINC 13 Sequence 56 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088413A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1947 RRKKCWWFTYIAC 13 Sequence 57 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088414A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1948 RRKKCAWFTFINC 13 Sequence 58 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088415A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1949 RRKKCCWFTFINC 13 Sequence 59 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088416A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1950 RRKKCDWFTFINC 13 Sequence 60 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088417A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1951 RRKKCEWFTFINC 13 Sequence 61 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088418A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1952 RRKKCFWFTFINC 13 Sequence 62 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088419A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1953 RRKKCGWFTFINC 13 Sequence 63 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088420A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1954 RRKKCHWFTFINC 13 Sequence 64 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088421A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1955 RRKKCIWFTFINC 13 Sequence 65 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088422A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1956 RRKKCKWFTFINC 13 Sequence 66 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088423A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1957 RRKKCLWFTFINC 13 Sequence 67 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088424A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1958 RRKKCMWFTFINC 13 Sequence 68 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088425A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1959 RRKKCNWFTFINC 13 Sequence 69 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088426A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1960 RRKKCPWFTFINC 13 Sequence 70 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088427A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1961 RRKKCQWFTFINC 13 Sequence 71 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088428A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1962 RRKKCRWFTFINC 13 Sequence 72 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088429A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1963 RRKKCSWFTFINC 13 Sequence 73 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088430A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1964 RRKKCTWFTFINC 13 Sequence 74 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088431A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1965 RRKKCVWFTFINC 13 Sequence 75 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088432A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1966 RRKKCWWFTFINC 13 Sequence 76 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088433A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1967 RRKKCYWFTFINC 13 Sequence 77 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088434A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1968 RRKKCWWFTFIAC 13 Sequence 78 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088435A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1969 RRKKCWWFTFICC 13 Sequence 79 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088436A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1970 RRKKCWWFTFIDC 13 Sequence 80 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088437A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1971 RRKKCWWFTFIEC 13 Sequence 81 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088438A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1972 RRKKCWWFTFIFC 13 Sequence 82 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088439A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1973 RRKKCWWFTFIGC 13 Sequence 83 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088440A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1974 RRKKCWWFTFIHC 13 Sequence 84 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088441A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1975 RRKKCWWFTFIIC 13 Sequence 85 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088442A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1976 RRKKCWWFTFIKC 13 Sequence 86 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088443A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1977 RRKKCWWFTFILC 13 Sequence 87 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088444A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1978 RRKKCWWFTFIMC 13 Sequence 88 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088445A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1979 RRKKCWWFTFIPC 13 Sequence 89 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088446A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1980 RRKKCWWFTFIQC 13 Sequence 90 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088447A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1981 RRKKCWWFTFIRC 13 Sequence 91 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088448A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1982 RRKKCWWFTFISC 13 Sequence 92 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088449A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1983 RRKKCWWFTFITC 13 Sequence 93 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088450A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1984 RRKKCWWFTFIVC 13 Sequence 94 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088451A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1985 RRKKCWWFTFIWC 13 Sequence 95 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088452A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1986 RRKKCWWFTFIYC 13 Sequence 96 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088453A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1987 CTKSRFANC 9 Sequence 97 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088454A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1988 CTKSRFCNC 9 Sequence 98 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088455A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1989 CTKSRFENC 9 Sequence 99 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088456A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1990 CTKSRFFNC 9 Sequence 100 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088457A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1991 CTKSRFGNC 9 Sequence 101 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088458A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1992 CTKSRFHNC 9 Sequence 102 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088459A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1993 CTKSRFINC 9 Sequence 103 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088460A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1994 CTKSRFKNC 9 Sequence 104 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088461A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1995 CTKSRFLNC 9 Sequence 105 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088462A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1996 CTKSRFMNC 9 Sequence 106 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088463A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1997 CTKSRFNNC 9 Sequence 107 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088464A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1998 CTKSRFPNC 9 Sequence 108 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088465A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa1999 CTKSRFQNC 9 Sequence 109 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088466A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2000 CTKSRFRNC 9 Sequence 110 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088467A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2001 CTKSRFTNC 9 Sequence 111 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088468A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2002 CTKSRFTNC 9 Sequence 112 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088469A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2003 CTKSRFVNC 9 Sequence 113 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088470A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2004 CTKSRFWNC 9 Sequence 114 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088471A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2005 CTKSRFYNC 9 Sequence 115 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088472A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2006 RRKKCTASRFINC 13 Sequence 116 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088473A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2007 RRKKCTCSRFINC 13 Sequence 117 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088474A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2008 RRKKCTDSRFINC 13 Sequence 118 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088475A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2009 RRKKCTESRFINC 13 Sequence 119 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088476A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2010 RRKKCTFSRFINC 13 Sequence 120 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088477A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2011 RRKKCTGSRFINC 13 Sequence 121 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088478A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2012 RRKKCTHSRFINC 13 Sequence 122 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088479A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2013 RRKKCTISRFINC 13 Sequence 123 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088480A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2014 RRKKCTKSRFINC 13 Sequence 124 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088481A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2015 RRKKCTLSRFINC 13 Sequence 125 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088482A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2016 RRKKCTMSRFINC 13 Sequence 126 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088483A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2017 RRKKCTNSRFINC 13 Sequence 127 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088484A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2018 RRKKCTPSRFINC 13 Sequence 128 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088485A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2019 RRKKCTQSRFINC 13 Sequence 129 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088486A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2020 RRKKCTRSRFINC 13 Sequence 130 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088487A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2021 RRKKCTSSRFINC 13 Sequence 131 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088488A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2022 RRKKCTTSRFINC 13 Sequence 132 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088489A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2023 RRKKCTVSRFINC 13 Sequence 133 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088490A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2024 RRKKCTWSRFINC 13 Sequence 134 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088491A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2025 RRKKCTWSRFINC 13 Sequence 136 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088492A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2026 RRKKCWWFTAIAC 13 Sequence 137 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088493A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2027 RRKKCWWFTCIAC 13 Sequence 138 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088494A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2028 RRKKCWWFTDIAC 13 Sequence 139 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088495A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2029 RRKKCWWFTEIAC 13 Sequence 140 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088496A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2030 RRKKCWWFTGIAC 13 Sequence 141 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088497A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2031 RRKKCWWFTHIAC 13 Sequence 142 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088498A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2032 RRKKCWWFTIIAC 13 Sequence 143 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088499A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2033 RRKKCWWFTKIAC 13 Sequence 144 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088500A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2034 RRKKCWWFTLIAC 13 Sequence 145 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088501A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2035 RRKKCWWFTMIAC 13 Sequence 146 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088502A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2036 RRKKCWWFTNIAC 13 Sequence 147 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088503A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2037 RRKKCWWFTPIAC 13 Sequence 148 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088504A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2038 RRKKCWWFTQIAC 13 Sequence 149 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088505A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2039 RRKKCWWFTRIAC 13 Sequence 150 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088506A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2040 RRKKCWWFTSIAC 13 Sequence 151 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088507A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2041 RRKKCWWFTTIAC 13 Sequence 152 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088508A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2042 RRKKCWWFTVIAC 13 Sequence 153 from Patent US10538554B2 Synthetic construct Influenza viruses Granted Patent US10538554B2 2020-01-21 "WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A£¬JP2022088509A" Peptides and uses therefor as antiviral agents "Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections." Anti-influenza virus DRAVPa2043 MLSYLIFALAVSPILG 16 Sequence 1 from Patent US10745448B2 Vesicular stomatitis virus VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2044 MKTIIALSYIFCLALG 16 Sequence 2 from Patent US10745448B2 Influenza A virus VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (3) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2045 MKAIIVLLMVVTSNA 15 Sequence 3 from Patent US10745448B2 Influenza B virus VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (4) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2046 MKCLLYLAFLFIGVNC 16 Sequence 4 from Patent US10745448B2 Vesicular stomatitis virus VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (5) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2047 MKTIIALSYIFCQVLA 16 Sequence 5 from Patent US10745448B2 Influenza A virus VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (6) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2048 MKTIIALSYIFCLVFA 16 Sequence 6 from Patent US10745448B2 Influenza A virus VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (7) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2049 MKTIIALSYIFCLVLG 16 Sequence 7 from Patent US10745448B2 Influenza A virus VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (8) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2050 RSRKYTSWYVALKR 14 Sequence 8 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (9) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2051 MAKSIRSKHRRQMRMM 19 Sequence 9 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (10) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2052 MARRRRHRGPRRPRPP 16 Sequence 10 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (11) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2053 GRCRRLANFGPRKRRRRRR 19 Sequence 11 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (12) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2054 RRRKRNRDARRRRRKQ 16 Sequence 12 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (13) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2055 MQRKPTIRRKNLRLRRK 17 Sequence 13 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (14) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2056 IMRRRGL 7 Sequence 14 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (15) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2057 KKLKKRNK 8 Sequence 15 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (16) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2058 RRRANNRRR 9 Sequence 16 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (17) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2059 RKKRKKK 7 Sequence 17 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (18) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2060 KRKGKLKNKGSKRKK 15 Sequence 18 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (19) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2061 SKRLSSRARKRAAKRRLG 18 Sequence 19 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (20) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2062 KRPRRRPSRPFRKP 14 Sequence 20 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (21) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2063 KKRTLRKNDRKKR 13 Sequence 21 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (22) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2064 WRRQARFK 8 Sequence 22 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (23) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2065 RKKRRQRRR 9 Sequence 23 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (24) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2066 YARAAARQARA 11 Sequence 24 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (25) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2067 KGRQVKVWFQNRRMKWKK 18 Sequence 25 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (26) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2068 MLSYLIFALAVSPILGKKRTLRKNDRKKR 29 Sequence 26 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (27) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2069 MKTIIALSYIFCLALGKKRTLRKNDRKKR 29 Sequence 27 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (28) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2070 MKAIIVLLMVVTSNAKKRTLRKNDRKKR 28 Sequence 28 from Patent US10745448B2 Synthetic peptide VSV Granted Patent US10745448B2 2020-08-18 JP6994714B2 Antiviral peptide and use therefor "An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (29) an amino acid sequence that functions as a cell penetrating peptide (CPP)." Anti-VSV DRAVPa2071 SGSWLRDVWTWLQSKL 16 Sequence 1 from Patent US10351604B2 Synthetic peptide "DENV,CHIKV,YFV,JEV" Granted Patent US10351604B2 2019-07-16 "WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2" Broad-spectrum anti-infective peptides Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides. "Anti-DENV,Anti-CHIKV,Anti-YFV,Anti-JEV" DRAVPa2072 GSSWLRDVWTWLQSKL 16 Sequence 2 from Patent US10351604B2 Synthetic peptide "DENV,YFV,JEV" Granted Patent US10351604B2 2019-07-16 "WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2" Broad-spectrum anti-infective peptides Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides. "Anti-DENV,Anti-YFV,Anti-JEV" DRAVPa2073 GSSWLRDVWTWLQSAL 16 Sequence 3 from Patent US10351604B2 Synthetic peptide "DENV,CHIKV,YFV," Granted Patent US10351604B2 2019-07-16 "WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2" Broad-spectrum anti-infective peptides Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides. "Anti-DENV,Anti-CHIKV,Anti-YFV" DRAVPa2074 GSSWLRDVWTKLQSWL 16 Sequence 4 from Patent US10351604B2 Synthetic peptide "DENV,CHIKV,YFV,JEV" Granted Patent US10351604B2 2019-07-16 "WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2" Broad-spectrum anti-infective peptides Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides. "Anti-DENV,Anti-CHIKV,Anti-YFV,Anti-JEV" DRAVPa2075 GSSWLRDIWTALQSWI 16 Sequence 6 from Patent US10351604B2 Synthetic peptide "DENV,,YFV,JEV" Granted Patent US10351604B2 2019-07-16 "WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2" Broad-spectrum anti-infective peptides Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides. "Anti-DENV,Anti-YFV,Anti-JEV" DRAVPa2076 RRKKAAWALLPAWLLALLAP 20 Sequence 1 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2077 RRKKAAVALIPAWLLALLA 19 Sequence 2 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2078 RRKKAAWALLPAWLLALL 18 Sequence 3 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2079 RRKKAAWALLPAWLLAL 17 Sequence 4 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2080 RRKKAAWALLPAWLLA 16 Sequence 5 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2081 RRKKAWALLPAWLLALLAP 19 Sequence 18 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2082 RRKKWALLPAWLLALLAP 18 Sequence 19 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2083 RRKKALLPAWLLALLAP 17 Sequence 20 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2084 RRKKLLPAWLLALLAP 16 Sequence 21 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2085 RRKKLPAWLLALLAP 15 Sequence 22 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2086 RRKKWLLALLAP 12 Sequence 23 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2087 RRKKWALLAWLLALLA 16 Sequence 32 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2088 RRKKAAWALLAWLLALLA 18 Sequence 43 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2089 RRKKLLAWLLALLA 14 Sequence 44 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2090 RRKKLAVILLALLA 13 Sequence 45 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2091 RKKLAWLLALLA 12 Sequence 50 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2092 RKAWLLALLA 10 Sequence 51 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2093 KLAVILALLA 10 Sequence 52 from Patent US9221874B2 Synthetic peptide influenza virus Granted Patent US9221874B2 2015-12-29 WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4 Antiviral peptides against influenza virus "The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections." Anti-influenza virus DRAVPa2094 CNDFRSKTC 9 Sequence 1 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N2 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2095 NDFRSKT 7 Sequence 2 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N3 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2096 QHSTKWF 7 Sequence 4 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N4 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2097 LPYAAKH 7 Sequence 5 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N5 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2098 ILGDKVG 7 Sequence 6 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N6 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2099 ILGYKVG 7 Sequence 7 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N7 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2100 HPOFLSL 7 Sequence 8 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N8 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2101 GLYNHPQ 7 Sequence 9 from Patent US8883480B2 Synthetic peptide H9N2 Granted Patent US8883480B2 2014-11-11 WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Antiviral peptide against avian influenza virus H9N9 "The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus." Anti-H9N2 DRAVPa2102 EVKLLEQSGAELVKPGASVRLSCTAS 26 Sequence 3 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2103 YMSWVKQRPEQGLEWIGRI 19 Sequence 4 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2104 TKYDPKFOGKATITADTSSNTAYLHLSSLTSGDTAVYYCSR 41 Sequence 5 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2105 WGQGTLVTVSA 11 Sequence 6 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2106 GFNIKDT 7 Sequence 7 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2107 DPANGD 6 Sequence 8 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2108 GWEGFAY 7 Sequence 9 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2109 ELVMTQTPASLAVSLGQRATISC 23 Sequence 10 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2110 WYQQKAGQPPKLLIY 15 Sequence 11 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2111 GIPARFSGSGSRTDFTLTINPVEADDVATYFC 32 Sequence 12 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2112 FGGGTKLEIKR 11 Sequence 13 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2113 RASENVDRYGNSFMH 15 Sequence 14 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2114 RASNLES 7 Sequence 15 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2115 QRSNEVPWT 9 Sequence 16 from Patent US9880167B2 Synthetic peptide Dengue Virus Granted Patent US9880167B2 2018-01-30 US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2## Anti-dengue virus antibodies and uses thereof "The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV." Anti-dengue virus DRAVPa2116 LRTRKRGRKLRTRKRGRK 18 Sequence 48 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2117 RTRKRGRKRTRKRGRK 16 Sequence 3 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2118 RTRKRGRRTRKRGR 14 Sequence 4 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2119 LRKRKRLLRKRKRL 14 Sequence 5 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2120 LRKRKRLRKLRKRKRLRK 18 Sequence 6 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2121 WRWRKRWRKWRWRKRWRK 18 Sequence 7 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2122 RRWRKRWRKWRWRKRWRK 18 Sequence 34 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2123 KRWRKRWRKWRWRKRWRK 18 Sequence 35 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2124 LRWRKRWRKWRWRKRWRK 18 Sequence 36 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2125 HRWRKRWRKWRWRKRWRK 18 Sequence 37 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2126 RWRKRWRKWRWRKRWRK 17 Sequence 38 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2127 RRWRKRWRKRRWRKRWRK 18 Sequence 39 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2128 KRWRKRWRKKRWRKRWRK 18 Sequence 40 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2129 LRWRKRWRKLRWRKRWRK 18 Sequence 41 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2130 HRWRKRWRKHRWRKRWRK 18 Sequence 42 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2131 RWRKRWRKRWRKRWRK 16 Sequence 43 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2132 RWRKRGRKRWRKRGRK 16 Sequence 44 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2133 RTRKRWRKRTRKRGRK 16 Sequence 45 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2134 RWRKRWRKRWRKRWRK 16 Sequence 46 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2135 RWRKRWRWRKRWRWRKRW 18 Sequence 47 from Patent US8017579B2 Homo sapiens "HIV,HSV" Granted Patent US8017579B2 2011-09-13 JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1 Treatment of viral infections "The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections." "Anti-HIV,Anti-HSV" DRAVPa2136 NFRHTHR 7 Sequence 1 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-19 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-19, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2137 FNRHTHR 7 Sequence 2 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-20 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-20, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2138 IGVRGGW 7 Sequence 3 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-21 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-21, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2139 KWPYKKS 7 Sequence 4 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-22 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-22, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2140 KTYHTHR 7 Sequence 5 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-23 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-23, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2141 IRQFFKK 7 Sequence 6 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-24 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-24, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2142 FYIKINH 7 Sequence 7 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-25 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-25, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2143 KSPPYHK 7 Sequence 8 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-26 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-26, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2144 WVHFYHF 7 Sequence 9 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-27 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-27, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2145 KPYIWKS 7 Sequence 10 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-28 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-28, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2146 KWPFKKS 7 Sequence 11 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-29 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-29, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2147 IGHVPGT 7 Sequence 12 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-30 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-30, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2148 WIGVRNW 7 Sequence 13 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-31 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-31, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2149 QGTHTAH 7 Sequence 14 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-32 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-32, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2150 NSGGSVH 7 Sequence 15 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-33 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-33, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2151 AAARFST 7 Sequence 16 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-34 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-34, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2152 PIGVPHT 7 Sequence 17 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-35 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-35, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2153 QVAVLYQ 7 Sequence 18 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-36 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-36, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2154 FLGVYYH 7 Sequence 19 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-37 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-37, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2155 ALTGIAV 7 Sequence 20 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-38 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-38, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2156 FVFLVLL 7 Sequence 21 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-39 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-39, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2157 VVIGIVN 7 Sequence 22 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-40 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-40, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2158 NFTISVTT 8 Sequence 23 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-41 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-41, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2159 RVVVLSFE 8 Sequence 24 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-42 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-42, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2160 AAYYVGYL 8 Sequence 25 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-43 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-43, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2161 SIIAYTMSLG 10 Sequence 26 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-44 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-44, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2162 GVVFLHVTYV 10 Sequence 27 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-45 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-45, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2163 FTGCVIAWNR 10 Sequence 28 from Patent CN111499692B Synthetic peptide SARS-CoV-2 Granted Patent CN111499692B 2020-12-04 Polypeptide of targeting novel coronavirus COVID-46 and application thereof "The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-46, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs." Anti-SARS-CoV-2 DRAVPa2164 SWETWEREIENYTROIYRILEESOEOODRNERDLLE. 36 Sequence 1 from Patent US8603965B2 homo sapiens HIV Granted Patent US8603965B2 2013-12-10 WO2007143934A1##CN101088557A Pharmaceutical composition for the prophylaxis and treatment of HIV infection and its use "Pharmaceutical compositions for the prophylaxis and treatment of HIV infection and its use are provided. Particularly, the present invention provides a pharmaceutical composition comprising anti-virus peptides, use of said composition for manufacturing a medicament for the prophylaxis and treatment of HIV infection, and method for preventing and treating HIV infection by using said composition." Anti-HIV DRAVPa2165 NGAICWGPCPTAFRQIGNCGHFKVRCCNIR 30 Sequence 13 from Patent US9822155B2 Synthetic peptide Influenza A virus Granted Patent US9822155B2 2017-11-21 WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B Method of preventively treating a subject at the risk of developing infections of a respiratory virus "A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a?peptide?synthesized through a chemical route or by a genetic engineering process, characterized in that the?peptide?has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the?peptide?has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the?peptide; and wherein the?peptide?consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 15. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum?antiviral?activities." Anti-Influenza A virus DRAVPa2166 NGAICWGPCPTAFRQIGNCGHFKVRCCNID 30 Sequence 14 from Patent US9822155B2 Synthetic peptide Influenza A virus Granted Patent US9822155B2 2017-11-21 WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B Method of preventively treating a subject at the risk of developing infections of a respiratory virus "A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a?peptide?synthesized through a chemical route or by a genetic engineering process, characterized in that the?peptide?has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the?peptide?has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the?peptide; and wherein the?peptide?consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 16. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum?antiviral?activities." Anti-Influenza A virus DRAVPa2167 NGAICWGPCPTAFRQIGNCGHFKVTCCNID 30 Sequence 15 from Patent US9822155B2 Synthetic peptide Influenza A virus Granted Patent US9822155B2 2017-11-21 WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B Method of preventively treating a subject at the risk of developing infections of a respiratory virus "A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a?peptide?synthesized through a chemical route or by a genetic engineering process, characterized in that the?peptide?has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the?peptide?has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the?peptide; and wherein the?peptide?consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 17. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum?antiviral?activities." Anti-Influenza A virus DRAVPa2168 DEDNGAICWGPCPTAFRQIGNCGHFKVRCCKIR 33 Sequence 16 from Patent US9822155B2 Synthetic peptide Influenza A virus Granted Patent US9822155B2 2017-11-21 WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B Method of preventively treating a subject at the risk of developing infections of a respiratory virus "A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a?peptide?synthesized through a chemical route or by a genetic engineering process, characterized in that the?peptide?has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the?peptide?has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the?peptide; and wherein the?peptide?consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 18. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum?antiviral?activities." Anti-Influenza A virus DRAVPa2169 KHRNGAICWGPCPTAFRQIGNCGHFKVRCCKIR 33 Sequence 17 from Patent US9822155B2 Synthetic peptide Influenza A virus Granted Patent US9822155B2 2017-11-21 WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B Method of preventively treating a subject at the risk of developing infections of a respiratory virus "A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a?peptide?synthesized through a chemical route or by a genetic engineering process, characterized in that the?peptide?has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the?peptide?has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the?peptide; and wherein the?peptide?consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 19. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum?antiviral?activities." Anti-Influenza A virus DRAVPa2170 SWLRDIWDWICEVLSDFK 18 Sequence 1 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2171 SWLRDIWDWICEVLSDFK 18 Sequence 2 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2172 GSWLRDIWDWICEVLSDFK 19 Sequence 3 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2173 SWLRDIWDWICEVLSDFKTW 20 Sequence 4 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2174 KFDSLVECIWDWIDRLWS 18 Sequence 5 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2175 KWLCRIWSWISDVLDDFE 18 Sequence 6 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2176 SIWRDWVDLICEFLSDWK 18 Sequence 7 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2177 DWLRIIWDWVCSVVSDFK 18 Sequence 8 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2178 PLKPTKRSFIKDLLFNKV 18 Sequence 9 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2179 SWLRDIWDWISEVLSDFK 18 Sequence 10 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2180 SWLRDIWDWISEVLSDFK 18 Sequence 11 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2181 SWLRDIWDWICEVLSDFR 18 Sequence 12 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2182 SYLRDIWDYICEVLSDFK 18 Sequence 13 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2183 SYLRDIWDYISEVLSDFK 18 Sequence 14 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2184 SYLREIWDYISEVLSDFR 18 Sequence 15 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2185 SWLREIWDWICEVLSDFK 18 Sequence 16 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2186 SWLRDIWDWISEVLSDFR 18 Sequence 32 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2187 SWLRDIWDYISEVLSDFR 18 Sequence 33 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2188 SWLRDIWDYISEVLSDFR 18 Sequence 34 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2189 SWLRDIWDYICEVLSDFR 18 Sequence 35 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2190 AWLRDIWDWICEVLSDFK 18 Sequence 40 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2191 SALRDIWDWICEVLSDFK 18 Sequence 41 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2192 SWARDIWDWICEVLSDFK 18 Sequence 42 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2193 SWLADIWDWICEVLSDFK 18 Sequence 43 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2194 SWLRAIWDWICEVLSDFK 18 Sequence 44 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2195 SWLRDAWDWICEVLSDFK 18 Sequence 45 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2196 SWLRDIADWICEVLSDFK 18 Sequence 46 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2197 SWLRDIWAWICEVLSDFK 18 Sequence 47 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2198 SWLRDIWDAICEVLSDFK 18 Sequence 48 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2199 SWLRDIWDWACEVLSDFK 18 Sequence 49 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2200 SWLRDIWDWIAEVLSDFK 18 Sequence 50 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2201 SWLRDIWDWICAVLSDFK 18 Sequence 51 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2202 SWLRDIWDWICEALSDFK 18 Sequence 52 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2203 SWLRDIWDWICEVASDFK 18 Sequence 53 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2204 SWLRDIWDWICEVLADFK 18 Sequence 54 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2205 SWLRDIWDWICEVLSAFK 18 Sequence 55 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2206 SWLRDIWDWICEVLSDAK 18 Sequence 56 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2207 SWLRDIWDWICEVLSDFA 18 Sequence 57 from Patent US20230256049A1 Synthetic peptide SARS-CoV-2 Patent Application US20230256049A1 2023-08-17 WO2022020766A1##EP4171746A4##CA3186948A1 Materials and methods for the prevention and treatment of viral respiratory diseases This disclosure is related to?the?use?of?a peptide with antimicrobial properties.?The?peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory?diseases?caused by viruses. A variety?of?formulations and uses are described as well as?methods?of?manufacture thereof.?The?formulations are safe and useful in patients¡ªboth humans and animals¡ªfor?the?delivery?of?appropriate bioactive substance(s) to?the?respiratory system. Anti-SARS-CoV-2 DRAVPa2208 WRCKVR 6 AP19 Synthetic peptide GAstV Patent Application CN115894614A 2023-04-04 Antiviral affinity peptide of targeted goose astrovirus Spike protein and application of antiviral affinity peptide "The invention relates to an?antiviral?affinity?peptide?of a targeted goose astrovirus Spike protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-2Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinity?peptide?for specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research on?antiviral?polypeptide drugs" Anti-GAstV DRAVPa2209 WKHKRR 6 AP21 Synthetic peptide GAstV Patent Application CN115894614A 2023-04-04 Antiviral affinity peptide of targeted goose astrovirus Spike protein and application of antiviral affinity peptide "The invention relates to an?antiviral?affinity?peptide?of a targeted goose astrovirus Spike protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-3Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinity?peptide?for specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research on?antiviral?polypeptide drugs" Anti-GAstV DRAVPa2210 WKHWYK 6 AP30 Synthetic peptide GAstV Patent Application CN115894614A 2023-04-04 Antiviral affinity peptide of targeted goose astrovirus Spike protein and application of antiviral affinity peptide "The invention relates to an?antiviral?affinity?peptide?of a targeted goose astrovirus Spike protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-4Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinity?peptide?for specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research on?antiviral?polypeptide drugs" Anti-GAstV DRAVPa2211 KYWQRE 6 Sequence 8 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-4 infection in the future." Anti-FAdV-4 DRAVPa2212 KYWGRN 6 Sequence 11 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber2 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-5 infection in the future." Anti-FAdV-4 DRAVPa2213 YMKKYA 6 Sequence 14 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber3 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-6 infection in the future." Anti-FAdV-4 DRAVPa2214 YMKHSD 6 Sequence 16 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber4 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-7 infection in the future." Anti-FAdV-4 DRAVPa2215 YMKHSR 6 Sequence 20 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber5 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-8 infection in the future." Anti-FAdV-4 DRAVPa2216 YMKHRH 6 Sequence 21 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber6 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-9 infection in the future." Anti-FAdV-4 DRAVPa2217 YMKHRV 6 Sequence 22 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber7 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-10 infection in the future." Anti-FAdV-4 DRAVPa2218 KQWKEH 6 Sequence 24 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber8 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-11 infection in the future." Anti-FAdV-4 DRAVPa2219 KQWYRT 6 Sequence 25 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber9 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-12 infection in the future." Anti-FAdV-4 DRAVPa2220 KQWGHR 6 Sequence 27 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber10 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-13 infection in the future." Anti-FAdV-4 DRAVPa2221 KQWCQW 6 Sequence 32 from Patent CN116874560A Synthetic peptide FAdV-4 Patent Application CN116874560A 2023-10-13 Antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber11 protein and application thereof "The invention provides an?antiviral?affinity?peptide?targeting fowl adenovirus 4 type Fiber1 protein and application of the?antiviral?affinity?peptide. The sequence of the affinity?peptide?is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity?peptide?targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal?peptide?having the?antiviral?activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the?antiviral?drug design, and the new thought is provided for the prevention and the control of the FAdV-14 infection in the future." Anti-FAdV-4 DRAVPa2222 VTFLVGLNQYLV 12 Sequence 47 from Patent US20140294942A1 Synthetic peptide vsv Patent Application US20140294942A1 2014-10-02 WO/2013/036622 ?ANTIVIRAL?PEPTIDES EFFECTIVE AGAINST HEPATITIS C VIRUS "In certain embodiments this invention provides novel?antiviral?peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The?peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like." Anti-vsv DRAVPa2223 VSFRVGLHEYPV 12 Sequence 48 from Patent US20140294942A1 Synthetic peptide vsv Patent Application US20140294942A1 2014-10-02 WO/2013/036622 ?ANTIVIRAL?PEPTIDES EFFECTIVE AGAINST HEPATITIS C VIRUS "In certain embodiments this invention provides novel?antiviral?peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The?peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like." Anti-vsv DRAVPa2224 SDWGVLTNLG ILLLLSIAVL IALSCICGSGKKRTLRKNDRKKR 43 Sequence 29 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2225 RQWIPAGIGVTGVIIAVIALFCICKFVGSGKKRTLRKNDRKKR 43 Sequence 30 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 101 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2226 RQWIPAGIGITGIIIAIIALLCVCKLLGSGKKRTLRKNDRKKR 43 Sequence 31 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 102 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2227 MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSGSGKKRTLRKNDRKKR 48 Sequence 32 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 103 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2228 MEGLSLLQLPRDKFRKSSFFVWVIILFQKAFSGSGKKRTLRKNDRKKR 48 Sequence 33 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 104 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2229 MKTTCFLISLILQGTKNGSGKKRTLRKNDRKKR 34 Sequence 34 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 105 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2230 MKTTCLLISLIQGCKTGSGKKRTLRKNDRKKR 34 Sequence 35 from Patent US20210380642B2 Synthetic peptide Ebola virus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 106 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2231 NAIVGIVLLIVVTFLAIKTKKRTLRKNDRKKR 32 Sequence 36 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 107 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2232 FFFIIGLIIGLFLVLRVGIHLKKRTLRKNDRKKR 34 Sequence 37 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 108 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2233 VLAVIIGFVILMFLIKLIGVLKKRTLRKNDRKKR 34 Sequence 38 from Patent US20210380642B2 Synthetic peptide Ebolavirus£¬Marburg virus Granted Patent US20210380642B2 2023-09-26 JP2021187810 Antiviral peptide and use thereof "The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 109 amino acid residues." Anti-Ebola virus£¬Anti-Marburg virus DRAVPa2234 SWLRDIWDWICEVLSDFK 18 Sequence 43 from Patent US20070073039A1 Hepatitis C Virus HCV£¬Dengue viral Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2235 SWLRDIWDWICEVL 14 Sequence 92 from Patent US20070073039A1 Hepatitis C Virus Dengue viral Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2236 LRDIWDWICEVLSDFK 16 Sequence 107 from Patent US20070073039A1 Hepatitis C Virus Dengue viral Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2237 LYGNEGCGWAGWLLSPRG 18 Sequence 6 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2238 IFLLALLSCLTVPASAYQ 18 Sequence 8 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2239 GSATLCSALYVGDLCGSV 18 Sequence 12 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2240 ALYVGDLCGSVFLVGQLF 18 Sequence 13 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2241 IMDMIAGAHWGVLAGIAY 18 Sequence 14 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2242 YLYGVGSSIASWAIKWEY 18 Sequence 24 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2243 WMMLLISQAEAALENLVI 18 Sequence 27 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2244 TLVFDITKLLLAIFGPLW 18 Sequence 30 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2245 ATQTFLATCINGVCWTVY 18 Sequence 32 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2246 DWICEVLSDFKTWLKAKL 18 Sequence 44 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2247 DTEDVVCCSMSYSW 14 Sequence 47 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2248 SSGADTEDVVCCSMSYSW 18 Sequence 48 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2249 CTMLVCGDDLVVICESAG 18 Sequence 53 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by more than ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2250 WMNSTGFTKVCGAPPCVI 18 Sequence 21 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by five-fold to ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2251 MYVGGVEHRLEAACNWTR 18 Sequence 23 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by five-fold to ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2252 GAVYAFYGMWPLLLLLLA 18 Sequence 28 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by five-fold to ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2253 TSTWVLVGGVLAAT 18 Sequence 37 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by five-fold to ten-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2254 QIVGGVYLLPRRGPRLGW 18 Sequence 4 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2255 QPGYPWPLYGNEGCGWAG 18 Sequence 5 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2256 GWAGWLLSPRGSRPSWGP 18 Sequence 7 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2257 DAILHTPGCVPCVREGNA 18 Sequence 9 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2258 LPTTQLRRHIDLLVGSAT 18 Sequence 10 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2259 RHIDLLVGSATLCSALYV 18 Sequence 11 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2260 HINSTALINCNESLNTGWL 18 Sequence 15 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2261 NCNESLNTGWLAGLFYQH 18 Sequence 16 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2262 LASCRRLTDFAQGWGPIS 18 Sequence 17 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2263 TDFAQGWGPISYANGSGL 18 Sequence 18 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2264 GPISYANGSGLDERPYCW 18 Sequence 19 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2265 GSGLDERPYCWHYPPRPC 18 Sequence 20 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2266 PCVIGGVGNNTLLCPTDC 18 Sequence 22 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2267 ASWAIKWEYVVLLFLL 18 Sequence 25 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2268 KWEYVVLLFLLLADARVC 18 Sequence 26 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2269 GMWPLLLLLLALPQRAYA 18 Sequence 29 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2270 VSTATQTFLATCIN 14 Sequence 31 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2271 DSSVLCECYDAGCAWYEL 18 Sequence 33 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2272 AYMNTPGLPVCQDHLEFW 18 Sequence 34 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2273 LEFWEGVFTGLTHIDAHF 18 Sequence 35 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2274 HPITKYIMTCMSADLEVV 18 Sequence 36 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2275 WVLVGGVLAALAAYCLST 18 Sequence 38 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2276 LAALAAYCLSTGCVV 15 Sequence 39 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2277 EVFWAKHMWNFISGIQYL 18 Sequence 40 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2278 MWNFISGIQYLAGLSTLP 18 Sequence 41 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2279 PAILSPGALVVGVVCAAI 18 Sequence 42 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2280 YVSGMTTDNLKCPCQIPS 18 Sequence 45 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2281 SSGADTEDVVCCSMS 15 Sequence 46 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2282 DVVCCSMSYSWTGAL 15 Sequence 49 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2283 TVTESDIRTEEAIYQCCD 18 Sequence 50 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2284 GNTILTCYIKARAACRAAG 18 Sequence 51 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2285 RAAGLQDCTMLVCGDDLV 18 Sequence 52 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2286 DDLVVICESAGVQEDAAS 18 Sequence 54 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2287 LELITSCSSNVSVAHDGA 18 Sequence 55 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2288 HTPVNSWLGNIIMFAPTL 18 Sequence 56 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2289 APTLWARMILMTHFFSVL 18 Sequence 57 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2290 DQLEQALNCEIYGACYSI 18 Sequence 58 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2291 GVPPLRAWRHRARSVRAR 18 Sequence 59 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2292 WRHRARSVRARLLSRGGR 18 Sequence 60 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2293 GWFTAGYSGGDIYHSVSH 18 Sequence 61 from Patent US20070073039A1 Hepatitis C Virus HCV Patent Application US20070073039A1 2007-03-29 EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122 Peptides?that?inhibit?viral?infections Inhibit HCV infection by two-fold to five-fold. "The present application is directed to?peptides?that?inhibit?infection of a virus from the Flaviviridae family, methods of using these?peptides?to?inhibit?viral?infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these?peptides." DRAVPa2294 ELSTTDDAGTICANIGVC 18 Sequence 1 from Patent CN113754750B Synthetic peptide SVCV Granted Patent CN113754750B 2023-08-25 Antibacterial?peptide?and application thereof in aquaculture "The invention discloses an antibacterial?peptide?and application thereof in aquaculture. The amino acid sequence of the antibacterial?peptide?is as shown in SEQ ID NO.1. A section of micromolecule polypeptide caNKL2102-119 with the length of 18aa is selected and artificially synthesized through bioinformatics analysis and fitting of a three-dimensional space structure of a crucian carp NK-lysin protein, and research finds that the micromolecule polypeptide has excellent antibacterial and?antiviral?activity, does not easily generate drug resistance, is short in synthesis sequence, small in molecular weight, small in chemical synthesis difficulty, and high in bioactivity, can greatly save the cost of large-scale production on the basis of killing pathogenic bacteria in organisms, is expected to become an effective substitute of antibiotics in aquaculture, has high economic value and production and application value, and can inhibit replication of spring viremia virus (SVCV) of carp, a new thought is provided for preparation of aquatic?antiviral?drugs, and prevention and control of related aquatic viral diseases are facilitated." DRAVPa2295 REYNNRSAIGNTIEALFQ 18 Sequence 1 from Patent CN113999286B Synthetic peptide Enterovirus Granted Patent CN113999286B 2024-08-02 WO/2022/021902##JP2023535570 Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 2C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor "The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 2C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs." DRAVPa2296 YGRKKRRQRRRGSGREYNNRSAIGNTIEALFQ 32 Sequence 2 from Patent CN113999286B Synthetic peptide Enterovirus Granted Patent CN113999286B 2024-08-02 WO/2022/021902##JP2023535570 Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 3C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor "The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 3C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs." DRAVPa2297 YGRKKRRQRRRGSGLIREYNNRSAIGNTIEALFQ 34 Sequence 3 from Patent CN113999286B Synthetic peptide Enterovirus Granted Patent CN113999286B 2024-08-02 WO/2022/021902##JP2023535570 Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 4C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor "The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 4C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs." DRAVPa2298 YGRKKRRQRRRGSGSELIREYNNRSAIGNTIEALFQ 36 Sequence 4 from Patent CN113999286B Synthetic peptide Enterovirus Granted Patent CN113999286B 2024-08-02 WO/2022/021902##JP2023535570 Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 5C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor "The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 5C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs." DRAVPa2299 YPFDDKMSFLFA 12 Sequence 1 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL8 (or homologues thereof) is also described. DRAVPa2300 AGVWGEGGKFVYPFDDKMSFLFA 23 Sequence 2 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL9 (or homologues thereof) is also described. DRAVPa2301 VLAGVWGEGGKFVYPFDDKMSFLFA 25 Sequence 3 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL10 (or homologues thereof) is also described. DRAVPa2302 TGVLAGVWGEGGKFVYPFDDKMSFLFA 27 Sequence 4 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL11 (or homologues thereof) is also described. DRAVPa2303 VFTGVLAGVWGEGGKFVYPFDDKMSFLFA 29 Sequence 5 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL12 (or homologues thereof) is also described. DRAVPa2304 TGVLAGVWGEGGKFV 15 Sequence 6 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL13 (or homologues thereof) is also described. DRAVPa2305 IELVFTGVLAGVWGEGGKFV 20 Sequence 7 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL14 (or homologues thereof) is also described. DRAVPa2306 EILREIELVFTGVLA 15 Sequence 8 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL15 (or homologues thereof) is also described. DRAVPa2307 IVEFLKVGFGTEGGVWLVAG 20 Sequence 9 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL16 (or homologues thereof) is also described. DRAVPa2308 VKLWYQLEKEPIVGA 15 Sequence 10 from Patent US6337074B1 Synthetic peptide Herpesviruses Granted Patent US6337074B1 2002-01-08 EP0918866##AU1997037013##WO/1998/004707##US20050164163 Anti-herpesviral agent An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL17 (or homologues thereof) is also described. DRAVPa2309 KHGHHRH 7 Sequence 1 from Patent US20210040153A1 Synthetic peptide DENV Patent Application US20210040153A1 2021-02-11 CN108395470##WO/2019/137247 OLIGOPEPTIDE HAVING DENGUE VIRUS REPLICATION INHIBITION FUNCTION AND APPLICATION THEREOF "The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in the present invention is KHGHHRH, i.e. Lys-His-Gly-His-His-Arg-His (SEQ ID NO. 1). The short peptide has a high specificity affinity with NS5 and has the function of efficiently inhibiting dengue virus replication, the anti-viral effect thereof not been limited to DENV-2, but also having a significant inhibitory effect on the replication of type 1, type 3, and type 4 dengue virus. One cysteine is added to the two ends of the short peptide sequence, the short peptide being cyclised by means of the cysteines at the two ends to form a cyclic peptide. The obtained cyclic peptide strengthens the dengue virus replication inhibition function, and can be used for specific treatment of dengue virus infection." DRAVPa2310 CKHGHHRHC 9 Sequence 2 from Patent US20210040153A1 Synthetic peptide DENV Patent Application US20210040153A1 2021-02-11 CN108395470##WO/2019/137247 OLIGOPEPTIDE HAVING DENGUE VIRUS REPLICATION INHIBITION FUNCTION AND APPLICATION THEREOF "The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in the present invention is KHGHHRH, i.e. Lys-His-Gly-His-His-Arg-His (SEQ ID NO. 1). The short peptide has a high specificity affinity with NS5 and has the function of efficiently inhibiting dengue virus replication, the anti-viral effect thereof not been limited to DENV-2, but also having a significant inhibitory effect on the replication of type 1, type 3, and type 5 dengue virus. One cysteine is added to the two ends of the short peptide sequence, the short peptide being cyclised by means of the cysteines at the two ends to form a cyclic peptide. The obtained cyclic peptide strengthens the dengue virus replication inhibition function, and can be used for specific treatment of dengue virus infection." DRAVPa2311 CHPVFCPRRYKQIGTCGLPGTKC 23 Sequence 2 from Patent CN118451094A Synthetic peptide SARS-CoV-2 Patent Application CN118451094A 2024-08-06 WO/2023/125432##EP4457237 Antiviral peptides and methods of use thereof "Antiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 2 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury." DRAVPa2312 CHPVFCPRRYKQIGTCGLPGTKCCKK 26 Sequence 3 from Patent CN118451094A Synthetic peptide SARS-CoV-2 Patent Application CN118451094A 2024-08-06 WO/2023/125432##EP4457237 Antiviral peptides and methods of use thereof "Antiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 3 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury." DRAVPa2313 GAICHPVFCPRRYKQIGTCGLPGTKCCKKP 30 Sequence 4 from Patent CN118451094A Synthetic peptide SARS-CoV-2 Patent Application CN118451094A 2024-08-06 WO/2023/125432##EP4457237 Antiviral peptides and methods of use thereof "Antiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 4 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury." DRAVPa2314 QPSVQIQVYQGEREIAAHAAAKLPDLCTEL 30 Sequence 1 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E7, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2315 QPSVQIQVYQGEREIAAHAAATLHEYMLDL 30 Sequence 2 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E8, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2316 QPSVQIQVYQGEREIAAHAAAYMLDLQPET 30 Sequence 3 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E9, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2317 QPSVQIQVYQGEREIAAHAAARAHYNIVTF 30 Sequence 4 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E10, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2318 QPSVQIQVYQGEREIAAHAAACDSTLRLCV 30 Sequence 5 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E11, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2319 QPSVQIQVYQGEREIAAHAAARLCVQSTHV 30 Sequence 6 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E12, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2320 QPSVQIQVYQGEREIAAHAAALIMGTLGIV 30 Sequence 7 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E13, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2321 QPSVQIQVYQGEREIAAHAAATLGIVCPI 29 Sequence 8 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E14, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2322 QPSVQIQVYQGEREIAAHAAAYKLPDLCTELNTSLQDIEITCVYCKTVLEL 51 Sequence 9 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E15, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2323 QPSVQIQVYQGEREIAAHAAASVYGDTLEKLTNTGLYNLLIRCLRCQK 48 Sequence 10 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E16, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." 3 DRAVPa2324 QPSVQIQVYQGEREIAAHAAAATLQDIVLHLEPQNEIPVDLL 42 Sequence 11 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E17, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2325 QPSVQIQVYQGEREIAAHAAAGVNHQHLPARRAEPQRHTMLCMCCKCEARI 51 Sequence 12 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E18, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2326 QPSVQIQVYQGEREIAAHAAAVVESSADDLRAFQQLFLSTLSFVCPWCA 49 Sequence 13 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E19, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2327 QPSVQIQVYQGEREIAAHAAAFQQLFLNTL 30 Sequence 14 from Patent CN108409866A Synthetic peptide HPV Patent Application CN108409866A 2018-08-17 WO/2019/144607 Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases "The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E20, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients." DRAVPa2328 FLKHIKSFWRGAKAIFRGARQGWREHR 27 Sequence 1 from CN119326871A Synthetic construct MSRV Patent Application CN119326871A 2025-01-21 CN 119326871 A Ms-Piscidin¿¹¾úëÄÔÚÖƱ¸´ó¿ÚºÚöÔµ¯×´²¡¶¾ÒÖÖƼÁ»òÖÎÁÆÒ©ÎïÖеÄÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËMs?Piscidin¿¹¾úëÄÔÚÖƱ¸´ó¿ÚºÚöÔµ¯×´²¡¶¾ÒÖÖƼÁ»òÖÎÁÆÒ©ÎïÖеÄÓ¦Óã¬ÌصãÊÇÌṩMs?Piscidin¿¹¾úëÄÔÚÖƱ¸´ó¿ÚºÚöÔµ¯×´²¡¶¾ÒÖÖƼÁÖеÄÓ¦ÓÃÒÔ¼°Ms?Piscidin¿¹¾úëÄÔÚÖƱ¸´ó¿ÚºÚöÔµ¯×´²¡¶¾¸ÐȾÖÎÁÆÒ©ÎïÖеÄÓ¦Óã¬Ms?Piscidin¿¹¾úëĵݱ»ùËáÐòÁÐΪSEQ ID NO.1Ëùʾ:FLKHIKSFWRGAKAIFRGARQGWREHR£¬ÓŵãÊÇMs?Piscidin¿¹¾úëÄÄܹ»ÒÖÖÆMSRVÔöÖ³¡¢Ìá¸ßMSRV¸ÐȾµÄ´ó¿ÚºÚöԵĴæ»îÂÊ£¬¿É×÷Ϊ·ÀÖÎMSRV¸ÐȾ¼²²¡µÄDZÔÚÒ©Îï¡£ Anti-MSRV DRAVPa2329 KYGPTPVRDGFK 12 Sequence 1 from CN 118767104 A Synthetic construct PEDV Patent Application CN 118767104 A 2024-10-15 CN 118767104 A Application of pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis "The invention discloses an application of pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis, and relates to the technical field of antiviral biologica.According to the application, synthesized pea active peptide is utilized, toxicity of peptides with different concentrations to Vero cells is determined by adopting a CCK-8 test, and the application of the pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis is achieved. The inhibition effect of the pea active peptide KYGPTPVRDGFK on the porcine epidemic diarrhea virus in Vero cells is determined through indirect immunofluorescence, virus copy number, immunoblotting and half tissue infection amount, and the inhibition effect of the KYGPTPVRDGFK on Vero cell apoptosis induced by the porcine epidemic diarrhea virus is verified through immunoblotting. Results show that the pea bioactive peptide can significantly inhibit the replication of the porcine epidemic diarrhea virus and significantly reduce the Vero cell apoptosis level induced by the porcine epidemic diarrhea virus, thereby providing a new idea and method for the prevention and treatment of the PEDV." Anti-PEDV DRAVPa2330 VSIPWTHKV 9 Sequence 124 from CN118620040A human HBV Patent Application CN118620040A 2024-09-10 CN 114478711 A## CN 118580321 A3## CN 118580322 A##CN 118620040 A##CN 114478711 B##CN 119039403 A Antigen peptide aiming at hepatitis B virus "The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-124. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis." Anti-HBV DRAVPa2331 FLLAQFTSAI 10 Sequence 3 from CN118620041A human HBV Patent Application CN118620040A 2024-09-10 "CN 114478711 A## CN 118580321 A,##CN 118580322 A,##CN 118620040 A##CN 114478711 B##CN 119039403 A" Antigen peptide aiming at hepatitis B virus "The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-125. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis." Anti-HBV DRAVPa2332 FLPDFFPSI 9 Sequence 6 from CN118620042A human HBV Patent Application CN118620040A 2024-09-10 CN 114478711 A##CN 118580321 A## CN 118580322 A## CN 118620040 A## CN 114478711 B##CN 119039403 A Antigen peptide aiming at hepatitis B virus "The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-126. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis." Anti-HBV DRAVPa2333 RVRALYFPA 9 Sequence 84 from CN118620043A human HBV Patent Application CN118620040A 2024-09-10 CN 114478711 A##CN 118580321 A##CN 118580322 A## CN 118620040 A##CN 114478711 B##CN 119039403 A Antigen peptide aiming at hepatitis B virus "The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-127. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis." Anti-HBV DRAVPa2334 GWKDFKKTIKKLLRGASRLLKF 22 Sequence 1 from CN117024530B Synthetic construct "Hantaan virus, Chikungunya virus" Granted Patent CN117024530B 2024-03-19 CN 117024530 A## CN 117024530 B ¿¹Î¢ÉúÎïëÄPerceptide-TJ-2¼°ÆäÔÚÖƱ¸¹ãÆ׿¹²¡¶¾Ò©ÎïÖеÄÓÃ; ±¾·¢Ã÷Éæ¼°Ò©ÎïÖƱ¸¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËÐÂÐÍ¿¹Î¢ÉúÎïëÄPerceptide?TJ?2¼°ÆäÔÚÖƱ¸¹ãÆ׿¹²¡¶¾Ò©ÎïÖеÄÓÃ;¡£±¾·¢Ã÷ÌṩµÄÐÂÐÍ¿¹Î¢ÉúÎïëÄPerceptide?TJ?2ÊÇ»ùÓÚÈ˹¤ÖÇÄÜ·½·¨È«ÐÂÉè¼Æ¡¢¹¹½¨²¢ºÏ³É£¬¾ßÓйãÆ׿¹²¡¶¾¸ÐȾ»îÐÔ£¬¸ßЧÒÖÖƺºÌ²²¡¶¾¡¢»ù¿×¿ÏÑŲ¡¶¾¡¢1Ð͵¥´¿ðåÕ¶¾ºÍ2Ð͵Ǹﲡ¶¾´«È¾ÐÔ²¡Ô­Ì壬ÓÐЧ½µµÍ²¡¶¾ÔØÁ¿£¬Îª¿ª·¢ÐÂÒ»´ú¹ãÆ׿¹²¡¶¾Ò©ÎïÌṩÒÀ¾ÝºÍ»ù´¡£¬Îª±£ÕÏÈËÀཡ¿µÌṩȫеļ¼ÊõÊֶΡ£ "Anti-Hantaan virus, Anti-Chikungunya virus" DRAVPa2335 MGVKVLFALICIAVAEA 17 Sequence 1 from CN119390792A Synthetic construct Monkeypox virus M1R Granted Patent CN116024265B 2025-02-07 CN 116024265 A##CN 116024265 B ÖƱ¸ºï¶»²¡¶¾M1r¿¹Ô­·ÖÃÚµ°°×µÄ·½·¨¼°ÆäËùÓúËËá·Ö×Ó ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖÖƱ¸ºï¶»²¡¶¾M1R¿¹Ô­·ÖÃÚµ°°×µÄ·½·¨¼°ÆäËùÓúËËá·Ö×Ó¡£±¾·¢Ã÷Éæ¼°ÉúÎï¼¼ÊõÁìÓò£¬¾ßÌåÉæ¼°Ò»ÖÖÖƱ¸ºï¶»²¡¶¾M1R¿¹Ô­·ÖÃÚµ°°×µÄ·½·¨¼°ÆäËùÓúËËá·Ö×Ó¡£±¾·¢Ã÷ÌṩµÄ·½·¨°üÀ¨Èçϲ½Ö裺(A1)½«ºËËá·Ö×Óµ¼ÈëËÞÖ÷ϸ°û£¬µÃµ½ÖØ×éϸ°û£»ºËËá·Ö×Ó±àÂëÈںϵ°°×£¬Èںϵ°°×Ϊ½«¶àëÄ(°±»ùËáÐòÁÐÊÇSEQ ID No.1)ÈÚºÏÓںﶻ²¡¶¾M1R¿¹Ô­µÄN¶ËµÃµ½µÄµ°°×ÖÊ£»(A2)ÅàÑøÖØ×éϸ°û£¬´ÓÅàÑøÉÏÇåÖлñµÃºï¶»²¡¶¾M1R¿¹Ô­·ÖÃÚµ°°×¡£²ÉÓÃÓ«¹âËØøÐźÅëÄGaÒýµ¼ºï¶»²¡¶¾M1RÕæºËϸ°û·ÖÃÚ±í´ïˮƽÏÔÖøÓÅÓÚ°×µ°°×ÐźÅëÄAlºÍ¿¹ÌåÇáÁ´ÐźÅëÄLc£¬¸üÊÊÓÃÓÚ´ó¹æÄ£¹¤Òµ»¯Éú²ú£¬½µµÍÉú²ú³É±¾¡£ Anti-Monkeypox virus M1R DRAVPa2336 APAICHDGKAHFPRE 15 Sequence 1 from CN119320428A Synthetic construct COVID-19 Patent Application CN119320428A 2025-01-17 CN 119320428 A ÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCd4+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïҽѧ¼¼ÊõÁìÓò£¬¹«¿ªÁËÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCD4+Tϸ°û±íλëÄ£¬°üÀ¨Õë¶ÔÐÂÐ͹Ú×´²¡¶¾Ô­Ê¼Öê¼°Æä±äÒìÖê¹²ÓеÄTh±íλëÄ£¬»¹°üÀ¨Õë¶Ô°ÂÃØ¿ËÈÖ±äÒìÖêÌØÓеÄÃâÒßÓÅÊÆÍ»±äTh±íλëÄ£»»¹¹«¿ªÁËTh±íλëÄ?MHCËľÛÌå¼°Ó¦Óᣱ¾·¢Ã÷»ñµÃµÄ±íλëıȽϷûºÏÌìȻ״̬ÏÂHLA?IIÀà·Ö×Ó½áºÏëı»Ìá³ÊµÄ¹æÂÉ£¬¶ÔTh±íλµÄ¼ì³öÂʽϸߣ¬ÇÒÄܹ»½µµÍËÄ·ÖÖ®Ò»µÄ¾­¼Ã³É±¾£»ÀûÓñ¾·¢Ã÷µÄ±íλëÄÖƱ¸µÄTh±íλëÄ?MHCËľÛÌå¾ßÓÐÇ¿ÁҵĴ̼¤CD4+Tϸ°û»î»¯µÄЧӦ£»±¾·¢Ã÷µÄ±íλëĺÍTh±íλëÄ?MHCËľÛÌå¿ÉÖÆ×÷³ÉÊÔ¼ÁºÐ¡£ Anti-COVID-19 DRAVPa2337 EGVFVSNGTHWFVTQ 15 Sequence 2 from CN119320428A Synthetic construct COVID-19 Patent Application CN119320428A 2025-01-17 CN 119320428 A ÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCd4+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïҽѧ¼¼ÊõÁìÓò£¬¹«¿ªÁËÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCD4+Tϸ°û±íλëÄ£¬°üÀ¨Õë¶ÔÐÂÐ͹Ú×´²¡¶¾Ô­Ê¼Öê¼°Æä±äÒìÖê¹²ÓеÄTh±íλëÄ£¬»¹°üÀ¨Õë¶Ô°ÂÃØ¿ËÈÖ±äÒìÖêÌØÓеÄÃâÒßÓÅÊÆÍ»±äTh±íλëÄ£»»¹¹«¿ªÁËTh±íλëÄ?MHCËľÛÌå¼°Ó¦Óᣱ¾·¢Ã÷»ñµÃµÄ±íλëıȽϷûºÏÌìȻ״̬ÏÂHLA?IIÀà·Ö×Ó½áºÏëı»Ìá³ÊµÄ¹æÂÉ£¬¶ÔTh±íλµÄ¼ì³öÂʽϸߣ¬ÇÒÄܹ»½µµÍËÄ·ÖÖ®Ò»µÄ¾­¼Ã³É±¾£»ÀûÓñ¾·¢Ã÷µÄ±íλëÄÖƱ¸µÄTh±íλëÄ?MHCËľÛÌå¾ßÓÐÇ¿ÁҵĴ̼¤CD4+Tϸ°û»î»¯µÄЧӦ£»±¾·¢Ã÷µÄ±íλëĺÍTh±íλëÄ?MHCËľÛÌå¿ÉÖÆ×÷³ÉÊÔ¼ÁºÐ¡£ Anti-COVID-19 DRAVPa2338 AGLIAIVMVTIMLCCM 16 Sequence 3 from CN119320428A Synthetic construct COVID-19 Patent Application CN119320428A 2025-01-17 CN 119320428 A ÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCd4+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïҽѧ¼¼ÊõÁìÓò£¬¹«¿ªÁËÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCD4+Tϸ°û±íλëÄ£¬°üÀ¨Õë¶ÔÐÂÐ͹Ú×´²¡¶¾Ô­Ê¼Öê¼°Æä±äÒìÖê¹²ÓеÄTh±íλëÄ£¬»¹°üÀ¨Õë¶Ô°ÂÃØ¿ËÈÖ±äÒìÖêÌØÓеÄÃâÒßÓÅÊÆÍ»±äTh±íλëÄ£»»¹¹«¿ªÁËTh±íλëÄ?MHCËľÛÌå¼°Ó¦Óᣱ¾·¢Ã÷»ñµÃµÄ±íλëıȽϷûºÏÌìȻ״̬ÏÂHLA?IIÀà·Ö×Ó½áºÏëı»Ìá³ÊµÄ¹æÂÉ£¬¶ÔTh±íλµÄ¼ì³öÂʽϸߣ¬ÇÒÄܹ»½µµÍËÄ·ÖÖ®Ò»µÄ¾­¼Ã³É±¾£»ÀûÓñ¾·¢Ã÷µÄ±íλëÄÖƱ¸µÄTh±íλëÄ?MHCËľÛÌå¾ßÓÐÇ¿ÁҵĴ̼¤CD4+Tϸ°û»î»¯µÄЧӦ£»±¾·¢Ã÷µÄ±íλëĺÍTh±íλëÄ?MHCËľÛÌå¿ÉÖÆ×÷³ÉÊÔ¼ÁºÐ¡£ Anti-COVID-19 DRAVPa2339 KFNGLTVLPPLLTDE 15 Sequence 4 from CN119320428A Synthetic construct COVID-19 Patent Application CN119320428A 2025-01-17 CN 119320428 A ÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCd4+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïҽѧ¼¼ÊõÁìÓò£¬¹«¿ªÁËÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCD4+Tϸ°û±íλëÄ£¬°üÀ¨Õë¶ÔÐÂÐ͹Ú×´²¡¶¾Ô­Ê¼Öê¼°Æä±äÒìÖê¹²ÓеÄTh±íλëÄ£¬»¹°üÀ¨Õë¶Ô°ÂÃØ¿ËÈÖ±äÒìÖêÌØÓеÄÃâÒßÓÅÊÆÍ»±äTh±íλëÄ£»»¹¹«¿ªÁËTh±íλëÄ?MHCËľÛÌå¼°Ó¦Óᣱ¾·¢Ã÷»ñµÃµÄ±íλëıȽϷûºÏÌìȻ״̬ÏÂHLA?IIÀà·Ö×Ó½áºÏëı»Ìá³ÊµÄ¹æÂÉ£¬¶ÔTh±íλµÄ¼ì³öÂʽϸߣ¬ÇÒÄܹ»½µµÍËÄ·ÖÖ®Ò»µÄ¾­¼Ã³É±¾£»ÀûÓñ¾·¢Ã÷µÄ±íλëÄÖƱ¸µÄTh±íλëÄ?MHCËľÛÌå¾ßÓÐÇ¿ÁҵĴ̼¤CD4+Tϸ°û»î»¯µÄЧӦ£»±¾·¢Ã÷µÄ±íλëĺÍTh±íλëÄ?MHCËľÛÌå¿ÉÖÆ×÷³ÉÊÔ¼ÁºÐ¡£ Anti-COVID-19 DRAVPa2340 GTHWFVTQRNFYEPQI 16 Sequence 5 from CN119320428A Synthetic construct COVID-19 Patent Application CN119320428A 2025-01-17 CN 119320428 A ÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCd4+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïҽѧ¼¼ÊõÁìÓò£¬¹«¿ªÁËÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCD4+Tϸ°û±íλëÄ£¬°üÀ¨Õë¶ÔÐÂÐ͹Ú×´²¡¶¾Ô­Ê¼Öê¼°Æä±äÒìÖê¹²ÓеÄTh±íλëÄ£¬»¹°üÀ¨Õë¶Ô°ÂÃØ¿ËÈÖ±äÒìÖêÌØÓеÄÃâÒßÓÅÊÆÍ»±äTh±íλëÄ£»»¹¹«¿ªÁËTh±íλëÄ?MHCËľÛÌå¼°Ó¦Óᣱ¾·¢Ã÷»ñµÃµÄ±íλëıȽϷûºÏÌìȻ״̬ÏÂHLA?IIÀà·Ö×Ó½áºÏëı»Ìá³ÊµÄ¹æÂÉ£¬¶ÔTh±íλµÄ¼ì³öÂʽϸߣ¬ÇÒÄܹ»½µµÍËÄ·ÖÖ®Ò»µÄ¾­¼Ã³É±¾£»ÀûÓñ¾·¢Ã÷µÄ±íλëÄÖƱ¸µÄTh±íλëÄ?MHCËľÛÌå¾ßÓÐÇ¿ÁҵĴ̼¤CD4+Tϸ°û»î»¯µÄЧӦ£»±¾·¢Ã÷µÄ±íλëĺÍTh±íλëÄ?MHCËľÛÌå¿ÉÖÆ×÷³ÉÊÔ¼ÁºÐ¡£ Anti-COVID-19 DRAVPa2341 EDLLFNKVTLADAG 14 Sequence 6 from CN119320428A Synthetic construct COVID-19 Patent Application CN119320428A 2025-01-17 CN 119320428 A ÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCd4+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïҽѧ¼¼ÊõÁìÓò£¬¹«¿ªÁËÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCD4+Tϸ°û±íλëÄ£¬°üÀ¨Õë¶ÔÐÂÐ͹Ú×´²¡¶¾Ô­Ê¼Öê¼°Æä±äÒìÖê¹²ÓеÄTh±íλëÄ£¬»¹°üÀ¨Õë¶Ô°ÂÃØ¿ËÈÖ±äÒìÖêÌØÓеÄÃâÒßÓÅÊÆÍ»±äTh±íλëÄ£»»¹¹«¿ªÁËTh±íλëÄ?MHCËľÛÌå¼°Ó¦Óᣱ¾·¢Ã÷»ñµÃµÄ±íλëıȽϷûºÏÌìȻ״̬ÏÂHLA?IIÀà·Ö×Ó½áºÏëı»Ìá³ÊµÄ¹æÂÉ£¬¶ÔTh±íλµÄ¼ì³öÂʽϸߣ¬ÇÒÄܹ»½µµÍËÄ·ÖÖ®Ò»µÄ¾­¼Ã³É±¾£»ÀûÓñ¾·¢Ã÷µÄ±íλëÄÖƱ¸µÄTh±íλëÄ?MHCËľÛÌå¾ßÓÐÇ¿ÁҵĴ̼¤CD4+Tϸ°û»î»¯µÄЧӦ£»±¾·¢Ã÷µÄ±íλëĺÍTh±íλëÄ?MHCËľÛÌå¿ÉÖÆ×÷³ÉÊÔ¼ÁºÐ¡£ Anti-COVID-19 DRAVPa2342 TFEYVSQPFLMDLEG 15 Sequence 7 from CN119320428A Synthetic construct COVID-19 Patent Application CN119320428A 2025-01-17 CN 119320428 A ÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCd4+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïҽѧ¼¼ÊõÁìÓò£¬¹«¿ªÁËÐÂÐ͹Ú×´²¡¶¾¹ãÆ×ÃâÒßÓÅÊÆCD4+Tϸ°û±íλëÄ£¬°üÀ¨Õë¶ÔÐÂÐ͹Ú×´²¡¶¾Ô­Ê¼Öê¼°Æä±äÒìÖê¹²ÓеÄTh±íλëÄ£¬»¹°üÀ¨Õë¶Ô°ÂÃØ¿ËÈÖ±äÒìÖêÌØÓеÄÃâÒßÓÅÊÆÍ»±äTh±íλëÄ£»»¹¹«¿ªÁËTh±íλëÄ?MHCËľÛÌå¼°Ó¦Óᣱ¾·¢Ã÷»ñµÃµÄ±íλëıȽϷûºÏÌìȻ״̬ÏÂHLA?IIÀà·Ö×Ó½áºÏëı»Ìá³ÊµÄ¹æÂÉ£¬¶ÔTh±íλµÄ¼ì³öÂʽϸߣ¬ÇÒÄܹ»½µµÍËÄ·ÖÖ®Ò»µÄ¾­¼Ã³É±¾£»ÀûÓñ¾·¢Ã÷µÄ±íλëÄÖƱ¸µÄTh±íλëÄ?MHCËľÛÌå¾ßÓÐÇ¿ÁҵĴ̼¤CD4+Tϸ°û»î»¯µÄЧӦ£»±¾·¢Ã÷µÄ±íλëĺÍTh±íλëÄ?MHCËľÛÌå¿ÉÖÆ×÷³ÉÊÔ¼ÁºÐ¡£ Anti-COVID-19 DRAVPa2343 NDDTPVDEALGRVLTPTAVDEALVDLAPDADP 32 Sequence 1 from CN119285713A Synthetic construct Seneca virus type A Patent Application CN119285713A 2025-01-10 CN 119285713 A AÐÍÈûÄÚ¿¨²¡¶¾3aµ°°×¿¹Ô­±íλëÄ¡¢µ¥¿Ë¡¿¹Ìå¼°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÉúÎïÒ½Ò©¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËÒ»ÖÖAÐÍÈûÄÚ¿¨²¡¶¾3Aµ°°×¿¹Ô­±íλëÄ»òÆä±àÂëºËËᣬÓëAÐÍÈûÄÚ¿¨²¡¶¾3Aµ°°×¿¹Ô­±íλÌØÒìÐÔ½áºÏµÄµ¥¿Ë¡¿¹Ì壬·ÖÃڸõ¥¿Ë¡¿¹ÌåµÄÔÓ½»Áöϸ°ûÖê¼°ÆäÔÚÖƱ¸Ô¤·ÀºÍ/»òÖÎÁÆAÐÍÈûÄÚ¿¨²¡¶¾¸ÐȾµÄÒ©Îï¡¢»òÕß¼ì²âºÍ/»òÕï¶ÏAÐÍÈûÄÚ¿¨²¡¶¾¸ÐȾµÄÊÔ¼ÁÖеÄÓ¦Óᣱ¾·¢Ã÷ÌṩµÄµ¥¿Ë¡¿¹ÌåÓɱ£²Ø±àºÅΪCCTCC NO£ºC202466µÄÔÓ½»Áöϸ°ûÖêSVA?3A?5A7·ÖÃÚ²úÉú£¬¸Ãµ¥¿¹Äܹ»ÌØÒìÐÔ½áºÏAÐÍÈûÄÚ¿¨²¡¶¾3Aµ°°×£¨¿¹Ô­±íλλÓÚ3Aµ°°×°ûÍâ½á¹¹ÓòµÚ5?36λ°±»ùËᣩ£¬¿ÉÓÃÓÚÖƱ¸Ô¤·ÀºÍ/»òÖÎÁÆAÐÍÈûÄÚ¿¨²¡¶¾¸ÐȾµÄÒ©Î»òÕß¼ì²âºÍ/»òÕï¶ÏAÐÍÈûÄÚ¿¨²¡¶¾¸ÐȾµÄÊÔ¼Á¡£ Anti-Seneca virus type A DRAVPa2344 SPTVWLSVI 9 Sequence 1 from CN119241665A Synthetic construct HBV Patent Application CN 119241665 A 2025-01-03 CN 119241665 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSPTVWLSVI£»LPLLPIFFCL£»CPTVQASKL£»LPSDFFPSI£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2345 LPLLPIFFCL 10 Sequence 2 from CN119241665A Synthetic construct HBV Patent Application CN 119241665 A 2025-01-03 CN 119241665 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSPTVWLSVI£»LPLLPIFFCL£»CPTVQASKL£»LPSDFFPSI£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2346 CPTVQASKL 9 Sequence 3 from CN119241665A Synthetic construct HBV Patent Application CN 119241665 A 2025-01-03 CN 119241665 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSPTVWLSVI£»LPLLPIFFCL£»CPTVQASKL£»LPSDFFPSI£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2347 LPSDFFPSI 9 Sequence 4 from CN119241665A Synthetic construct HBV Patent Application CN 119241665 A 2025-01-03 CN 119241665 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSPTVWLSVI£»LPLLPIFFCL£»CPTVQASKL£»LPSDFFPSI£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2348 GYSITSDFA 9 Sequence 31 from CN119119255A Synthetic construct PEDV Patent Application CN119119255A 2024-12-13 CN 119119255 A Pig acute diarrhea syndrome coronavirus spike protein antigen epitope peptide and monoclonal antibody and application thereof "The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment." Anti-PEDV DRAVPa2349 ISYSGTT 7 Sequence 32 from CN119119255A Synthetic construct PEDV Patent Application CN119119255A 2024-12-13 CN 119119255 A Pig acute diarrhea syndrome coronavirus spike protein antigen epitope peptide and monoclonal antibody and application thereof "The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment." Anti-PEDV DRAVPa2350 QSLLHSDGKTY 11 Sequence 37 from CN119119255A Synthetic construct PEDV Patent Application CN119119255A 2024-12-13 CN 119119255 A Pig acute diarrhea syndrome coronavirus spike protein antigen epitope peptide and monoclonal antibody and application thereof "The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment." Anti-PEDV DRAVPa2351 APFARLLNL 9 Sequence 1 from CN119080879A Synthetic construct EBOV Patent Application CN119080879A 2024-12-06 CN 119080879 A "Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof" "The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future." Anti-EBOV DRAVPa2352 SAPDDLVLF 9 Sequence 2 from CN119080879A Synthetic construct EBOV Patent Application CN119080879A 2024-12-06 CN 119080879 A "Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof" "The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future." Anti-EBOV DRAVPa2353 FEEMYRHIL 9 Sequence 3 from CN119080879A Synthetic construct EBOV Patent Application CN119080879A 2024-12-06 CN 119080879 A "Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof" "The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future." Anti-EBOV DRAVPa2354 TEANAGQFL 9 Sequence 4 from CN119080879A Synthetic construct EBOV Patent Application CN119080879A 2024-12-06 CN 119080879 A "Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof" "The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future." Anti-EBOV DRAVPa2355 ESLVNEYDDN 10 Sequence 1 from CN119020340A human RV Patent Application CN119020340A 2024-11-26 CN 119020340 A Polypeptide and application thereof in preparation of anti-rabies virus medicine "The invention discloses a polypeptide and application thereof in preparation of anti-rabies virus drugs, and belongs to the technical field of biological medicines. The amino acid sequence of the polypeptide is as shown in SEQ ID NO.1, the polypeptide is derived from 190-199 amino acids of human PDIA3 protein, the polypeptide can be fused with a cell penetrating peptide to form a polypeptide with an amino acid sequence as shown in SEQ ID NO.2, and the problems that the polypeptide is easy to degrade and difficult to enter cells are solved. The polypeptide can be combined with surface glycoprotein of the rabies virus to resist infection of the rabies virus, and can be used for preparing anti-rabies virus drugs. The polypeptide disclosed by the invention has the advantages of simple and feasible preparation method, good biocompatibility, small side effect, safety, high efficiency and the like, and can be produced on a large scale in a short time. The invention lays a foundation for designing safe and effective polypeptide for treating rabies, and has good development and application prospects." Anti-RV DRAVPa2356 YGRKKRRQRRRESLVNEYDDN 21 Sequence 2 from CN119020340A human RV Patent Application CN119020340A 2024-11-26 CN 119020340 A Polypeptide and application thereof in preparation of anti-rabies virus medicine "The invention discloses a polypeptide and application thereof in preparation of anti-rabies virus drugs, and belongs to the technical field of biological medicines. The amino acid sequence of the polypeptide is as shown in SEQ ID NO.1, the polypeptide is derived from 190-199 amino acids of human PDIA3 protein, the polypeptide can be fused with a cell penetrating peptide to form a polypeptide with an amino acid sequence as shown in SEQ ID NO.2, and the problems that the polypeptide is easy to degrade and difficult to enter cells are solved. The polypeptide can be combined with surface glycoprotein of the rabies virus to resist infection of the rabies virus, and can be used for preparing anti-rabies virus drugs. The polypeptide disclosed by the invention has the advantages of simple and feasible preparation method, good biocompatibility, small side effect, safety, high efficiency and the like, and can be produced on a large scale in a short time. The invention lays a foundation for designing safe and effective polypeptide for treating rabies, and has good development and application prospects." Anti-RV DRAVPa2357 LVIARQKVR 9 Sequence 2 from CN118994306A Synthetic construct "Hantaan virus, Chikungunya virus" Patent Application CN118994306A 2024-11-22 CN 118994306 A Advanced epitope peptide of hantavirus nucleocapsid protein and application of dominant epitope peptide in preparation of anti-hantavirus vaccine "The invention belongs to the technical field of microbial immunity, and particularly relates to dominant epitope peptide of hantavirus nucleocapsid protein and application of the dominant epitope peptide in preparation of an anti-hantavirus vaccine. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO.1-9, the common amino acid fragment of the dominant epitope peptide is an MHC-II type antigenic nonapeptide, and the nonapeptide sequence is shown as SEQ ID NO.10-12. The invention further discloses a preparation method of the MHC-II type antigenic nonapeptide. According to the present invention, the binding capacity and the immune response effect of the dominant epitope peptides and MHC II molecules are verified through the ELISpot test, and the immunological characteristics of the dominant epitope peptides are determined by the nonapeptide core, such that the immunobiology of the HTNV NP can be easily understood, and the epitope vaccine design for the HTNV NP can be perfected in the future." Anti-Hantaan virus DRAVPa2358 YVSLPNAQS 9 Sequence 2 from CN118994306A Synthetic construct "Hantaan virus, Chikungunya virus" Patent Application CN118994306A 2024-11-22 CN 118994306 A Advanced epitope peptide of hantavirus nucleocapsid protein and application of dominant epitope peptide in preparation of anti-hantavirus vaccine "The invention belongs to the technical field of microbial immunity, and particularly relates to dominant epitope peptide of hantavirus nucleocapsid protein and application of the dominant epitope peptide in preparation of an anti-hantavirus vaccine. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO.1-9, the common amino acid fragment of the dominant epitope peptide is an MHC-II type antigenic nonapeptide, and the nonapeptide sequence is shown as SEQ ID NO.10-12. The invention further discloses a preparation method of the MHC-II type antigenic nonapeptide. According to the present invention, the binding capacity and the immune response effect of the dominant epitope peptides and MHC II molecules are verified through the ELISpot test, and the immunological characteristics of the dominant epitope peptides are determined by the nonapeptide core, such that the immunobiology of the HTNV NP can be easily understood, and the epitope vaccine design for the HTNV NP can be perfected in the future." Anti-Hantaan virus DRAVPa2359 ILQDMRNTI 9 Sequence 2 from CN118994306A Synthetic construct "Hantaan virus, Chikungunya virus" Patent Application CN118994306A 2024-11-22 CN 118994306 A Advanced epitope peptide of hantavirus nucleocapsid protein and application of dominant epitope peptide in preparation of anti-hantavirus vaccine "The invention belongs to the technical field of microbial immunity, and particularly relates to dominant epitope peptide of hantavirus nucleocapsid protein and application of the dominant epitope peptide in preparation of an anti-hantavirus vaccine. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO.1-9, the common amino acid fragment of the dominant epitope peptide is an MHC-II type antigenic nonapeptide, and the nonapeptide sequence is shown as SEQ ID NO.10-12. The invention further discloses a preparation method of the MHC-II type antigenic nonapeptide. According to the present invention, the binding capacity and the immune response effect of the dominant epitope peptides and MHC II molecules are verified through the ELISpot test, and the immunological characteristics of the dominant epitope peptides are determined by the nonapeptide core, such that the immunobiology of the HTNV NP can be easily understood, and the epitope vaccine design for the HTNV NP can be perfected in the future." Anti-Hantaan virus DRAVPa2360 ADSFVIRGDEVRQIAPGQ 18 Sequence 14 from CN118852366A SARS-CoV-2 SARS-CoV-2 Patent Application CN118852366A 2024-10-29 CN 118852366 A Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof "The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines." Anti-SARS-CoV-2 DRAVPa2361 YNYKLPDDFTGCVIAWNS 18 Sequence 18 from CN118852366A SARS-CoV-2 SARS-CoV-2 Patent Application CN118852366A 2024-10-29 CN 118852366 A Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof "The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines." Anti-SARS-CoV-2 DRAVPa2362 NCYFPLQSYGFQPTNGVG 18 Sequence 29 from CN118852366A SARS-CoV-2 SARS-CoV-2 Patent Application CN118852366A 2024-10-29 CN 118852366 A Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof "The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines." Anti-SARS-CoV-2 DRAVPa2363 YQPYRVVVLSFELLHAPA 18 Sequence 32 from CN118852366A SARS-CoV-2 SARS-CoV-2 Patent Application CN118852366A 2024-10-29 CN 118852366 A Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof "The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines." Anti-SARS-CoV-2 DRAVPa2364 IRLQAEA 7 Sequence 1 from CN118725023A Synthetic construct COVID-19 Patent Application CN118725023A 2024-10-01 CN 118725023 A Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus "The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN" Anti-COVID-19 DRAVPa2365 LMLQAEP 7 Sequence 2 from CN118725023A Synthetic construct COVID-19 Patent Application CN118725023A 2024-10-01 CN 118725023 A Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus "The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN" Anti-COVID-19 DRAVPa2366 GRLQSLQ 7 Sequence 3 from CN118725023A Synthetic construct COVID-19 Patent Application CN118725023A 2024-10-01 CN 118725023 A Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus "The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN" Anti-COVID-19 DRAVPa2367 VQRQAFN 7 Sequence 4 from CN118725023A Synthetic construct COVID-19 Patent Application CN118725023A 2024-10-01 CN 118725023 A Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus "The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN" Anti-COVID-19 DRAVPa2368 KKWRKVIKKVVARYK 15 Sequence 2 from Patent CN118615425A Synthetic construct IAV Patent Application CN118615425A 2024-09-10 CN 118615425 A Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus "The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A." Anti-IAV DRAVPa2369 FWKKVIKRVRKAVKK 15 Sequence 3 from Patent CN118615425A Synthetic construct IAV Patent Application CN118615425A 2024-09-10 CN 118615425 A Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus "The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A." Anti-IAV DRAVPa2370 VVKKVRKLYKKIYKR 15 Sequence 4 from Patent CN118615425A Synthetic construct IAV Patent Application CN118615425A 2024-09-10 CN 118615425 A Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus "The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A." Anti-IAV DRAVPa2371 VCVKKVRKLYKKIYKCR 17 Sequence 5 from Patent CN118615425A Synthetic construct IAV Patent Application CN118615425A 2024-09-10 CN 118615425 A Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus "The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A." Anti-IAV DRAVPa2372 AKVGDEAYYRGSYYYTRPYYYGMKY 25 Sequence 1 from Patent CN118530344A Synthetic construct AAV Patent Application CN118530344A 2024-08-23 CN 118530344 A##CN 118530344 B Small peptide sequence for combining various serotype adenoviruses and application of small peptide sequence "The invention discloses a small peptide sequence for binding various serotype adenoviruses and application of the small peptide sequence, and belongs to the technical field of biological medicines. The small peptide sequence can be used for manufacturing AAV affinity chromatography medium ligands; an adenovirus for binding a plurality of different serotypes; the alkali resistance is relatively high; the affinity is high; the method can be used for purifying AAV virus particles or AAV virus vectors." Anti-AAV DRAVPa2373 AAGPTLMSGSYNSARDYDY 19 Sequence 1 from Patent CN118530345A Synthetic construct AAV Patent Application CN118530345A 2024-08-23 CN 118530345 A##CN 118530345 B Two small peptide sequences for binding multiple serotype adenoviruses and application thereof "The invention discloses two small peptide sequences for combining various serotype adenoviruses and application of the two small peptide sequences, and belongs to the technical field of biological medicines. The two small peptide sequences can be used for manufacturing AAV affinity chromatography medium ligands; an adenovirus for binding a plurality of different serotypes; the alkali resistance is relatively high; the affinity is high; the method can be used for purifying AAV virus particles or AAV virus vectors." Anti-AAV DRAVPa2374 ADAAGISDYGGSYYVCPHPYGMEY 24 Sequence 2 from Patent CN118530345A Synthetic construct AAV Patent Application CN118530345A 2024-08-23 CN 118530345 A##CN 118530345 B Two small peptide sequences for binding multiple serotype adenoviruses and application thereof "The invention discloses two small peptide sequences for combining various serotype adenoviruses and application of the two small peptide sequences, and belongs to the technical field of biological medicines. The two small peptide sequences can be used for manufacturing AAV affinity chromatography medium ligands; an adenovirus for binding a plurality of different serotypes; the alkali resistance is relatively high; the affinity is high; the method can be used for purifying AAV virus particles or AAV virus vectors." Anti-AAV DRAVPa2375 SYVNVNMGL 9 Sequence 1 from Patent CN119613505A Synthetic construct HBV Patent Application CN119613505A 2025-03-14 CN 119613505 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSYVNVNMGL£»LATWVGSNL£»RRMETTVNA£»MAARVCCQL£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2376 LATWVGSNL 9 Sequence 2 from Patent CN119613505A Synthetic construct HBV Patent Application CN119613505A 2025-03-14 CN 119613505 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSYVNVNMGL£»LATWVGSNL£»RRMETTVNA£»MAARVCCQL£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2377 RRMETTVNA 9 Sequence 3 from Patent CN119613505A Synthetic construct HBV Patent Application CN119613505A 2025-03-14 CN 119613505 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSYVNVNMGL£»LATWVGSNL£»RRMETTVNA£»MAARVCCQL£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2378 MAARVCCQL 9 Sequence 4 from Patent CN119613505A Synthetic construct HBV Patent Application CN119613505A 2025-03-14 CN 119613505 A ÒÒÐ͸ÎÑײ¡¶¾µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëļ°Ó¦Óã¬ÊôÓÚҽѧÃâÒßѧºÍ¸ÐȾ²¡Ñ§ÁìÓò¡£ÒÒÐ͸ÎÑײ¡¶¾¿¹Ô­µÄÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û¿¹Ô­±íλëÄ£¬ËùÊö±íλëĵݱ»ùËáÐòÁаüÀ¨ÒÔÏÂÈÎÒâÒ»ÖÖ»ò¶àÖÖ£ºSYVNVNMGL£»LATWVGSNL£»RRMETTVNA£»MAARVCCQL£»ÉÏÊö°±»ùËáÐòÁе¥¸ö°±»ùËáµÄÈ¥³ý»òÕ߸ü»»ºóµÄ°±»ùËáÐòÁС£±¾ÉêÇëµÄ±íλëÄ¿ÉÒÔÌØÒìÐÔµØÓëϸ°û¶¾ÐÔÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°û½áºÏ£¬´Ì¼¤ºóÕ߻¡¢ÔöÖ³ºÍ·Ö»¯£¬´Ó¶ø·¢»Ó¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÃâÒßЧӦ×÷Óã»ÕâЩ¿¹Ô­ëÄ¿ÉÒÔÓÃÀ´ÖƱ¸ÒÒÐ͸ÎÑײ¡¶¾¸ÐȾµÄÖÎÁÆÐÔºÍÔ¤·ÀÐÔÒßÃ磬Ҳ¿ÉÒÔÓÃÀ´ÖƱ¸¼ì²âÒÒÐ͸ÎÑײ¡¶¾ÌØÒìÐÔϸ°û¶¾ÐÍÐØÏÙÒÀÀµÐÔÁÜ°Íϸ°ûµÄ¼ì²âÊÔ¼Á£¬ÔÚÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢ÖÎÁƺÍÕï¶ÏÖÐÓÐ×ÅDZÔÚµÄÓ¦ÓüÛÖµ¡£ Anti-HBV DRAVPa2379 RRPREQIIIGSLWVF 15 Sequence 1 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2380 IVWHDSLYSTHVQYV 15 Sequence 2 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2381 NARILQRWFPELAHL 15 Sequence 3 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2382 SIENYLKKLGYVLLW 15 Sequence 4 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2383 VIWHPDRWTSVVLQI 15 Sequence 5 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2384 SVVFSADGRHYYWDS 15 Sequence 6 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2385 LVFHDNVYTVTVVHV 15 Sequence 7 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2386 IVLHDGLRSATVLWI 15 Sequence 8 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2387 RVPRKLVIIGSVWNF 15 Sequence 9 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2388 LIWYQSYYQTEVVWF 15 Sequence 10 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2389 IILYRTYFQPFRWEF 15 Sequence 11 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2390 CFFWYENYYTAITVT 15 Sequence 12 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2391 TSQICQELDALGDWI 15 Sequence 13 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2392 RAPREQIIIGSLWVF 15 Sequence 17 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2393 RRAREQIIIGSLWVF 15 Sequence 18 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2394 RRPAEQIIIGSLWVF 15 Sequence 19 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2395 RRPRAQIIIGSLWVF 15 Sequence 20 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2396 RRPREAIIIGSLWVF 15 Sequence 21 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2397 RRPREQIAIGSLWVF 15 Sequence 23 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2398 RRPREQIIAGSLWVF 15 Sequence 24 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2399 RRPREQIIIASLWVF 15 Sequence 25 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2400 RRPREQIIIGALWVF 15 Sequence 26 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2401 RRPREQIIIGSLAVF 15 Sequence 28 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2402 RRPREQIIIGSLWAF 15 Sequence 29 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2403 RRPREQIIIGSLWVA 15 Sequence 30 from Patent CN119630683A Synthetic construct SARS-CoV-2 Patent Application CN119630683A 2025-03-14 WO 2024/013390 A1##CN 119630683 A ¿¹²¡¶¾»·×´»¯ºÏÎï ±¾·¢Ã÷Éæ¼°ÐÂÐÍ»·×´ëÄ¡£ÕâЩëĽáºÏ²¡¶¾µ°°×£¬ÌرðÊÇSARS?CoV?2´ÌÍ»µ°°×Éϵı£ÊØλµã£¬²¢ÇÒÒò´ËÕâЩëÄ¿ÉÒÔÓÃÓÚÖкÍSARS?CoV?2±äÌå¡£Òò´Ë£¬±¾·¢Ã÷»¹Éæ¼°ÕâЩëĵÄҽѧÓÃ;¡£ Anti-SARS-CoV-2 DRAVPa2404 GFSLTSYV 8 Sequence 1 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2405 IWAGGST 7 Sequence 2 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2406 ASPYYYGSSAWFAY 14 Sequence 3 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2407 ASVSY 5 Sequence 4 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2408 QQWSSNPPIT 10 Sequence 5 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2409 QVQLKESGPGLVAPSQSLSITCTVS 25 Sequence 6 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2410 VHWVRQPPGKGLEWLGE 17 Sequence 7 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2411 NYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYC 38 Sequence 8 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2412 WGQGTLVTVSA 11 Sequence 9 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2413 QIVLTQSPAIMSASPGEKVTMTCSPS 26 Sequence 10 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2414 MHWYQQKSGTSPKRWIF 17 Sequence 11 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2415 KLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYC 36 Sequence 12 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2416 FGAGTKLELK 10 Sequence 13 from Patent CN118725094B Synthetic construct FCV Granted Patent CN118725094B 2025-03-11 CN 118725094 A##CN 118725094 B è±­×´²¡¶¾Vp1µ°°×µÄµ¥¿Ë¡¿¹Ìå¼°Æ俹ԭ±íλëĺÍÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖè±­×´²¡¶¾VP1µ°°×µÄµ¥¿Ë¡¿¹Ì壬ͨ¹ýʹÓÃSH14ÖêFCVÈ«²¡¶¾×÷ΪÃâÒßÔ­£¬¸¹Ç»×¢Éä·¨ÃâÒßBALB/cСÊó£¬ÖƱ¸ÁËÕë¶ÔVP1µ°°×µÄmAb¡£Í¨¹ýELISAɸѡ£¬³É¹¦»ñµÃÌØÒìÐÔµ¥¿Ë¡¿¹Ìå3A3C1Ö꣬ÄÜÌØÒìÐÔµØʶ±ð²¢½áºÏFCV SH14Öê¡¢F9ÖêºÍGZ22Öê¡£±¾·¢Ã÷»¹¹«¿ªÁË3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλ£¬Í¨¹ý½Ø¶Ì±í´ïVP1µ°°×²¢½øÐÐÏêϸµÄWestern blot·ÖÎö£¬×îÖÕÈ·¶¨3A3C1ÖêmAbµÄÏßÐÔ¿¹Ô­±íλλÓÚVP1µ°°×µÄ426PSRLTPAGDYAITSG440ÇøÓò¡£³ý´ËÖ®Í⣬±¾·¢Ã÷»¹¹«¿ªÁ˱àÂëËùÊö3A3C1Öê¿É±äÇømAbµÄºËËᣬÒÔ¼°¸Ãµ¥¿Ë¡¿¹ÌåÔÚÖƱ¸FCV¼ì²âÊÔ¼ÁºÐÖеÄÓ¦Óᣱ¾·¢Ã÷ÖƱ¸µÄ3A3C1ÖêmAb²»½öÊÇÀí½âFCVÃâÒßѧÌØÐÔµÄÖØÒª¹¤¾ß£¬Ò²¶Ô·¢Õ¹FCVÕï¶Ï·½·¨ºÍÒßÃç²ßÂÔ¾ßÓÐDZÔÚÓ¦ÓüÛÖµ¡£ Anti-FCV DRAVPa2417 MALQEACEAYLVGLFEDTNLCAIHAKRVTIMPKDIQ 36 Sequence 1 from Patent CN119564829A Synthetic construct TiLV Patent Application CN119564829A 2025-03-07 CN 119564829 A ¿¹¾úëÄÔÚÖƱ¸Ô¤·À»òÖÎÁÆÂÞ·ÇÓãºþ²¡¶¾²¡µÄÒ©ÎïÖеÄÓ¦Óà ±¾ÉêÇ빫¿ªÁËÒ»ÖÖ¿¹¾úëÄÔÚÖƱ¸Ô¤·À»òÖÎÁÆÂÞ·ÇÓãºþ²¡¶¾²¡µÄÒ©ÎïÖеÄÓ¦Ó㬱¾ÉêÇëµÄ¿¹¾úëÄΪSeq ID No.1ËùʾÐòÁеĶàëÄ¡£±¾ÉêÇëÑо¿·¢ÏÖ£¬Seq IDNo.1ËùʾÐòÁеĶàëÄÄܹ»ÓÐЧµÄÒÖÖÆÂÞ·ÇÓãºþ²¡¶¾µÄÔÚÂÞ·ÇÓãÌåÄÚµÄÉú³¤£¬´Ó¶øÆðµ½Ô¤·ÀºÍÖÎÁÆÂÞ·ÇÓãºþ²¡¶¾²¡µÄ×÷Óã¬ÎªÂÞ·ÇÓãºþ²¡¶¾²¡µÄÔ¤·ÀºÍÖÎÁÆÌṩÁËÒ»ÖÖеķ½°¸ºÍ;¾¶¡£ Anti-TiLV DRAVPa2418 AHIVMVDAYKPTK 13 Sequence 19 from Patent CN119552227A Synthetic construct RABV Patent Application CN119552227A 2025-03-04 CN 119552227 A ¿ñÈ®²¡²¡¶¾Gµ°°×Í»±äÌå¼°ÆäÖƱ¸·½·¨ºÍÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïÒ½Ò©¼¼ÊõÁìÓò£¬ÌرðÉæ¼°¿ñÈ®²¡²¡¶¾Gµ°°×Í»±äÌå¼°ÆäÖƱ¸·½·¨ºÍÓ¦Óᣱ¾·¢Ã÷µÄ¿ñÈ®²¡²¡¶¾Gµ°°×Í»±äÌåΪ¶ÔGµ°°×µÄ°ûÍâÓò½øÐеãÍ»±ä»ñµÃ£¬ËùÊöµÄÍ»±äÌåʵÏÖÁËGµ°°×°ûÍâÓòµÄ¿ÉÈÜÐÔ±í´ï£¬ÇÒÄÜÓÕµ¼²úÉú¸ßµÎ¶ÈµÄÖкͿ¹Ì壬ÓëÉÌÆ·»¯ÈËÓÿñÈ®ÒßÃ硢ȮÓÿñÈ®ÒßÃçÏà±È£¬¾ßÓиüÓÅÒìµÄϸ°ûÃâÒߺͿ¹ÌåÃâÒß·´Ó¦£¬ÓÐÍû¼õÉÙ½ÓÖֵĴÎÊý£¬Ëõ¶ÌÃâÒß³ÌÐòºÍ¼õÉÙÃâÒß¼ÁÁ¿¡£ Anti-RABV DRAVPa2419 DSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDFYLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHI 92 Sequence 20 from Patent CN119552227A Synthetic construct RABV Patent Application CN119552227A 2025-03-04 CN 119552227 A ¿ñÈ®²¡²¡¶¾Gµ°°×Í»±äÌå¼°ÆäÖƱ¸·½·¨ºÍÓ¦Óà ±¾·¢Ã÷Éæ¼°ÉúÎïÒ½Ò©¼¼ÊõÁìÓò£¬ÌرðÉæ¼°¿ñÈ®²¡²¡¶¾Gµ°°×Í»±äÌå¼°ÆäÖƱ¸·½·¨ºÍÓ¦Óᣱ¾·¢Ã÷µÄ¿ñÈ®²¡²¡¶¾Gµ°°×Í»±äÌåΪ¶ÔGµ°°×µÄ°ûÍâÓò½øÐеãÍ»±ä»ñµÃ£¬ËùÊöµÄÍ»±äÌåʵÏÖÁËGµ°°×°ûÍâÓòµÄ¿ÉÈÜÐÔ±í´ï£¬ÇÒÄÜÓÕµ¼²úÉú¸ßµÎ¶ÈµÄÖкͿ¹Ì壬ÓëÉÌÆ·»¯ÈËÓÿñÈ®ÒßÃ硢ȮÓÿñÈ®ÒßÃçÏà±È£¬¾ßÓиüÓÅÒìµÄϸ°ûÃâÒߺͿ¹ÌåÃâÒß·´Ó¦£¬ÓÐÍû¼õÉÙ½ÓÖֵĴÎÊý£¬Ëõ¶ÌÃâÒß³ÌÐòºÍ¼õÉÙÃâÒß¼ÁÁ¿¡£ Anti-RABV DRAVPa2420 AAIEEEDIQFINP 13 Sequence 1 from Patent CN118240031A Synthetic construct ASFV Patent Application CN118240031A 2024-06-25 CN 118240031 A African swine fever virus p54 protein antigen epitope peptide and monoclonal antibody and application thereof "The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein. The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein." Anti-ASFV DRAVPa2421 MATGGPAAAPAAASAPAHPAE 21 Sequence 2 from Patent CN118240031A Synthetic construct ASFV Patent Application CN118240031A 2024-06-25 CN 118240031 A African swine fever virus p54 protein antigen epitope peptide and monoclonal antibody and application thereof "The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein. The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein." Anti-ASFV DRAVPa2422 MSAIENLRQRNTY 13 Sequence 3 from Patent CN118240031A Synthetic construct ASFV Patent Application CN118240031A 2024-06-25 CN 118240031 A African swine fever virus p54 protein antigen epitope peptide and monoclonal antibody and application thereof "The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein. The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein." Anti-ASFV DRAVPa2423 KTFPPTEPK 9 Sequence 1 from Patent CN116375822B SARS-CoV-2 SARS-CoV-2 Granted Patent CN116375822B 2024-06-25 CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B йڲ¡¶¾ÌØÒìÐÔCd8+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßѧ¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄ£¬°±»ùËáÐòÁÐΪSEQ ID NO:18¡£±¾·¢Ã÷»¹¹«¿ªÁËÉÏÊöйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëĵÄÓ¦Óᣱ¾·¢Ã÷ËùÌṩµÄйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄÄܹ»²úÉúÇ¿ÁÒµÄϸ°ûÃâÒßÓ¦´ð£¬·ÖÃÚ¸ßˮƽIFN?¦Ã£¬¶ÔÓÚÐÂÐ͹Ú×´²¡¶¾¸ÐȾµÄÔ¤·À¡¢ÁÙ´²ÖÎÁƺÍÒßÃçµÄÑз¢¾ù¾ßÓÐÖØÒªµÄ¿ÆѧÒâÒåºÍÓ¦ÓÃÇ°¾°¡£ Anti-SARS-CoV-2 DRAVPa2424 NYNYLYRLF 9 Sequence 9 from Patent CN116375822B SARS-CoV-2 SARS-CoV-2 Granted Patent CN116375822B 2024-06-25 CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B йڲ¡¶¾ÌØÒìÐÔCd8+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßѧ¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄ£¬°±»ùËáÐòÁÐΪSEQ ID NO:18¡£±¾·¢Ã÷»¹¹«¿ªÁËÉÏÊöйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëĵÄÓ¦Óᣱ¾·¢Ã÷ËùÌṩµÄйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄÄܹ»²úÉúÇ¿ÁÒµÄϸ°ûÃâÒßÓ¦´ð£¬·ÖÃÚ¸ßˮƽIFN?¦Ã£¬¶ÔÓÚÐÂÐ͹Ú×´²¡¶¾¸ÐȾµÄÔ¤·À¡¢ÁÙ´²ÖÎÁƺÍÒßÃçµÄÑз¢¾ù¾ßÓÐÖØÒªµÄ¿ÆѧÒâÒåºÍÓ¦ÓÃÇ°¾°¡£ Anti-SARS-CoV-2 DRAVPa2425 NATRFASVYAWNRKR 15 Sequence 16 from Patent CN116375822B SARS-CoV-2 SARS-CoV-2 Granted Patent CN116375822B 2024-06-25 CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B йڲ¡¶¾ÌØÒìÐÔCd8+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßѧ¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄ£¬°±»ùËáÐòÁÐΪSEQ ID NO:18¡£±¾·¢Ã÷»¹¹«¿ªÁËÉÏÊöйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëĵÄÓ¦Óᣱ¾·¢Ã÷ËùÌṩµÄйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄÄܹ»²úÉúÇ¿ÁÒµÄϸ°ûÃâÒßÓ¦´ð£¬·ÖÃÚ¸ßˮƽIFN?¦Ã£¬¶ÔÓÚÐÂÐ͹Ú×´²¡¶¾¸ÐȾµÄÔ¤·À¡¢ÁÙ´²ÖÎÁƺÍÒßÃçµÄÑз¢¾ù¾ßÓÐÖØÒªµÄ¿ÆѧÒâÒåºÍÓ¦ÓÃÇ°¾°¡£ Anti-SARS-CoV-2 DRAVPa2426 FASVYAWNRKRISNC 15 Sequence 17 from Patent CN116375822B SARS-CoV-2 SARS-CoV-2 Granted Patent CN116375822B 2024-06-25 CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B йڲ¡¶¾ÌØÒìÐÔCd8+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßѧ¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄ£¬°±»ùËáÐòÁÐΪSEQ ID NO:18¡£±¾·¢Ã÷»¹¹«¿ªÁËÉÏÊöйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëĵÄÓ¦Óᣱ¾·¢Ã÷ËùÌṩµÄйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄÄܹ»²úÉúÇ¿ÁÒµÄϸ°ûÃâÒßÓ¦´ð£¬·ÖÃÚ¸ßˮƽIFN?¦Ã£¬¶ÔÓÚÐÂÐ͹Ú×´²¡¶¾¸ÐȾµÄÔ¤·À¡¢ÁÙ´²ÖÎÁƺÍÒßÃçµÄÑз¢¾ù¾ßÓÐÖØÒªµÄ¿ÆѧÒâÒåºÍÓ¦ÓÃÇ°¾°¡£ Anti-SARS-CoV-2 DRAVPa2427 RKRISNCVADYSVLY 15 Sequence 18 from Patent CN116375822B SARS-CoV-2 SARS-CoV-2 Granted Patent CN116375822B 2024-06-25 CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B йڲ¡¶¾ÌØÒìÐÔCd8+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßѧ¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄ£¬°±»ùËáÐòÁÐΪSEQ ID NO:18¡£±¾·¢Ã÷»¹¹«¿ªÁËÉÏÊöйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëĵÄÓ¦Óᣱ¾·¢Ã÷ËùÌṩµÄйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄÄܹ»²úÉúÇ¿ÁÒµÄϸ°ûÃâÒßÓ¦´ð£¬·ÖÃÚ¸ßˮƽIFN?¦Ã£¬¶ÔÓÚÐÂÐ͹Ú×´²¡¶¾¸ÐȾµÄÔ¤·À¡¢ÁÙ´²ÖÎÁƺÍÒßÃçµÄÑз¢¾ù¾ßÓÐÖØÒªµÄ¿ÆѧÒâÒåºÍÓ¦ÓÃÇ°¾°¡£ Anti-SARS-CoV-2 DRAVPa2428 SNCVADYSVLYNSAS 15 Sequence 19 from Patent CN116375822B SARS-CoV-2 SARS-CoV-2 Granted Patent CN116375822B 2024-06-25 CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B йڲ¡¶¾ÌØÒìÐÔCd8+tϸ°û±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßѧ¼¼ÊõÁìÓò£¬¾ßÌ幫¿ªÁËйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄ£¬°±»ùËáÐòÁÐΪSEQ ID NO:18¡£±¾·¢Ã÷»¹¹«¿ªÁËÉÏÊöйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëĵÄÓ¦Óᣱ¾·¢Ã÷ËùÌṩµÄйڲ¡¶¾ÌØÒìÐÔCD8+Tϸ°û±íλëÄÄܹ»²úÉúÇ¿ÁÒµÄϸ°ûÃâÒßÓ¦´ð£¬·ÖÃÚ¸ßˮƽIFN?¦Ã£¬¶ÔÓÚÐÂÐ͹Ú×´²¡¶¾¸ÐȾµÄÔ¤·À¡¢ÁÙ´²ÖÎÁƺÍÒßÃçµÄÑз¢¾ù¾ßÓÐÖØÒªµÄ¿ÆѧÒâÒåºÍÓ¦ÓÃÇ°¾°¡£ Anti-SARS-CoV-2 DRAVPa2429 FHDMVGHHILGACH 14 Sequence 1 from Patent CN118221784A Synthetic construct ASFV Patent Application CN118221784A 2024-06-21 CN 118221784 A African swine fever virus p72 protein antigen epitope peptide as well as monoclonal antibody and application thereof "The invention discloses an antigen epitope peptide of an African swine fever virus p72 protein, which is a peptide fragment 102 to 114 or/and a peptide fragment 239 to 248 of the African swine fever virus p72 protein, and the amino acid sequence of the antigen epitope peptide is 102FHDMVGHHILGACH114 or/and 239GPLLCNIHDL248. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p72 protein." Anti-ASFV DRAVPa2430 GPLLCNIHDL 10 Sequence 2 from Patent CN118221784A Synthetic construct ASFV Patent Application CN118221784A 2024-06-21 CN 118221784 A African swine fever virus p72 protein antigen epitope peptide as well as monoclonal antibody and application thereof "The invention discloses an antigen epitope peptide of an African swine fever virus p72 protein, which is a peptide fragment 102 to 114 or/and a peptide fragment 239 to 248 of the African swine fever virus p72 protein, and the amino acid sequence of the antigen epitope peptide is 102FHDMVGHHILGACH114 or/and 239GPLLCNIHDL248. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p72 protein." Anti-ASFV DRAVPa2431 MSILEKITSSPSECAEHLTNKDSCL 25 Sequence 1 from Patent CN118184749A Synthetic construct ASFV Patent Application CN118184749A 2024-06-14 CN 118184749 A African swine fever virus pS273R protein antigen epitope peptide as well as monoclonal antibody and application thereof "The invention discloses an antigen epitope peptide of an African swine fever virus pS273R protein and a monoclonal antibody aiming at the antigen epitope, the antigen epitope peptide is 1-25 peptide fragments of the African swine fever virus pS273R protein, and the amino acid sequence of the antigen epitope peptide is 1MSILEKITSSPSECAEHLTNKDSCL25. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for researching the biological function of the African swine fever virus pS273R protein." Anti-ASFV DRAVPa2432 DAEFRHDSGYEVHHQK 16 Sequence 1 from Patent CN118161592A Synthetic construct SARS-CoV-2 Patent Application CN118161592A 2024-06-11 CN 118161592 A Glycopeptide compound for inhibiting SARS-CoV-2 virus infection and application thereof "The invention relates to the field of biological medicine, in particular to a glycopeptide compound for inhibiting SARS-CoV-2 virus infection. The glycopeptide compound disclosed by the invention comprises polypeptide and polysaccharide, wherein the polypeptide comprises a polypeptide P1 or a polypeptide P2, and the amino acid sequence of the polypeptide P1 is as shown in SEQ ID NO.1; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.1 through amino acid substitution, deletion or increase; the amino acid sequence of the polypeptide P2 is as shown in SEQ ID NO. 2; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.2 through amino acid substitution, deletion or increase; the structural fragment of the polysaccharide comprises any one or more than two of xFuc-N1Gal-N1 (xFuc-N1) GlcNAc structural units, x is equal to 0 or 1, and N1 is equal to 1, 2, 3, 4 or 6. The glycopeptide compound can be combined with S protein of the novel coronavirus and heparin molecules on the surface of human cells, and host cells are protected from invasion of the novel coronavirus through competitive inhibition." Anti-SARS-CoV-2 DRAVPa2433 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 42 Sequence 2 from Patent CN118161592A Synthetic construct SARS-CoV-2 Patent Application CN118161592A 2024-06-11 CN 118161592 A Glycopeptide compound for inhibiting SARS-CoV-2 virus infection and application thereof "The invention relates to the field of biological medicine, in particular to a glycopeptide compound for inhibiting SARS-CoV-2 virus infection. The glycopeptide compound disclosed by the invention comprises polypeptide and polysaccharide, wherein the polypeptide comprises a polypeptide P1 or a polypeptide P2, and the amino acid sequence of the polypeptide P1 is as shown in SEQ ID NO.1; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.1 through amino acid substitution, deletion or increase; the amino acid sequence of the polypeptide P2 is as shown in SEQ ID NO. 2; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.2 through amino acid substitution, deletion or increase; the structural fragment of the polysaccharide comprises any one or more than two of xFuc-N1Gal-N1 (xFuc-N1) GlcNAc structural units, x is equal to 0 or 1, and N1 is equal to 1, 2, 3, 4 or 6. The glycopeptide compound can be combined with S protein of the novel coronavirus and heparin molecules on the surface of human cells, and host cells are protected from invasion of the novel coronavirus through competitive inhibition." Anti-SARS-CoV-2 DRAVPa2434 NMLSTVLGV 9 Sequence 1 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2435 FMYSDFHFI 9 Sequence 2 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2436 STICFFMQI 9 Sequence 3 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2437 CLPACVYGL 9 Sequence 4 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2438 AMDSNTLEL 9 Sequence 5 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2439 MQIAILITT 9 Sequence 6 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2440 FQGRGVFEL 9 Sequence 7 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2441 AIMDKNIIL 9 Sequence 8 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2442 CVNGSCFTV 9 Sequence 9 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2443 KADTKILFI 9 Sequence 10 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2444 IVLEANFSV 9 Sequence 11 from Patent CN117430665B Synthetic construct IAV Granted Patent CN117430665B 2024-06-04 CN 117430665 A##CN 117430665 B ¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óà ±¾·¢Ã÷ÊôÓÚÃâÒßÖÎÁƼ¼ÊõÁìÓò£¬¾ßÌåÉæ¼°¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëļ°ÆäÓ¦Óᣱ¾·¢Ã÷Òª½â¾öµÄ¼¼ÊõÎÊÌâÊÇÄ¿Ç°ÔÚ¼×ÐÍÁ÷¸Ð²¡¶¾ÁìÓòÉÐûÓпª·¢Ò»ÖÖÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçµÄTϸ°û¿¹Ô­±íλëÄ¡£±¾·¢Ã÷µÄ¼¼Êõ·½°¸¼×ÐÍÁ÷¸Ð²¡¶¾Tϸ°û¿¹Ô­±íλëÄ£¬Æä°±»ùËáÐòÁÐÈçSEQ ID No.10Ëùʾ¡£±¾·¢Ã÷ÌṩÁ˵Ŀ¹Ô­±íλëľßÓкÜÇ¿µÄÃâÒßÔ­ÐÔ£¬ÄÜÓÕµ¼¿¹Ô­ÌØÒìÐÔµÄCD8+Tϸ°û£»Æä¿ÉÒÔºÍHLA?A2ÖØÁ´ºÍHLA?A2ÇáÁ´¦Â2mµ°°××é×°³ÉpMHC¸´ºÏÎ»òÖ±½Ó¸ººÉµ½¿¹Ô­µÝ³Êϸ°û£¬ÄܻTϸ°û£¬ÓÐЧÓÕµ¼Tϸ°ûÃâÒߣ¬¿ÉÓÃÓÚ¼×ÐÍÁ÷¸Ð²¡¶¾Í¨ÓÃÒßÃçÑз¢¡¢ÖƱ¸ºÍÒ©ÎïÑз¢¡¢ÁÙ´²ÖÎÁÆ¡£ Anti-IAV DRAVPa2445 AEQRASPLTSIVSAVVGILLVVVLGVVFGILIKRRQQKIRKYT 43 Sequence 1 from Patent CN116574685B Synthetic construct ZIKV Granted Patent CN116574685B 2024-05-31 CN 116574685 A##CN 116574685 B Ò»ÖÖ×°ÔØ¿¹¾úëÄLl-37µÄÍâÃÚÌå¼°ÆäÔÚ¿¹Õ¯¿¨²¡¶¾ÖеÄÓ¦Óà ±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖ×°ÔØ¿¹¾úëÄLL?37µÄÍâÃÚÌå¼°ÆäÔÚ¿¹Õ¯¿¨²¡¶¾ÖеÄÓ¦Óã¬ÆäÖУ¬¿¹¾úëÄLL?37ͨ¹ýÐÞÊÎÔÚÆäN¶Ë»òC¶ËµÄ¿çĤµ°°××°ÔØÓÚÍâÃÚÌåĤÉÏ£¬ÖƱ¸µÃµ½µÄ²úÆ·°²È«ÐԺã¬ÑªÇåÎȶ¨ÐÔÒ²´ó´óÌá¸ß£¬ÎÞÂÛÔÚÌåÄÚ»¹ÊÇÌåÍⶼÓÐÏÔÖøµÄ¿¹²¡¶¾×÷Óã¬ÓÈÆäÊÇLL?37?TM?exo£¬ÔÚ¶ÔZIKV¸ÐȾµÄÔ¤·ÀºÍÖÎÁÆÉϾùÓм«ÎªÓÅÒìµÄЧ¹û£¬¿ÉÒÔ×÷Ϊ·ÀÖÎÕ¯¿¨²¡¶¾¸ÐȾҩÎïµÄÓÐÁ¦±¸Ñ¡¡£ Anti-ZIKV DRAVPa2446 KFLNPDREYDFRDLR 15 Sequence 1 from Patent CN107033225B Synthetic construct PPRV Granted Patent CN107033225B 2024-05-14 CN 107033225 A##CN 107033225 B Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾Hnµ°°×¿¹Ô­±íλëļ°ÆäÈ·¶¨¡¢ÖƱ¸·½·¨ºÍÓ¦Óà "±¾·¢Ã÷Éæ¼°Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾HNµ°°×¿¹Ô­±íλëÄ£¬¿¹Ô­±íλëĵݱ»ùËáÐòÁÐΪ£ºH123£º123KFLNPDREYDFRDLR137,»ò/ºÍH185£º185GTGCLGRTVTRA196,»ò/ºÍH487£º487IRGPRGRCH495,»ò/ºÍH569£º569ECFPWYHKVWCYHDCLI585£»±¾·¢Ã÷ʹÓöàÖÖÃâÒßÐÅϢѧÈí¼þ¶ÔÄ¿±êµ°°×½øÐÐBϸ°û±íλ½øÐÐÔ¤²â£¬È»ºó¶ÔÔ¤²âµÄ²»Í¬±íλ·Ö±ð½øÐÐÈ˹¤ºÏ³É£¬Ó¦Óüä½ÓELISA·½·¨½øÐÐÑéÖ¤Æä·´Ó¦Ô­ÐÔ£¬²»Í¬µÄ¶àëÄ°ü±»°±»ù»¯Ã¸±ê°å£¬¼ì²âÓëHNµ°°×µÄ¿¹ÌåµÄ·´Ó¦Ô­ÐÔ£¬´Ó¶ø¼ø¶¨³öPPRV HNµ°°×µÄBϸ°û±íλ¡£" Anti-PPRV DRAVPa2447 GTGCLGRTVTRA 12 Sequence 2 from Patent CN107033225B Synthetic construct PPRV Granted Patent CN107033225B 2024-05-14 CN 107033225 A##CN 107033225 B Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾Hnµ°°×¿¹Ô­±íλëļ°ÆäÈ·¶¨¡¢ÖƱ¸·½·¨ºÍÓ¦Óà "±¾·¢Ã÷Éæ¼°Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾HNµ°°×¿¹Ô­±íλëÄ£¬¿¹Ô­±íλëĵݱ»ùËáÐòÁÐΪ£ºH123£º123KFLNPDREYDFRDLR137,»ò/ºÍH185£º185GTGCLGRTVTRA196,»ò/ºÍH487£º487IRGPRGRCH495,»ò/ºÍH569£º569ECFPWYHKVWCYHDCLI585£»±¾·¢Ã÷ʹÓöàÖÖÃâÒßÐÅϢѧÈí¼þ¶ÔÄ¿±êµ°°×½øÐÐBϸ°û±íλ½øÐÐÔ¤²â£¬È»ºó¶ÔÔ¤²âµÄ²»Í¬±íλ·Ö±ð½øÐÐÈ˹¤ºÏ³É£¬Ó¦Óüä½ÓELISA·½·¨½øÐÐÑéÖ¤Æä·´Ó¦Ô­ÐÔ£¬²»Í¬µÄ¶àëÄ°ü±»°±»ù»¯Ã¸±ê°å£¬¼ì²âÓëHNµ°°×µÄ¿¹ÌåµÄ·´Ó¦Ô­ÐÔ£¬´Ó¶ø¼ø¶¨³öPPRV HNµ°°×µÄBϸ°û±íλ¡£" Anti-PPRV DRAVPa2448 IRGPRGRCH 9 Sequence 3 from Patent CN107033225B Synthetic construct PPRV Granted Patent CN107033225B 2024-05-14 CN 107033225 A##CN 107033225 B Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾Hnµ°°×¿¹Ô­±íλëļ°ÆäÈ·¶¨¡¢ÖƱ¸·½·¨ºÍÓ¦Óà "±¾·¢Ã÷Éæ¼°Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾HNµ°°×¿¹Ô­±íλëÄ£¬¿¹Ô­±íλëĵݱ»ùËáÐòÁÐΪ£ºH123£º123KFLNPDREYDFRDLR137,»ò/ºÍH185£º185GTGCLGRTVTRA196,»ò/ºÍH487£º487IRGPRGRCH495,»ò/ºÍH569£º569ECFPWYHKVWCYHDCLI585£»±¾·¢Ã÷ʹÓöàÖÖÃâÒßÐÅϢѧÈí¼þ¶ÔÄ¿±êµ°°×½øÐÐBϸ°û±íλ½øÐÐÔ¤²â£¬È»ºó¶ÔÔ¤²âµÄ²»Í¬±íλ·Ö±ð½øÐÐÈ˹¤ºÏ³É£¬Ó¦Óüä½ÓELISA·½·¨½øÐÐÑéÖ¤Æä·´Ó¦Ô­ÐÔ£¬²»Í¬µÄ¶àëÄ°ü±»°±»ù»¯Ã¸±ê°å£¬¼ì²âÓëHNµ°°×µÄ¿¹ÌåµÄ·´Ó¦Ô­ÐÔ£¬´Ó¶ø¼ø¶¨³öPPRV HNµ°°×µÄBϸ°û±íλ¡£" Anti-PPRV DRAVPa2449 ECFPWYHKVWCYHDCLI 17 Sequence 4 from Patent CN107033225B Synthetic construct PPRV Granted Patent CN107033225B 2024-05-14 CN 107033225 A##CN 107033225 B Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾Hnµ°°×¿¹Ô­±íλëļ°ÆäÈ·¶¨¡¢ÖƱ¸·½·¨ºÍÓ¦Óà "±¾·¢Ã÷Éæ¼°Ò»ÖÖС·´Û»ÊÞÒß²¡¶¾HNµ°°×¿¹Ô­±íλëÄ£¬¿¹Ô­±íλëĵݱ»ùËáÐòÁÐΪ£ºH123£º123KFLNPDREYDFRDLR137,»ò/ºÍH185£º185GTGCLGRTVTRA196,»ò/ºÍH487£º487IRGPRGRCH495,»ò/ºÍH569£º569ECFPWYHKVWCYHDCLI585£»±¾·¢Ã÷ʹÓöàÖÖÃâÒßÐÅϢѧÈí¼þ¶ÔÄ¿±êµ°°×½øÐÐBϸ°û±íλ½øÐÐÔ¤²â£¬È»ºó¶ÔÔ¤²âµÄ²»Í¬±íλ·Ö±ð½øÐÐÈ˹¤ºÏ³É£¬Ó¦Óüä½ÓELISA·½·¨½øÐÐÑéÖ¤Æä·´Ó¦Ô­ÐÔ£¬²»Í¬µÄ¶àëÄ°ü±»°±»ù»¯Ã¸±ê°å£¬¼ì²âÓëHNµ°°×µÄ¿¹ÌåµÄ·´Ó¦Ô­ÐÔ£¬´Ó¶ø¼ø¶¨³öPPRV HNµ°°×µÄBϸ°û±íλ¡£" Anti-PPRV DRAVPa2450 GLYILEPHEGLYALAILEALAGLYPHEILEGLUASNGLYTRPGLUGLYMETVALASPGLYTRPTYRGLY 69 Sequence 1 from Patent CN116947982B Influenza virus Influenza virus Granted Patent CN116947982B 2024-05-14 CN 116947982 A##CN 116947982 B ÈýÌõÓÅÊƱíλëÄÐòÁм°ÆäÔÚÁ÷¸Ð²¡¶¾ÒßÃçµÄÓ¦Óà ±¾·¢Ã÷Éæ¼°ÃâÒßѧ¼¼ÊõÁìÓò£¬Éæ¼°°üº¬ÓÃÓÚÔ¤·ÀºÍÖÎÁÆÁ÷¸Ð²¡¶¾½éµ¼µÄ¼²²¡µÄëÄÃâÒßÔ­µÄ×éºÏÎ¹«¿ªÁËÈýÌõÁ÷¸Ð²¡¶¾HA2µÄÓÅÊƱíλëÄÐòÁм°ÆäÔÚÁ÷¸Ð²¡¶¾ÒßÃçÑз¢µÄÓ¦Óᣱ¾·¢Ã÷µÄÈýÌõÓÅÊƱíλëĵݱ»ùËáÐòÁÐÈçSEQ ID NO:1?3Ëùʾ¡£±¾·¢Ã÷ͨ¹ý¶ÔÁ÷¸Ð²¡¶¾HA2½øÐÐÃâÒßÐÅϢѧԤ²âºÍ¶¯ÎïʵÑéÑéÖ¤Ïà½áºÏɸѡ³öÈýÌõ¾ßÓÐÃâÒßÔ­ÐÔµÄÓÅÊƱíλëÄ£¬ÕâÈýÌõÓÅÊƱíλëľßÓÐT/Bϸ°û±í룬Äܹ»ÓÕµ¼Ï¸°ûÃâÒߺÍÌåÒºÃâÒߣ»×÷Ϊ±ÇÄÚÒßÃçµÄÃâÒßÔ­Äܹ»ÓÕµ¼Ç¿Ð§µÄð¤Ä¤ÃâÒߣ¬¿ÉÓÕµ¼Õë¶ÔÁ÷¸Ð²¡¶¾µÄ¸ßµÎ¶ÈµÄsIgA¡£Ïà±ÈͬÑùÕë¶Ô¸Ã¿¹Ô­ÇøµÄÆäËû¶àëÄ£¬±¾·¢Ã÷µÄÓÅÊƱíλëľßÓиßЧ¼ÛºÍ¸ß±£ÊØÐÔ£¬¿É×÷ΪÁ÷¸ÐÒßÃçµÄºòÑ¡ÃâÒßÔ­¡£ Anti-Influenza virus DRAVPa2451 ARGLEUILEGLYLYSTHRASNGLULYSPHEHISGLNILEGLULYSGLUPHESERGLUVAL 60 Sequence 2 from Patent CN116947982B Influenza virus Influenza virus Granted Patent CN116947982B 2024-05-14 CN 116947982 A##CN 116947982 B ÈýÌõÓÅÊƱíλëÄÐòÁм°ÆäÔÚÁ÷¸Ð²¡¶¾ÒßÃçµÄÓ¦Óà ±¾·¢Ã÷Éæ¼°ÃâÒßѧ¼¼ÊõÁìÓò£¬Éæ¼°°üº¬ÓÃÓÚÔ¤·ÀºÍÖÎÁÆÁ÷¸Ð²¡¶¾½éµ¼µÄ¼²²¡µÄëÄÃâÒßÔ­µÄ×éºÏÎ¹«¿ªÁËÈýÌõÁ÷¸Ð²¡¶¾HA2µÄÓÅÊƱíλëÄÐòÁм°ÆäÔÚÁ÷¸Ð²¡¶¾ÒßÃçÑз¢µÄÓ¦Óᣱ¾·¢Ã÷µÄÈýÌõÓÅÊƱíλëĵݱ»ùËáÐòÁÐÈçSEQ ID NO:1?3Ëùʾ¡£±¾·¢Ã÷ͨ¹ý¶ÔÁ÷¸Ð²¡¶¾HA2½øÐÐÃâÒßÐÅϢѧԤ²âºÍ¶¯ÎïʵÑéÑéÖ¤Ïà½áºÏɸѡ³öÈýÌõ¾ßÓÐÃâÒßÔ­ÐÔµÄÓÅÊƱíλëÄ£¬ÕâÈýÌõÓÅÊƱíλëľßÓÐT/Bϸ°û±í룬Äܹ»ÓÕµ¼Ï¸°ûÃâÒߺÍÌåÒºÃâÒߣ»×÷Ϊ±ÇÄÚÒßÃçµÄÃâÒßÔ­Äܹ»ÓÕµ¼Ç¿Ð§µÄð¤Ä¤ÃâÒߣ¬¿ÉÓÕµ¼Õë¶ÔÁ÷¸Ð²¡¶¾µÄ¸ßµÎ¶ÈµÄsIgA¡£Ïà±ÈͬÑùÕë¶Ô¸Ã¿¹Ô­ÇøµÄÆäËû¶àëÄ£¬±¾·¢Ã÷µÄÓÅÊƱíλëľßÓиßЧ¼ÛºÍ¸ß±£ÊØÐÔ£¬¿É×÷ΪÁ÷¸ÐÒßÃçµÄºòÑ¡ÃâÒßÔ­¡£ Anti-Influenza virus DRAVPa2452 GLYSERILEARGASNGLYTHRTYRASPHISASPVALTYRARGASPGLUALALEUASNASN 60 Sequence 3 from Patent CN116947982B Influenza virus Influenza virus Granted Patent CN116947982B 2024-05-14 CN 116947982 A##CN 116947982 B ÈýÌõÓÅÊƱíλëÄÐòÁм°ÆäÔÚÁ÷¸Ð²¡¶¾ÒßÃçµÄÓ¦Óà ±¾·¢Ã÷Éæ¼°ÃâÒßѧ¼¼ÊõÁìÓò£¬Éæ¼°°üº¬ÓÃÓÚÔ¤·ÀºÍÖÎÁÆÁ÷¸Ð²¡¶¾½éµ¼µÄ¼²²¡µÄëÄÃâÒßÔ­µÄ×éºÏÎ¹«¿ªÁËÈýÌõÁ÷¸Ð²¡¶¾HA2µÄÓÅÊƱíλëÄÐòÁм°ÆäÔÚÁ÷¸Ð²¡¶¾ÒßÃçÑз¢µÄÓ¦Óᣱ¾·¢Ã÷µÄÈýÌõÓÅÊƱíλëĵݱ»ùËáÐòÁÐÈçSEQ ID NO:1?3Ëùʾ¡£±¾·¢Ã÷ͨ¹ý¶ÔÁ÷¸Ð²¡¶¾HA2½øÐÐÃâÒßÐÅϢѧԤ²âºÍ¶¯ÎïʵÑéÑéÖ¤Ïà½áºÏɸѡ³öÈýÌõ¾ßÓÐÃâÒßÔ­ÐÔµÄÓÅÊƱíλëÄ£¬ÕâÈýÌõÓÅÊƱíλëľßÓÐT/Bϸ°û±í룬Äܹ»ÓÕµ¼Ï¸°ûÃâÒߺÍÌåÒºÃâÒߣ»×÷Ϊ±ÇÄÚÒßÃçµÄÃâÒßÔ­Äܹ»ÓÕµ¼Ç¿Ð§µÄð¤Ä¤ÃâÒߣ¬¿ÉÓÕµ¼Õë¶ÔÁ÷¸Ð²¡¶¾µÄ¸ßµÎ¶ÈµÄsIgA¡£Ïà±ÈͬÑùÕë¶Ô¸Ã¿¹Ô­ÇøµÄÆäËû¶àëÄ£¬±¾·¢Ã÷µÄÓÅÊƱíλëľßÓиßЧ¼ÛºÍ¸ß±£ÊØÐÔ£¬¿É×÷ΪÁ÷¸ÐÒßÃçµÄºòÑ¡ÃâÒßÔ­¡£ Anti-Influenza virus DRAVPa2453 ENNVPVTHAKELLHTEHNGM 20 Sequence 3 from Patent CN118027159A Synthetic construct AIV Patent Application CN118027159A 2024-05-14 CN 118027159 A Broad-spectrum B cell epitope peptide of HA1 protein of H9 subtype avian influenza virus and application of broad-spectrum B cell epitope peptide "The invention belongs to the technical field of biology, and particularly relates to an H9 subtype avian influenza virus HA1 protein broad-spectrum B cell epitope peptide and application thereof, two sections of H9 subtype AIV HA1-derived B cell epitopes of an aa 39-59 polypeptide (ENNVPVTHAKELLHTEHNGM) and an aa 309-329 polypeptide (YAFGNCPKYIGVKSLKLAVG) are screened and identified, the B cell epitopes have high conservative property, besides the 320 < th > amino acid of the aa 309-329 polypeptide, the B cell epitopes of the aa 39-59 polypeptide and the YAFGNCPKYIGVKSLKLAVG are added into the B cell epitopes of the aa 309-329 polypeptide, and The conservative rates of other sites of the two polypeptides in the H9 AIV subtype are both greater than 96%. Serological experiments find that the two polypeptides can be specifically combined with different branch strains in the H9 AIV subtype and do not react with other subtype avian influenza viruses; meanwhile, the aa 309-329 polypeptide immune serum can also be specifically combined with different branched strains." Anti-AIV DRAVPa2454 YAFGNCPKYIGVKSLKLAVG 20 Sequence 30 from Patent CN118027159A Synthetic construct AIV Patent Application CN118027159A 2024-05-14 CN 118027159 A Broad-spectrum B cell epitope peptide of HA1 protein of H9 subtype avian influenza virus and application of broad-spectrum B cell epitope peptide "The invention belongs to the technical field of biology, and particularly relates to an H9 subtype avian influenza virus HA1 protein broad-spectrum B cell epitope peptide and application thereof, two sections of H9 subtype AIV HA1-derived B cell epitopes of an aa 39-59 polypeptide (ENNVPVTHAKELLHTEHNGM) and an aa 309-329 polypeptide (YAFGNCPKYIGVKSLKLAVG) are screened and identified, the B cell epitopes have high conservative property, besides the 320 < th > amino acid of the aa 309-329 polypeptide, the B cell epitopes of the aa 39-59 polypeptide and the YAFGNCPKYIGVKSLKLAVG are added into the B cell epitopes of the aa 309-329 polypeptide, and The conservative rates of other sites of the two polypeptides in the H9 AIV subtype are both greater than 96%. Serological experiments find that the two polypeptides can be specifically combined with different branch strains in the H9 AIV subtype and do not react with other subtype avian influenza viruses; meanwhile, the aa 309-329 polypeptide immune serum can also be specifically combined with different branched strains." Anti-AIV DRAVPa2455 QVQLQQPGAELVKPGASVKLSCKSSGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTKYNEKFKTKATLTADKSSSTAYMQLSSLTSEDSAVYYCARAF 116 Sequence 1 from Patent CN116903709B Synthetic construct ASFV Granted Patent CN116903709B 2024-05-07 CN 116903709 A##CN 116903709 B Ò»ÖÖ·ÇÖÞÖíÎÁ²¡¶¾pK205Rµ°°×¿¹Ô­±íλëļ°Æäµ¥¿Ë¡¿¹ÌåÓëÓ¦Óà "±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖ·ÇÖÞÖíÎÁ²¡¶¾(African swine fever virus,ASFV)pK205Rµ°°×¿¹Ô­±íλëÄ£¬ËùÊö¿¹Ô­±íλëĵݱ»ùËáÐòÁÐÈçSEQ ID NO£º3Ëùʾ£¬±¾·¢Ã÷»¹¹«¿ªÁËÒ»ÖÖ¿¹ËùÊö¿¹Ô­±íλëĵĵ¥¿Ë¡¿¹Ìå¼°ÆäÖƱ¸·½·¨ºÍÓ¦Óã¬ÊôÓÚ·Ö×ÓÉúÎïѧÁìÓò¡£±¾·¢Ã÷ÌṩµÄ¿¹Ô­±íλëĺ͵¥¿Ë¡¿¹ÌåÄÜÓÃÓÚ·ÇÖÞÖíÎÁ²¡¶¾µÄ¼ì²â£¬¾ßÓÐÌØÒìÐÔºÃ׼ȷ¶È¸ßµÈÓŵ㣬ΪÑо¿·ÇÖÞÖíÎÁ²¡¶¾pK205Rµ°°×µÄÉúÎïѧ¹¦Äܼ°¿ª·¢¼ì²â·½·¨ÌṩÁËÓмÛÖµµÄй¤¾ß¡£" Anti-ASFV DRAVPa2456 DVQITQSPSYLAASPGETITINCRASKSINKYLAWYQEKPGKTNKLLIQSGSSLQSGIPSRFSGSGSGTDFALTISSLEPEDFAMYYCQQNLEYPWTFGG 107 Sequence 2 from Patent CN116903709B Synthetic construct ASFV Granted Patent CN116903709B 2024-05-07 CN 116903709 A##CN 116903709 B Ò»ÖÖ·ÇÖÞÖíÎÁ²¡¶¾pK205Rµ°°×¿¹Ô­±íλëļ°Æäµ¥¿Ë¡¿¹ÌåÓëÓ¦Óà "±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖ·ÇÖÞÖíÎÁ²¡¶¾(African swine fever virus,ASFV)pK205Rµ°°×¿¹Ô­±íλëÄ£¬ËùÊö¿¹Ô­±íλëĵݱ»ùËáÐòÁÐÈçSEQ ID NO£º3Ëùʾ£¬±¾·¢Ã÷»¹¹«¿ªÁËÒ»ÖÖ¿¹ËùÊö¿¹Ô­±íλëĵĵ¥¿Ë¡¿¹Ìå¼°ÆäÖƱ¸·½·¨ºÍÓ¦Óã¬ÊôÓÚ·Ö×ÓÉúÎïѧÁìÓò¡£±¾·¢Ã÷ÌṩµÄ¿¹Ô­±íλëĺ͵¥¿Ë¡¿¹ÌåÄÜÓÃÓÚ·ÇÖÞÖíÎÁ²¡¶¾µÄ¼ì²â£¬¾ßÓÐÌØÒìÐÔºÃ׼ȷ¶È¸ßµÈÓŵ㣬ΪÑо¿·ÇÖÞÖíÎÁ²¡¶¾pK205Rµ°°×µÄÉúÎïѧ¹¦Äܼ°¿ª·¢¼ì²â·½·¨ÌṩÁËÓмÛÖµµÄй¤¾ß¡£" Anti-ASFV DRAVPa2457 GAIIAQLEILMINGTPLPA 19 Sequence 3 from Patent CN116903709B ASFV ASFV Granted Patent CN116903709B 2024-05-07 CN 116903709 A##CN 116903709 B Ò»ÖÖ·ÇÖÞÖíÎÁ²¡¶¾pK205Rµ°°×¿¹Ô­±íλëļ°Æäµ¥¿Ë¡¿¹ÌåÓëÓ¦Óà "±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖ·ÇÖÞÖíÎÁ²¡¶¾(African swine fever virus,ASFV)pK205Rµ°°×¿¹Ô­±íλëÄ£¬ËùÊö¿¹Ô­±íλëĵݱ»ùËáÐòÁÐÈçSEQ ID NO£º3Ëùʾ£¬±¾·¢Ã÷»¹¹«¿ªÁËÒ»ÖÖ¿¹ËùÊö¿¹Ô­±íλëĵĵ¥¿Ë¡¿¹Ìå¼°ÆäÖƱ¸·½·¨ºÍÓ¦Óã¬ÊôÓÚ·Ö×ÓÉúÎïѧÁìÓò¡£±¾·¢Ã÷ÌṩµÄ¿¹Ô­±íλëĺ͵¥¿Ë¡¿¹ÌåÄÜÓÃÓÚ·ÇÖÞÖíÎÁ²¡¶¾µÄ¼ì²â£¬¾ßÓÐÌØÒìÐÔºÃ׼ȷ¶È¸ßµÈÓŵ㣬ΪÑо¿·ÇÖÞÖíÎÁ²¡¶¾pK205Rµ°°×µÄÉúÎïѧ¹¦Äܼ°¿ª·¢¼ì²â·½·¨ÌṩÁËÓмÛÖµµÄй¤¾ß¡£" Anti-ASFV DRAVPa2458 KINKQKIKNGAKKALGVASKVAPVVAAFAR 30 Sib3 Simulium bannaense ZIKV Patent Application CN117919378A 2024-04-26 CN 117919378 A Application of Simulium bannaense host defense peptide Siba3 "The invention discloses an application of a Simulium bannaense host defense peptide Siba3. The invention also discloses an application of the Simulium bannaense host defense peptide Siba3 in preparation of a medicine for resisting Zika virus infection diseases. The amino acid sequence of the Simulium bannaense host defense peptide Siba3 is as follows: KINKQKIKNGAKKALGVASKVAPVVAAFAR-NH2, and the amino acid sequence of the Simulium bannaense host defense peptide Siba3 is as follows. According to the invention, a host defense peptide Siba3 derived from Simulium bannaense is taken as a research object, and the effect of Siba3 in ZIKV infection is planned to be clarified. Research finds that Siba3 can significantly inhibit ZIKV infection in vitro and also can significantly inhibit ZIKV infection in vivo, and has both prevention and treatment effects. Results show that Siba3 can directly act on ZIKV, destroy virus envelopes and induce virus genomes to leak, so that virus particles are inactivated; the Siba3 can also reduce the susceptibility of the host cell to the Zika virus. The molecular weight is small, the structure is simple, and therefore the wide development and application prospects are achieved." Anti-ZIKV DRAVPa2459 PKCPEPCPP 9 Sequence 5 from Patent CN117919373A Synthetic construct TLR9 Patent Application CN117919373A 2024-04-26 CN 117919373 A Application of polypeptide and polypeptide combination in improvement of antiviral immunity "The invention belongs to the field of biological medicines, and particularly relates to a polypeptide and an effect of a polypeptide combination in improvement of antiviral immunity. The invention proves that the polypeptide or polypeptide combination containing 9 amino acids (PKCPEPCPP), for example, SPRR2 family polypeptide (such as antibacterial peptide SPRR2A from a host) can effectively activate a natural immune signal channel, can be used as an endogenous agonist of TLR9, is crucial to activation of the SPRR2 family mediated TLR9 signal channel, and has a remarkable effect in the aspect of virus resistance for the first time." Activate-TLR9 DRAVPa2460 IFLWLLWPV 9 Sequence 2 from Patent CN117903264A Synthetic construct SARS-CoV-2 Patent Application CN117903264A 2024-04-19 CN 117903264 A Novel coronavirus SARS-CoV-2 HLA-A2 restrictive epitope peptide and application thereof "The invention provides a novel coronavirus SARS-CoV-2HLA-A2 restrictive epitope peptide and an application thereof. Specifically, the invention provides a separated polypeptide, the amino acid sequence of the separated polypeptide is IFLWLLWPV (SEQ ID NO: 2), and the separated polypeptide is a novel coronavirus SARS-CoV-2HLA-A2 restrictive epitope polypeptide. Also provided herein are complexes comprising the polypeptides, articles of manufacture, and uses thereof. The related active substances and products can be used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related diseases." Anti-SARS-CoV-2 DRAVPa2461 RESGGIDKEPMGFTYNGIRTNGVTS 25 Sequence 1 from Patent CN117886901A Synthetic construct AIV Patent Application CN117886901A 2024-04-16 CN 117886901 A Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide "The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses." Anti-AIV DRAVPa2462 FNGAFIAPDRASFLRGKSMGIQSGV 25 Sequence 2 from Patent CN117886901A Synthetic construct AIV Patent Application CN117886901A 2024-04-16 CN 117886901 A Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide "The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses." Anti-AIV DRAVPa2463 LPFQNIDSRAVGKCPRYVKQRSLLL 25 Sequence 3 from Patent CN117886901A Synthetic construct AIV Patent Application CN117886901A 2024-04-16 CN 117886901 A Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide "The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses." Anti-AIV DRAVPa2464 RNNTYDHRKYREEAMQNRIQIDPVK 25 Sequence 4 from Patent CN117886901A Synthetic construct AIV Patent Application CN117886901A 2024-04-16 CN 117886901 A Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide "The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses." Anti-AIV DRAVPa2465 PAYTNSFTRGVYYPD 15 Sequence 1 from Patent CN117843735A Synthetic construct SARS-CoV-2 Patent Application CN117843735A 2024-04-09 CN 117843735 A Novel specific CD4T cell epitope peptide for screening coronavirus S1 holoproteome and application of specific CD4T cell epitope peptide "The invention discloses a specific CD4T cell epitope peptide for screening a novel coronavirus S1 holoproteome and application of the specific CD4T cell epitope peptide, relates to the technical field of biological medicines, and is technically characterized in that the scheme of the invention provides a novel coronavirus CD4T cell epitope peptide. The invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The specific CD4T cell epitope peptide screened by the novel coronavirus S1 holoproteome can safely and effectively induce CD4T cell immune response aiming at novel coronavirus protein, and has important significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2466 GSH 3 Glutathione Synthetic construct BmNPV Granted Patent CN117257914B 2024-03-22 CN 117257914 A##CN 117257914 B ¹Èë׸ÊëÄÔÚÖƱ¸Ô¤·À»òÖÎÁƼҲϺËÐͶà½ÇÌ岡¶¾²¡Ò©ÎïÖеÄÓ¦Óà ±¾·¢Ã÷¹«¿ªÁ˹Èë׸ÊëÄÓÃÓÚÖÎÁÆ»òÔ¤·À¼Ò²ÏºËÐͶà½ÇÌ岡¶¾Ò©ÎïÖеÄÓ¦Ó㬱¾·¢Ã÷Ñо¿±íÃ÷¼Ò²ÏСëĹÈë׸ÊëÄ¿ÉÒÔÓÐЧÒÖÖƼҲϺËÐͶà½ÇÌ岡¶¾(BmNPV)ÔÚ¼Ò²Ïϸ°ûÄڵĸ´ÖÆ£¬Òò´Ë£¬Í¨¹ýºÏÊʵÄŨ¶ÈºÍÒ©ÎïÌí¼Óʱ¼ä¿ÉÀûÓùÈë׸ÊëÄÒÖÖƸò¡¶¾ÔÚ¼Ò²Ïϸ°ûºÍ¼Ò²ÏÌåÄڵĸ´ÖÆ£¬Îª¼Ò²ÏµÄBmNPV¸ÐȾµÄÔ¤·ÀÌṩÁËеÄ˼·¡£ Anti-BmNPV DRAVPa2467 SDPPVVWLGGRPGDF 15 Sequence 1 from Patent CN117659134A Synthetic construct ASFV Patent Application CN117659134A 2024-03-12 CN 117659134 A "Antigen epitope peptide of African swine fever virus pD205R protein, monoclonal antibody and application of antigen epitope peptide and monoclonal antibody" "The invention belongs to the field of biotechnology and biomedicine, and particularly discloses an antigen epitope peptide of African swine fever virus pD205R protein, a monoclonal antibody and application of the antigen epitope peptide and the monoclonal antibody. The antigenic epitope of the African swine fever virus pD205R protein provided by the invention is a linear epitope and is located at the 167th to 181th amino acids (namely 167-SDPPVVWLGGRPGDF-181) of the African swine fever virus pD205R protein, and the key amino acids are S167, W173, L174, G175, P178 and D180. Meanwhile, the monoclonal antibody for resisting the African swine fever virus pD205R protein provided by the invention can specifically recognize and combine with the epitope, and can be used for preparing medicines for preventing and/or treating African swine fever virus infection and reagents for detecting and/or diagnosing African swine fever virus infection. And a new thought is provided for vaccine development and serological diagnosis method establishment." Anti-ASFV DRAVPa2468 DPLASQRDIYY 11 Sequence 1 from Patent CN117659135A Synthetic construct ASFV Patent Application CN117659135A 2024-03-08 CN 117659135 A "Antigen epitope peptide of African swine fever virus pB125R protein, monoclonal antibody and application of antigen epitope peptide and monoclonal antibody" "The invention belongs to the field of biotechnology and biomedicine, and particularly discloses an antigen epitope peptide of African swine fever virus pB125R protein, a monoclonal antibody and application of the antigen epitope peptide and the monoclonal antibody. The antigenic epitope of the African swine fever virus pB125R protein provided by the invention is a B cell linear epitope, and the minimum antigenic epitope is located at the 52nd-62nd amino acids of the African swine fever virus pB125R protein. A mouse model experiment verifies that the antigen epitope has immunocompetence and is highly conserved in different African swine fever virus strains. Meanwhile, the monoclonal antibody for resisting the African swine fever virus pB125R protein and the hybridoma cell strain provided by the invention can specifically recognize and combine the African swine fever virus pB125R protein, and have stronger reaction activity compared with a screened 15A9 antibody; the compound can be used for preparing a reagent for detecting and/or diagnosing African swine fever virus infection and a medicine for preventing and/or treating African swine fever virus infection." Anti-ASFV DRAVPa2469 FLWLLWPVT 9 Sequence 5 from Patent CN117659140A Synthetic construct SARS-CoV-2 Patent Application CN117659140A 2024-03-08 CN 117659140 A New coronavirus HLA-A2 restrictive epitope peptide and application thereof "The invention provides a novel coronavirus HLA-A2 restrictive epitope peptide and application thereof. Specifically, the invention provides a separated polypeptide, the amino acid sequence of the separated polypeptide is FLWLLWPVT (SEQ ID NO: 5), and the separated polypeptide is a novel coronavirus SARS-CoV-2HLA-A2 restrictive epitope polypeptide. Also provided herein are complexes comprising the polypeptides, articles of manufacture, and uses thereof. The related active substances and products can be used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related diseases." Anti-SARS-CoV-2 DRAVPa2470 VVIKVCEFQFCNDPF 15 Sequence 1 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2471 SVLHSTQDLFLPFFS 15 Sequence 2 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2472 HKNNKSWMESEFRVY 15 Sequence 3 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2473 LYIIKLIFLWLLWPV 15 Sequence 4 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2474 FIASFRLFARTRSMW 15 Sequence 5 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2475 RPLLESELVIGAVIL 15 Sequence 6 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2476 SELVIGAVILRGHLR 15 Sequence 7 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2477 LNTDHSSSSDNIALL 15 Sequence 8 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2478 LPYGANKDGIIWVAT 15 Sequence 9 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2479 IWVATEGALNTPKDH 15 Sequence 10 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2480 KAYNVTQAFGRRGPE 15 Sequence 11 from Patent CN117659141A Synthetic construct SARS-CoV-2 Patent Application CN117659141A 2024-03-08 CN 117659141 A "Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof" "The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus." Anti-SARS-CoV-2 DRAVPa2481 ITVATSRT 8 Sequence 27 from Patent CN117535323A Synthetic construct SARS-CoV-2 Patent Application CN117535323A 2024-02-09 CN 117535323 A "Recombinant lactic acid bacteria vector for expressing coronavirus M protein epitope peptide, recombinant lactobacillus plantarum and application" "The invention provides a fusion gene for expressing coronavirus M protein epitope peptide, a recombinant lactic acid bacteria vector, recombinant lactobacillus plantarum and application, and belongs to the technical field of molecular biology. The fusion gene for expressing the coronavirus M protein epitope peptide comprises a gene sequence for coding a signal peptide, a target gene and an SCWA signal peptide. The invention also provides a recombinant lactic acid bacteria vector containing the fusion gene and recombinant lactobacillus plantarum constructed by the recombinant lactic acid bacteria vector, and results show that the recombinant lactobacillus plantarum has high exogenous gene expression efficiency and good immunogenicity, and has high application value in mucosal immunity. And a foundation is laid for developing a novel crown M protein peptide epitope novel nasal drop vaccine." Anti-SARS-CoV-2 DRAVPa2482 GQPSGRRRGRRSGG 14 Sequence 4 from Patent CN112384530B Synthetic construct HEV Granted Patent CN112384530B 2024-02-06 WO 2020/011752 A1##CN 112384530 A##EP 3820892 A1##US 2021/0269510 A1##JP 2021524483 A##EP 3820892 B1 ÎìÐ͸ÎÑײ¡¶¾Orf2iµ°°×µÄ±íλëÄ ±¾·¢Ã÷ÌṩһÖÖ±íλëÄ£¬ÆäÀ´×ÔÎìÐ͸ÎÑײ¡¶¾µÄORF2iµ°°×£¬ÆäÖÐËùÊö±íλëÄ°üº¬ÈçSEQ ID NO£º4ËùʾµÄ°±»ùËáÐòÁС£ Anti-HEV DRAVPa2483 NSASQS 6 Sequence 1 from Patent CN116751280B Synthetic construct SARS-CoV-2 Granted Patent CN116751280B 2024-01-26 CN 116751280 A##CN 116751280 B Ò»ÖÖÌØÒìÐÔʶ±ðSARS-CoV-2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌå¼°ÖƱ¸ºÍÓ¦Óà һÖÖÌØÒìÐÔʶ±ðSARS?CoV?2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌ壬°üÀ¨¦ÁÁ´¿É±äÇøºÍ¦ÂÁ´¿É±äÇø£»¦ÁÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.1ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ»¥²¹¾ö¶¨ÇøACDR1£¬ÈçSEQ ID NO.2ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR2£¬ÒÔ¼°ÈçSEQ ID NO.3ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR3£»¦ÂÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.4ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR1¡¢ÈçSEQ ID NO.5ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR2ÒÔ¼°ÈçSEQ ID NO.6ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR3¡£»¹ÌṩÁËÉÏÊöTϸ°ûÊÜÌåµÄÖƱ¸·½·¨¡£»¹ÌṩÁËÉÏÊöµÄTϸ°ûÊÜÌåÔÚÖƱ¸ÓÃÓÚ¼ì²â»òÕï¶Ïйڲ¡¶¾SARS?CoV?2µÄ²úÆ·ÖеÄÓ¦Óá¢ÓÃÓÚÖÎÁÆ»òÔ¤·Àйڲ¡¶¾SARS?CoV?2ËùÒýÆð¼²²¡µÄÒ©ÎïÖеÄÓ¦ÓᣠAnti-SARS-CoV-2 DRAVPa2484 VYSSGN 6 Sequence 2 from Patent CN116751280B Synthetic construct SARS-CoV-2 Granted Patent CN116751280B 2024-01-26 CN 116751280 A##CN 116751280 B Ò»ÖÖÌØÒìÐÔʶ±ðSARS-CoV-2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌå¼°ÖƱ¸ºÍÓ¦Óà һÖÖÌØÒìÐÔʶ±ðSARS?CoV?2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌ壬°üÀ¨¦ÁÁ´¿É±äÇøºÍ¦ÂÁ´¿É±äÇø£»¦ÁÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.1ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ»¥²¹¾ö¶¨ÇøACDR1£¬ÈçSEQ ID NO.2ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR2£¬ÒÔ¼°ÈçSEQ ID NO.3ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR3£»¦ÂÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.4ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR1¡¢ÈçSEQ ID NO.5ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR2ÒÔ¼°ÈçSEQ ID NO.6ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR3¡£»¹ÌṩÁËÉÏÊöTϸ°ûÊÜÌåµÄÖƱ¸·½·¨¡£»¹ÌṩÁËÉÏÊöµÄTϸ°ûÊÜÌåÔÚÖƱ¸ÓÃÓÚ¼ì²â»òÕï¶Ïйڲ¡¶¾SARS?CoV?2µÄ²úÆ·ÖеÄÓ¦Óá¢ÓÃÓÚÖÎÁÆ»òÔ¤·Àйڲ¡¶¾SARS?CoV?2ËùÒýÆð¼²²¡µÄÒ©ÎïÖеÄÓ¦ÓᣠAnti-SARS-CoV-2 DRAVPa2485 VVTKTSYDKVI 11 Sequence 3 from Patent CN116751280B Synthetic construct SARS-CoV-2 Granted Patent CN116751280B 2024-01-26 CN 116751280 A##CN 116751280 B Ò»ÖÖÌØÒìÐÔʶ±ðSARS-CoV-2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌå¼°ÖƱ¸ºÍÓ¦Óà һÖÖÌØÒìÐÔʶ±ðSARS?CoV?2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌ壬°üÀ¨¦ÁÁ´¿É±äÇøºÍ¦ÂÁ´¿É±äÇø£»¦ÁÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.1ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ»¥²¹¾ö¶¨ÇøACDR1£¬ÈçSEQ ID NO.2ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR2£¬ÒÔ¼°ÈçSEQ ID NO.3ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR3£»¦ÂÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.4ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR1¡¢ÈçSEQ ID NO.5ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR2ÒÔ¼°ÈçSEQ ID NO.6ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR3¡£»¹ÌṩÁËÉÏÊöTϸ°ûÊÜÌåµÄÖƱ¸·½·¨¡£»¹ÌṩÁËÉÏÊöµÄTϸ°ûÊÜÌåÔÚÖƱ¸ÓÃÓÚ¼ì²â»òÕï¶Ïйڲ¡¶¾SARS?CoV?2µÄ²úÆ·ÖеÄÓ¦Óá¢ÓÃÓÚÖÎÁÆ»òÔ¤·Àйڲ¡¶¾SARS?CoV?2ËùÒýÆð¼²²¡µÄÒ©ÎïÖеÄÓ¦ÓᣠAnti-SARS-CoV-2 DRAVPa2486 SGHAT 5 Sequence 4 from Patent CN116751280B Synthetic construct SARS-CoV-2 Granted Patent CN116751280B 2024-01-26 CN 116751280 A##CN 116751280 B Ò»ÖÖÌØÒìÐÔʶ±ðSARS-CoV-2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌå¼°ÖƱ¸ºÍÓ¦Óà һÖÖÌØÒìÐÔʶ±ðSARS?CoV?2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌ壬°üÀ¨¦ÁÁ´¿É±äÇøºÍ¦ÂÁ´¿É±äÇø£»¦ÁÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.1ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ»¥²¹¾ö¶¨ÇøACDR1£¬ÈçSEQ ID NO.2ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR2£¬ÒÔ¼°ÈçSEQ ID NO.3ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR3£»¦ÂÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.4ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR1¡¢ÈçSEQ ID NO.5ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR2ÒÔ¼°ÈçSEQ ID NO.6ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR3¡£»¹ÌṩÁËÉÏÊöTϸ°ûÊÜÌåµÄÖƱ¸·½·¨¡£»¹ÌṩÁËÉÏÊöµÄTϸ°ûÊÜÌåÔÚÖƱ¸ÓÃÓÚ¼ì²â»òÕï¶Ïйڲ¡¶¾SARS?CoV?2µÄ²úÆ·ÖеÄÓ¦Óá¢ÓÃÓÚÖÎÁÆ»òÔ¤·Àйڲ¡¶¾SARS?CoV?2ËùÒýÆð¼²²¡µÄÒ©ÎïÖеÄÓ¦ÓᣠAnti-SARS-CoV-2 DRAVPa2487 FQNNGV 6 Sequence 5 from Patent CN116751280B Synthetic construct SARS-CoV-2 Granted Patent CN116751280B 2024-01-26 CN 116751280 A##CN 116751280 B Ò»ÖÖÌØÒìÐÔʶ±ðSARS-CoV-2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌå¼°ÖƱ¸ºÍÓ¦Óà һÖÖÌØÒìÐÔʶ±ðSARS?CoV?2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌ壬°üÀ¨¦ÁÁ´¿É±äÇøºÍ¦ÂÁ´¿É±äÇø£»¦ÁÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.1ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ»¥²¹¾ö¶¨ÇøACDR1£¬ÈçSEQ ID NO.2ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR2£¬ÒÔ¼°ÈçSEQ ID NO.3ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR3£»¦ÂÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.4ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR1¡¢ÈçSEQ ID NO.5ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR2ÒÔ¼°ÈçSEQ ID NO.6ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR3¡£»¹ÌṩÁËÉÏÊöTϸ°ûÊÜÌåµÄÖƱ¸·½·¨¡£»¹ÌṩÁËÉÏÊöµÄTϸ°ûÊÜÌåÔÚÖƱ¸ÓÃÓÚ¼ì²â»òÕï¶Ïйڲ¡¶¾SARS?CoV?2µÄ²úÆ·ÖеÄÓ¦Óá¢ÓÃÓÚÖÎÁÆ»òÔ¤·Àйڲ¡¶¾SARS?CoV?2ËùÒýÆð¼²²¡µÄÒ©ÎïÖеÄÓ¦ÓᣠAnti-SARS-CoV-2 DRAVPa2488 ASRGLAGSETQY 12 Sequence 6 from Patent CN116751280B Synthetic construct SARS-CoV-2 Granted Patent CN116751280B 2024-01-26 CN 116751280 A##CN 116751280 B Ò»ÖÖÌØÒìÐÔʶ±ðSARS-CoV-2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌå¼°ÖƱ¸ºÍÓ¦Óà һÖÖÌØÒìÐÔʶ±ðSARS?CoV?2йڲ¡¶¾Sµ°°×¿¹Ô­ëĵÄTϸ°ûÊÜÌ壬°üÀ¨¦ÁÁ´¿É±äÇøºÍ¦ÂÁ´¿É±äÇø£»¦ÁÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.1ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ»¥²¹¾ö¶¨ÇøACDR1£¬ÈçSEQ ID NO.2ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR2£¬ÒÔ¼°ÈçSEQ ID NO.3ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÁÁ´»¥²¹¾ö¶¨ÇøACDR3£»¦ÂÁ´¿É±äÇø°üº¬ÈçSEQ ID NO.4ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR1¡¢ÈçSEQ ID NO.5ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR2ÒÔ¼°ÈçSEQ ID NO.6ËùʾµÄ°±»ùËáÐòÁÐ×é³ÉµÄ¦ÂÁ´»¥²¹¾ö¶¨ÇøBCDR3¡£»¹ÌṩÁËÉÏÊöTϸ°ûÊÜÌåµÄÖƱ¸·½·¨¡£»¹ÌṩÁËÉÏÊöµÄTϸ°ûÊÜÌåÔÚÖƱ¸ÓÃÓÚ¼ì²â»òÕï¶Ïйڲ¡¶¾SARS?CoV?2µÄ²úÆ·ÖеÄÓ¦Óá¢ÓÃÓÚÖÎÁÆ»òÔ¤·Àйڲ¡¶¾SARS?CoV?2ËùÒýÆð¼²²¡µÄÒ©ÎïÖеÄÓ¦ÓᣠAnti-SARS-CoV-2 DRAVPa2489 MGRFKRFRKKFKKLFKKLS 19 Sequence 1 from Patent CN117427145A Synthetic construct EV Patent Application CN117427145A 2024-01-23 CN 117427145 A Ò»ÖÖÔ¤·À»òÒÖÖƳ¦µÀ²¡¶¾µÄëÄÀà×éºÏÎï¼°ÆäÓÃ; "±¾·¢Ã÷Éæ¼°ÉúÎïÒ½Ò©ÁìÓò,¾ßÌåÉæ¼°Ò»ÖÖÔ¤·À»òÒÖÖƳ¦µÀ²¡¶¾µÄëÄÀà×éºÏÎï¼°ÆäÓÃ;,ËùÊöëÄÀà×éºÏÎï°üº¬¶àëĺÍÃÉÍÑʯɢ,Ò²¿ÉÒÔ°üÀ¨ÆäËûÒ©ÎïÓÐЧ³É·Ö¡¢¸¨ÁÏ¡¢ÔØÌå»ò¸¨ÖúÐԳɷ֡£±¾·¢Ã÷»¹¹«¿ªÁ˸ÃëÄÀà×éºÏÎïÔÚÔ¤·À»òÒÖÖƳ¦µÀ²¡¶¾·½ÃæµÄÓÃ;,ËùÊöëÄÀà×éºÏÎïÔÚ½µµÍ¶àëÄ¡¢ÃÉÍÑʯɢʹÓÃŨ¶ÈµÄͬʱ,¿ÉÓÐЧÌá¸ß¿¹²¡¶¾×÷ÓÃ,Á½ÕßµÄ×éºÏ¶ÔÔ¤·À»òÒÖÖƳ¦µÀ²¡¶¾¾ßÓÐЭͬ×÷Óá£ÓëÏÖÓм¼ÊõÏà±È,¸ÃëÄÀà×éºÏÎï¶Ô³¦µÀ²¡¶¾µÄÔ¤·À»òÒÖÖƾßÓÐЭͬ×÷ÓÃ,ÓÈÆä¶Ô¿ÂÈøÆ没¶¾¼°³¦µÀ²¡¶¾71ÐÍ,²¢ÇÒ°²È«ÐÔ¸ß,ÎÞ¼¤ËØ,¸ßЧ,°²È«,Òò´Ë¾ßÓкܺõÄÉÌÒµÓ¦ÓÃÇ°¾°¡£" Anti-EV DRAVPa2490 KLNSGDSKV 9 Sequence 1 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2491 KMNSGDSKV 9 Sequence 2 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2492 KINSGDSKV 9 Sequence 3 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2493 KQNSGDSKV 9 Sequence 4 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2494 KVNSGDSKV 9 Sequence 5 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2495 KLNSGDSFV 9 Sequence 6 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2496 KLNSGDSKL 9 Sequence 7 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2497 KLNSGDSKI 9 Sequence 8 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2498 KLNSGDSKA 9 Sequence 9 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2499 KLNSGDSPV 9 Sequence 10 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2500 KLNSGISKV 9 Sequence 11 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2501 KLNSGLSKV 9 Sequence 12 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2502 KLNSGVSKV 9 Sequence 13 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2503 KLMSGDSKV 9 Sequence 14 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2504 KLWSGDSKV 9 Sequence 15 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2505 KLFSGDSKV 9 Sequence 16 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2506 KLYSGDSKV 9 Sequence 17 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2507 FLNSGDSKV 9 Sequence 18 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2508 YLNSGDSKV 9 Sequence 19 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2509 KLNSGDWKV 9 Sequence 20 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2510 KLNSGDFKV 9 Sequence 21 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2511 KLNSGDYKV 9 Sequence 22 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2512 KLNSGDSYV 9 Sequence 23 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2513 KLNSGDSKVV 9 Sequence 24 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2514 KLNSGDSKVL 9 Sequence 25 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2515 FKLNSGDSKV 9 Sequence 26 from Patent CN117377679A Synthetic construct SARS-CoV-2 Patent Application CN117377679A 2024-01-09 WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A Peptide vaccines against viral infection "The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)." Anti-SARS-CoV-2 DRAVPa2516 DQPAKDPRMSPRESD 15 Sequence 1 from Patent CN117343149A Synthetic construct PRRSV Patent Application CN117343149A 2024-01-05 CN 117343149 A Preparation and application of PRRSV non-structural protein Nsp2 synthetic peptide polyclonal antibody "The invention relates to the technical field of biology, and particularly discloses an antigen peptide of a porcine reproductive and respiratory syndrome virus non-structural protein 2, a polyclonal antibody prepared by using the antigen peptide and application of the polyclonal antibody. The amino acid sequence of the antigen peptide disclosed by the invention is as shown in SEQ ID NO. 1. Meanwhile, the invention also discloses a preparation method of the antigen peptide and a polyclonal antibody prepared by using the antigen peptide. The polyclonal antibody prepared by the invention is relatively high in sensitivity and specificity, can specifically recognize the Nsp2 protein, can be used for detection of the Nsp2 protein, protein function identification, cell localization and the like, provides an important experimental material for researching biological functions of the Nsp2 protein, and lays a biological foundation for detection of porcine reproductive and respiratory syndrome virus." Anti-PRRSV DRAVPa2517 LKKLKWLAHRLKGMLKKYLKPTAASS 26 Sequence 1 from Patent CN117343148A Synthetic construct "CHIKV,HTNV,DENV,HSV" Patent Application CN117343148A 2024-01-05 CN 117343148 A Antibacterial peptide and application thereof in preparation of antibacterial drugs or antiviral drugs "The invention discloses an antibacterial peptide and application thereof in preparation of an antibacterial drug or an antiviral drug. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.1. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.2. The MIC of the antibacterial peptide disclosed by the invention on escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and acinetobacter baumannii is less than or equal to 20 mu g/mL; multiple drug-resistant escherichia coli, drug-resistant staphylococcus aureus, drug-resistant pseudomonas aeruginosa and drug-resistant acinetobacter baumannii can be inhibited; the inhibition effect on drug-resistant acinetobacter baumannii which is focused by WHO is outstanding; the antibacterial peptide disclosed by the invention is good in safety and has relatively low cytotoxicity and hemolytic activity, and the animal toxicity is lower than that of the existing clinical antibacterial peptide polymyxin B; the compound also has a broad-spectrum antiviral effect, and has an inhibiting effect on hantavirus, chikungunya virus, herpes simplex virus type 1 or dengue virus type 2." Anti-CHIKV##Anti-HTNV##Anti-DENV##Anti-HSV DRAVPa2518 ITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQ 35 T-166 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-178, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2519 KENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQS 35 T-154 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-179, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2520 QITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSV 35 T-165 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-180, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2521 EKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYV 35 T-182 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-181, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2522 NSVALDPIDISIELNKAKSDLEESKEWIRRSNQK 34 T-197 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-182, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2523 EAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEI 35 T-186 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-183, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2524 IKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQ 35 T-153 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-184, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2525 DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH 34 T-205 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-185, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2526 AQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQS 35 T-164 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-186, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2527 TIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTE 35 T-147 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-187, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2528 FDASISQVNEKINQSLAFIRKSDELLHNVNAGKSI 35 T-118 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-188, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2529 SVITIELSNIKENKCNGTDAKVKLIKQELDKYKNA 35 T-144 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-189, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2530 LGVATSAQITAAVALVEAKQARSDIEKLKEAIRDT 35 T-158 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-190, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2531 DIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQD 35 T-180 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-191, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2532 IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW 34 T-204 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-192, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2533 VALDPIDISIELNKAKSDLEESKEWIRRSNQKLD 34 T-199 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-193, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2534 TPNITLNNSVALDPIDISIELNKAKSDLEESKEW 34 T-190 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-194, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2535 ELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQ 35 T-149 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-195, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2536 ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST 34 T-209 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-196, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2537 PNITLNNSVALDPIDISIELNKAKSDLEESKEWI 34 T-191 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-197, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2538 VATSAQITAAVALVEAKQARSDIEKLKEAIRDTNK 35 T-160 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-198, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 4 DRAVPa2539 IEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDY 35 T-181 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-199, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 5 DRAVPa2540 TSVITIELSNIKENKCNGTDAKVKLIKQELDKYKN 35 T-143 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-200, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2541 PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN 34 T-203 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-201, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2542 DASISQVNEKINQSLAFIRKSDELLHNVNAGKSIT 35 T-119 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-202, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2543 NIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLM 35 T-152 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-203, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2544 IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS 34 T-208 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-204, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2545 SNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLL 35 T-151 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-205, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2546 ITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVT 35 T-146 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-206, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2547 LSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQL 35 T-150 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-207, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2548 TSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAV 35 T-162 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-208, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2549 YTPNITLNNSVALDPIDISIELNKAKSDLEESKE 34 T-189 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-209, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2550 LNNSVALDPIDISIELNKAKSDLEESKEWIRRSN 34 T-195 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-210, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2551 IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTEL 35 T-148 RSV fusion (F) protein RSV Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-211, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-RSV DRAVPa2552 NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ 34 T-196 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-212, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2553 LNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT 34 T-210 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-213, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2554 ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ 34 T-206 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-214, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2555 NITLNNSVALDPIDISIELNKAKSDLEESKEWIR 34 T-192 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-215, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2556 ALGVATSAQITAAVALVEAKQARSDIEKLKEAIRD 35 T-157 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-216, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2557 ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS 34 T-200 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-217, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2558 SVALDPIDISIELNKAKSDLEESKEWIRRSNQKL 34 T-198 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-218, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2559 ALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGN 35 T-171 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-219, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2560 GVATSAQITAAVALVEAKQARSDIEKLKEAIRDTN 35 T-159 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-220, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2561 ATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKA 35 T-161 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-221, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2562 SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS 34 T-207 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-222, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2563 VALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIG 35 T-170 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-223, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2564 SAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQ 35 T-163 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-224, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2565 DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG 34 T-202 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-225, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2566 IRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP 35 T-188 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-226, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2567 LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI 34 T-201 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-227, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2568 KEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKE 35 T-185 HPIV3 fusion (F) protein HPIV 3 Granted Patent US6440656 2002-08-27 WO9428920A1##US7514397B1##US5464933A##US6133418A##AU692777B2##AU7042694A##CA2164698A1##CA2164698C##EP1595890A3##ES2238674T3##JP4205159B2##JPH08511525A##KR100355407B1 Methods for the inhibition of respiratory syncytial virus transmission "Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-228, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections." Anti-HPIV 3 DRAVPa2569 AHWGVLAGIKYFSMVGNW 18 SEQ ID NO:62 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2570 GIKYFSMVGNWAKVLVVL 18 SEQ ID NO:63 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E3 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2571 LLRIPQAIMDMIAGAHWG 18 SEQ ID NO:60 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E4 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2572 SSGLYHVTNDCPNSSIVY 18 SEQ ID NO:40 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E5 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2573 VGNWAKVLVVLLLFAGVD 18 SEQ ID NO:64 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E6 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2574 CGSVFLVGQLFTFSPRHH 18 SEQ ID NO:52 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E7 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2575 MMNWSPTAALVVAQLLRI 18 SEQ ID NO:58 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E8 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2576 SAYQVRNSSGLYHVTNDC 18 SEQ ID NO:39 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E9 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2577 YPGHITGHRMANMMMNW 17 SEQ ID NO:56 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E10 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2578 PRHHWTTQDCNCSIYPGH 18 SEQ ID NO:54 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E11 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2579 TNDCPNSSVVYEAADAIL 18 SEQ ID NO:41 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E12 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2580 QDCNCSIYPGHITGHRMA 18 SEQ ID NO:55 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E13 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2581 GCVPCVREGNASRCWVAV 18 POLG_HCV77 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E14 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2582 LVVLLLFAGVDAETHVTG 18 SEQ ID NO:65 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E15 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2583 SCLTVPASAYQVRNSSGL 18 SEQ ID NO:38 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E16 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2584 IMDMIAGAHWGVLAGIKY 18 SEQ ID NO:61 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E17 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2585 HRMANMMMNWSPTAALV 17 SEQ ID NO:57 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E18 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2586 WVAVTPTVATRDGKLPTT 18 SEQ ID NO:45 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E19 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2587 GQLFTFSPRHHWTTQDCN 18 SEQ ID NO:53 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E20 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2588 WVAVTPTVATRDGKLPTT 18 SEQ ID NO:46 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E21 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2589 SIVYEAADAILHTPGCVP 18 SEQ ID NO:42 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E22 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2590 AALVVAQLLRIPQAIMDM 18 SEQ ID NO:59 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E23 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2591 VATRDGKLPTTQLRRHID 18 SEQ ID NO:47 "HCV envelope glycoprotein (E1, E2)" HCV Granted Patent US7416733 2008-08-26 DK1558276T3##WO2004044220A2##JP2010167496A##EP20100181693 Flavivirus fusion inhibitors "The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E24 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses." Anti-HCV DRAVPa2592 HRSLLGRMKGA 11 SEQ ID NO: 32 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2593 SLLGRMKGA 9 SEQ ID NO: 25 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2594 ADGTLLGRMKLA 12 SEQ ID NO: 5 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2595 ADGSRSSLLGRMKGA 15 SEQ ID NO: 8 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2596 ADGALLGRMKGA 12 SEQ ID NO: 1 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2597 SLLGRMKG 8 SEQ ID NO: 23 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2598 SLLGRMKG 10 SEQ ID NO: 29 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2599 GSLLGRMKGA 10 SEQ ID NO: 26 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2600 ADGALLGRMKRA 12 SEQ ID NO: 4 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2601 ADGSLLGRMKPA 12 SEQ ID NO: 3 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2602 SLLGRMK 7 SEQ ID NO: 24 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2603 ADGPRSSLLGRMKGA 15 SEQ ID NO: 11 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2604 ADGYQRSLLGRMKGA 15 SEQ ID NO: 13 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2605 RSLLGRMKGA 10 SEQ ID NO: 31 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2606 ALLGRMKG 8 SEQ ID NO: 16 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2607 ADGSLLGRMKGAAG 15 SEQ ID NO: 28 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2608 LLGRM 5 SEQ ID NO: 20 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2609 CLLGRMKC 8 SEQ ID NO: 21 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2610 ADGSLLGRMKGA 12 SEQ ID NO: 6 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2611 MHRSLLGRMKGA 12 SEQ ID NO: 33 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2612 ADGHRSSLLGRMKGA 15 SEQ ID NO: 10 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2613 ADRSLLGRMKGA 12 SEQ ID NO: 7 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2614 ADGALLGRMKPA 12 SEQ ID NO: 2 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2615 ADGMHRSLLGRMKGA 15 SEQ ID NO: 15 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2616 ALLPRMKG 8 SEQ ID NO: 22 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2617 DGSLLGRMKGAA 12 SEQ ID NO: 27 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2618 ADGAHRSLLGRMKGA 15 SEQ ID NO: 12 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2619 ADGAHSSLLGRMKGA 15 SEQ ID NO: 9 Synthetic construct HBV Granted Patent US6544520 2003-04-08 DK97946476T##DK97946476T##DK97946476T##WO1998018818A2 Hepatitis B virus inhibitors "Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them." Anti-HBV DRAVPa2620 GIGVTQNVLYENQKQIANQF 20 SEQ ID NO:9 Synthetic construct SARS-CoV Granted Patent US7491489 2009-02-17 CN2005101315809A Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR. Anti-SARS-CoV DRAVPa2621 FKLPLGINITNFRAILTAFS 20 SEQ ID NO:1 Synthetic construct SARS-CoV Granted Patent US7491489 2009-02-18 CN2005101315809A Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR. Anti-SARS-CoV DRAVPa2622 RDVSDFTDSVRDPKTSEILD 20 SEQ ID NO:5 Synthetic construct SARS-CoV Granted Patent US7491489 2009-02-19 CN2005101315809A Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR. Anti-SARS-CoV DRAVPa2623 PTTFMLKYDENGTITDAVDC 20 SEQ ID NO:2 Synthetic construct SARS-CoV Granted Patent US7491489 2009-02-20 CN2005101315809A Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR. Anti-SARS-CoV DRAVPa2624 VLYNSTFFSTFKCYGVSATK 20 SEQ ID NO:3 Synthetic construct SARS-CoV Granted Patent US7491489 2009-02-21 CN2005101315809A Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR. Anti-SARS-CoV DRAVPa2625 SNNTIAIPTNFSISITTEVM 20 SEQ ID NO:7 Synthetic construct SARS-CoV Granted Patent US7491489 2009-02-22 CN2005101315809A Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR. Anti-SARS-CoV DRAVPa2626 PALNCYWPLNDYGFYTTSGI 20 SEQ ID NO:4 Synthetic construct SARS-CoV Granted Patent US7491489 2009-02-23 CN2005101315809A Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR. Anti-SARS-CoV